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Abstract 
 
Fungal pathogens, particularly species of the Candida genus, are responsible 
for superficial infections and invasive disease in humans, the latter of which is 
responsible for more deaths than tuberculosis or malaria. Despite this, fungal 
infections receive considerably less research attention than those of bacteria. 
Mixed-Candida species infections are increasing in prevalence, and occur as 
secondary infections in HIV and cancer patients. Resources are important in 
infection environments, in which competition between species and interactions 
with the host can influence community composition. After C. albicans, C. 
glabrata is the second most commonly isolated species, which colonises 
different host sites and patients and rapidly develops drug resistance. In this 
thesis, we investigate competition between C. albicans and C. glabrata in 
clinically-relevant in vitro cultures and in an invertebrate model. We then 
measure in vitro growth of C. glabrata strains over different glucose 
concentrations and the influence on virulence and antifungal adaptation. 
Following culture propagation in environments containing antifungal drug, we 
analyse C. glabrata fitness in evolved populations. 
 
We found that outcomes of short and long-term competition between C. 
albicans and C. glabrata were dependent on resource level in clinically-relevant 
media, with C. albicans favoured at low and C. glabrata favoured at high 
glucose (Chapter 2). C. glabrata clinical strains varied in competitive abilities 
(Chapter 2), and in their strength of interaction with C. albicans evidenced by 
differing levels of host survival in dual-species infections of the wax moth 
Galleria mellonella (Chapter 3). For growth on glucose, we identified a strain of 
C. glabrata (3605) isolated from a diabetic patient that had a significantly 
greater growth rate but lower final growth density than a lab reference strain 
(2001) (Chapter 4). We found that a higher growth density was correlated with 
greater virulence and adaptability to the antifungal caspofungin (Chapters 4 and 
5). Finally, we found that caspofungin resistance could incur fitness costs and 
that sub-population variation in phenotypic adaptations evolved in parallel 
populations. These results improve understanding of microbial species 
interactions in infections by considering effects of resource levels and pathogen 
growth strategies on competitive abilities, virulence and antifungal resistance. 
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This could lead to better characterisation of fungal infections and evolutionary 
adaptations in different host environments.  
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percentage (x), relative to a non-drug-
treated control 
 
K Carrying Capacity 
 
LCV Large Colony Variant 
 
MIC Minimum Inhibitory Concentration: 
lowest concentration of drug required 
to substantially inhibit microbial 
growth, usually to 50 or 90% 
inhibition 
 
MSC Multi-Species Candidemia 
 
NCPF National Collection of Pathogenic 
Fungi 
 
OD Optical Density 
 
PxCy Population (x) Colony (y): notation for 
a specific colony (y) from a replicate 
population (x) 
 
PBS Phosphate Buffered Saline 
 
PCR Polymerase Chain Reaction 
 
r Exponential phase intrinsic growth 
rate (h-1) 
 
SC Synthetic Complete medium 
 
SCV Small Colony Variant 
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SDA Sabouraud Dextrose Agar 
 
SE Standard Error 
 
SU Synthetic Urine 
 
TCA Tricarboxylic Acid Cycle 
 
WHO World Health Organisation 
 
WT Wild-Type or Wild Type 
 
YNB Yeast Nitrogen Base 
 
YPD Yeast Peptone Dextrose 
 
YPG Yeast Peptone Glycerol 
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1. Chapter 1: Introduction 
 
1.1 Fungi as Pathogens of Humans 
 
Fungal pathogens are emerging as major causes of severe, invasive disease in 
humans with a particularly dramatic rise of bloodstream infections (Brown et al., 
2012). Annually, fungi are responsible for greater than one billion skin and 
mucosal infections and more than one million deaths from invasive disease 
(Gow and Netea, 2016). Given that mortality rates from invasive disease 
parallel those of tuberculosis and malaria and 2 million people worldwide are 
affected annually, surprisingly the severity of fungal disease is poorly 
recognised and under researched amongst the scientific community (Brown et 
al., 2012; Barnes et al., 2014). Research funding for fungal diseases comprises 
less than 5% of UK budgets on infection biology (Head et al., 2014; Fisher et 
al., 2016) and there is minimal reporting of fungal epidemiology worldwide, with 
the exception of surveillance by the US Centers for Disease Control and 
Prevention (CDC) (Brown et al., 2012). There is now an important need to 
research fungal disease prevention and control strategies due to the threats 
posed to crops, wildlife and human health from a variety of animal and plant 
pathogens (Fisher et al., 2016).  
 
Fungi are healthy components of human microbial communities (Underhill and 
Iliev, 2014) but cause infection due to pathogenic overgrowth. This results in 
superficial infections of the skin and nails in otherwise healthy individuals or 
those on antibiotic treatment, or invasive disease in patients with severe 
underlying disease such as HIV (Segal, 2005; Brown et al., 2012; Kumar and 
Singhi, 2013). Opportunistic species of the Candida genus are the “fourth most 
common cause of nosocomial bloodstream infections” in the United States 
(Wisplinghoff et al. 2004) and are responsible for a worldwide 46-75% mortality 
rate (Brown et al. 2012). Candida species are carried in approximately a third to 
a half of human oral cavities (Ito-Kuwa et al., 1997; Thein et al. 2009) and in 
many other host sites, existing as healthy commensals (Fidel et al., 1999). 
Often, more than one species is found in commensal carriage and a study of 
oral sites found that 31% of colonised individuals had mixed-Candida species 
carriage, with C. albicans and C. glabrata most common (Lockhart et al. 1999). 
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Infections occur due to immune compromise and range from superficial 
mucosal to invasive candidiasis involving respiratory, gastrointestinal and urino-
genital tracts, due to pathogenic overgrowth (Segal 2005; Kumar and Singhi, 
2013).  
 
Invasive candidiasis affects greater than 250,000 people worldwide annually 
and includes bloodstream infections (candidemia) and lesions in organs such 
as the kidneys and lungs and other sites including the bones and eyes (Kullberg 
and Arendrup, 2015). The most common risk factors for infection include 
intravenous catheters, surgery and widespread antibiotic usage. Broad-
spectrum antibiotics promote Candida species colonization, and dissemination 
into the bloodstream in severe infection, as antibiotics eliminate healthy 
intestinal bacteria that are important in maintaining microbial balance and act as 
a physical barrier against infection (colonisation resistance) (Saiman et al., 
2001; Kumar and Singhi, 2013). 
 
1.2 Microbial Species Interactions in Infections 
 
Infections consisting of more than one Candida species are increasing in 
prevalence and have been isolated in the bloodstream (Nace et al., 2009) and 
oral cavities (Soll, 2002; Coco et al., 2008), often occurring alongside serious 
pathologies such as HIV (Junqueira et al., 2011) and cancer (Boktour et al., 
2004). Often, C. albicans and C. glabrata are the most common species co-
isolated (Coco et al., 2008; Nace et al., 2009). Mixed Candida species 
infections are more difficult to treat than single-species infections due to 
combined pathogenic effects on the host (Silva et al., 2011) and the presence 
of drug-resistant species (Mikulska et al., 2012). Multi-species infections derive 
from the presence of multiple commensal Candida species, as the causative 
species are entirely endogenous (Jenkinson and Douglas, 2002).  
 
Mixed species carriage has been described in oral cavities (Lockhart et al. 
1999) but Candida species are carried at a range of diverse sites including the 
intestinal tract and the vagina (Underhill and Iliev, 2014), and in patients with 
different underlying risk factors (Li et al., 2007). This indicates that Candida 
species will form ecological interactions in a range of different host 
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environments under different abiotic conditions, which are likely to impact on 
pathogenesis and the evolution of drug resistance (Jenkinson and Douglas, 
2002). Inter-specific competition in host niches usually occurs for limiting 
resources and for space (Payne et al., 2003). Differences in pathogen glucose 
metabolism have influenced competition outcomes in mixed Candida-bacterial 
species environments (Basson, 2000), but the effects of resources on mixed 
Candida species interactions in host environments were not explored.  
 
Resources are important in host environments as host diet has been shown to 
cause rapid changes in commensal microbial community structure (David et al., 
2014) and competition for resources can occur between host cells, pathogens 
and commensals (Smith and Holt, 1996). Ecological interactions that are 
influenced by spatially and temporally heterogeneous resource levels in 
different host sites and patients, can influence pathogenesis. In competition 
between commensal bacterial species, species abundance is controlled by 
resource use efficiency and the number of resources available (Freter et al., 
1983). Bacteria can evolve strategies to become better competitors in natural 
communities, for example through toxin production, a mechanism of 
interference competition (Hibbing et al., 2010). Competitive interactions can 
also be described as exploitative due to differential rates of resource uptake 
and growth rates of competitors. These types of interactions are antagonistic as 
competitor growth is inhibited; alternatively, microbial species can interact 
synergistically by production of growth-promoting molecules that increase 
pathogenesis (Harrison, 2007).  
 
Species interactions may be modulated by the host immune response 
(Pedersen and Fenton, 2007; Smith, 2007), affecting pathogen community 
structure and the outcome of infections if competitors differ in virulence or drug 
resistance (Lello et al., 2004). Reciprocally, pathogen interactions can influence 
host fitness and affect activation of host immunity, as well as depleting host 
resources to indirectly affect growth of microbial competitors (Pedersen and 
Fenton, 2007). The interactions between pathogen resource competition, 
metabolism and host immunity remain to be studied in detail for mixed-species 
fungal infections.  
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1.3 Laboratory Evolution of Microbial Species 
 
Experimental evolution has been used to study long-term adaptation of model 
bacterial and yeast species, but laboratory evolution of non-model pathogenic 
fungal species lacks research. Experiments with Escherichia coli and yeast 
have studied adaptation to defined nutrient environments (Lenski et al., 1991; 
Ferea et al., 1999) and evolution of competitor interactions (Turner et al., 1996). 
Yeast can be evolved under controlled experimental conditions via sequential 
batch cultivation to generate mutants resistant to stresses such as high 
concentrations of nickel (Küçükgöze et al., 2013), salt and oxidative stress 
(Dhar et al., 2012). Some model bacterial species (E. coli, Pseudomonas 
aeruginosa and Salmonella typhimurium (Buckling et al., 2009)) that have well 
characterised genetics and molecular biology are also human pathogens 
(MacLean et al., 2010).  
 
A few studies have described evolution of antibiotic resistance in non-model 
pathogenic bacteria, such as Mycobacterium tuberculosis (Gagneux et al., 
2006), Staphylococcus aureus (Nagaev et al., 2001) and Streptococcus 
pneumoniae (Rozen et al., 2007), and evolution of fungal pathogens of 
amphibians, plants and insects via in vitro (Jeon et al., 2013; Voyles et al., 
2014) or in vivo serial passaging (Valero-Jiménez et al., 2017). Experimental 
evolution of fungal human pathogens is limited, apart from a few studies of 
antifungal resistance evolution in Saccharomyces cerevisiae (Anderson et al., 
2003) and C. albicans (Cowen et al., 2000; Vincent et al., 2013). More research 
is needed to understand adaptation of fungal human pathogens under different 
environmental conditions of relevance to the host.  
 
1.4 Candida Species Biology and Epidemiology 
 
For completeness, we now provide more details on the biology, epidemiology 
and drug resistance of Candida species. The Candida genus is composed of 
more than 150 yeast species with 15 of these identified as pathogens of 
humans (Henry-Stanley et al., 2005; Yapar, 2014). C. albicans is responsible for 
approximately 75% of infections (Jenkinson and Douglas, 2002), particularly 
systemic infections (candidemia), but C. glabrata is the second most commonly 
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identified Candida species in intensive care units and candidemia surveys 
(Odds, 1996; Henry-Stanley et al. 2005). Recently, C. auris has been classified 
as an important emerging pathogen due to its global spread and multi-drug 
resistance (Chowdhary et al., 2017). C. albicans and C. glabrata are classified 
in the subphylum Saccharomycotina of the hemiascomycetous yeasts 
(Diezmann et al., 2004) (phylum Ascomycota (Hendriks et al., 1989)), but are 
distantly related, as C. albicans is classified as a CTG clade yeast, whilst C. 
glabrata (formally denoted Torulopsis glabrata) and S. cerevisiae are post-
whole genome duplication (WGD) yeasts (Figure 1.1) (Barns et al., 1991; 
Marcet-Houben and Gabaldón, 2009; Roetzer et al., 2011). CTG clade fungal 
species use the CUG codon to encode serine instead of the universally-coded 
leucine (Sugita and Nakase, 1999; Santos et al., 2011). A whole genome 
duplication event occurred in the ancestor of C. glabrata and S. cerevisiae, 
followed by subsequent loss of paralogous genes in the two species (Dujon et 
al., 2004).  
 
C. glabrata shares a close evolutionary relation to the non-pathogenic yeast 
Saccharomyces cerevisiae (Barns et al., 1991; Dujon et al., 2004) but has 
evolved adaptations to survive in the human host and exist as an opportunistic 
pathogen, due to prolonged starvation survival, shorter generation times, stress 
resistance and loss of metabolic genes due to its obligate association with the 
host (Roetzer et al., 2011; Rodrigues et al., 2014). Unlike S. cerevisiae, C. 
glabrata is not known to undergo sexual reproduction (Dujon et al., 2004).  
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Figure 1.1. Phylogeny of the Saccharomycotina subphylum of the 
hemiascomycetes (yeasts). This figure is taken from Figure 1a of Roetzer et al. 
(2011) and shows evolutionary distance between C. albicans, C. glabrata and S. 
cerevisiae (circled in red). C. albicans is found in a separate branch of the tree with 
CTG clade yeasts, including other species of the Candida genus. C. glabrata shows a 
closer evolutionary relation to species of the Saccharomyces genus than those of the 
Candida genus as it is descended from an ancestor that underwent a random whole 
genome duplication (WGD) event. 
 
C. albicans and C. glabrata show distinct differences in their biology and 
virulence (Fidel et al., 1999). Both species form yeast cells but those of C. 
glabrata are significantly smaller than C. albicans. On SDA (Sabouraud 
Dextrose Agar), C. glabrata forms smooth, shiny colonies whereas C. albicans 
forms flatter, larger colonies with a rougher morphology (Figure 1.2). C. 
albicans is a diploid species that exhibits dimorphic growth due to formation of 
yeast cells and filamentous hyphal elements, as well as pseudohyphae 
(elongated cells) (Brunke and Hube, 2013) that aid its tissue colonisation and 
invasion stages during infection (Sudbery, 2011). In contrast, C. glabrata is a 
haploid species (Whelan et al., 1984) and grows only as yeast cells (Fidel et al., 
1999). The two species differ in their virulence factors and infection strategies 
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as both species produce adhesins for attachment to host cells, but C. albicans 
causes greater host damage, triggers a greater host inflammatory response and 
has greater metabolic flexibility (Brunke and Hube, 2013). In contrast, C. 
glabrata shows greater intracellular survival and persistence but is more 
metabolically specialised to specific host niches in in vitro studies. Co-infection 
by the two species may allow C. glabrata to access a greater range of nutrients 
due to tissue destruction by C. albicans, or allow systemic dissemination.    
 
 
Figure 1.2. Colony morphology of C. glabrata (left) and C. albicans (right) on SDA 
(Sabouraud Dextrose Agar). 
 
Candida glabrata is a pathogen of great clinical importance, as it is associated 
with a greater than 50% death rate and high resistance to the antifungal drug 
fluconazole (Fidel et al., 1999; Gudlaugsson et al., 2003; Pfaller et al., 2012). 
Although Fidel et al. (1999) described fluconazole use as a main cause of 
increased prevalence, Diekema et al. (2012) reported increased C. glabrata 
prevalence in hospital-associated candidemia without increased resistance over 
a three-decade study. C. glabrata is a non-pathogenic component of the healthy 
microbiota (Fidel et al. 1999; Li et al. 2007) although increased C. glabrata 
commensal colonisation and infections have been associated with 
immunosuppression, antibiotic usage, dentures and aging (Li et al. 2007; 
Malani et al. 2010), with C. glabrata-associated candidemia exhibiting global 
geographical variation (Guinea, 2014). C. glabrata affects a diverse range of 
clinical patients including those with cancer (Farmakiotis et al., 2014), HIV 
(Diamond, 1991) and diabetes (Goswami et al., 2006). Diabetes is a common 
risk factor for C. glabrata infections (Fidel et al., 1996), which is concerning as 
diabetes now affects nearly 1 in 11 adults (WHO, 2016) 
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Antifungal resistance across the main classes of antifungals is increasing in 
Candida species infections and poses challenges to clinical therapy (Sanglard, 
2016). As human and fungal cells share structural similarities due to their close 
evolutionary relation within the eukaryotes (Baldauf et al., 2000), it remains a 
challenge to identify novel antifungal drug targets to specifically target fungal 
cells (Anderson, 2005). The main classes of antifungal drugs include the azoles 
(fluconazole), echinocandins, polyenes and nucleoside analogues (flucytosine) 
which all target the fungal cell wall or membrane sterol and ergosterol 
components and slow growth (fungistatic agents: fluconazole and flucytosine) 
or kill cells (fungicidal agents: echinocandins and polyenes) (Odds et al. 2003; 
Mikulska et al., 2012). The main mechanisms of drug resistance amongst 
Candida species include drug efflux, altered expression or affinity of the drug 
target, or changes in cell metabolism (Sanglard, 2016). Azoles have the 
greatest use in the clinic, which has led to widespread emergence of non-
albicans species with intrinsic resistance (Mikulska et al., 2012).  
 
C. albicans is intrinsically susceptible to the azole drug fluconazole and the 
echinocandins and has low levels of resistance (Cleveland et al., 2012). In 
contrast, C. glabrata has intrinsic fluconazole resistance and rates of acquired 
resistance have increased over time (Pfaller et al., 2009; Sanglard, 2016). As a 
result, echinocandins are often used as a first-line therapy, but acquired 
resistance in the clinic is increasing (Alexander et al., 2013). This poses an 
important clinical challenge, so the dynamics of adaptation and mechanisms of 
resistance require further study.  
 
1.5 Thesis Aims and Outline 
 
In this thesis, we investigated the influence of resource levels and pathogen 
metabolism on the ecology and evolution of single and mixed-species Candida 
infections, using C. albicans and C. glabrata, which are the species most 
commonly isolated in infections. 
 
Firstly, in Chapter 2, we investigated whether resource levels impact on the 
outcomes of mixed-species competition in clinically relevant environments 
limited by a single carbon source. C. albicans and C. glabrata are co-isolated as 
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commensals and in mixed-species infections in different body sites and host 
patients, but ecological interactions and their stability have not been explored at 
different resource levels in physiological conditions. We studied how resources 
influence species’ competitive abilities in short and long-term competition 
experiments in synthetic urine media and variation in competitive outcomes with 
different clinical species strains. 
 
Next, in Chapter 3, we investigated the types of interactions formed between C. 
albicans and C. glabrata clinical strains in an invertebrate host infection model. 
Microbial competitors can interact antagonistically or synergistically in infections 
but the diversity of interactions and impact on host survival have not been fully 
characterised in mixed-species fungal infections. We studied mixed-species 
Candida interactions for a set of clinical strain combinations, monitoring host 
survival, pathogenicity and virulence in the wax moth larval model Galleria 
mellonella.  
 
We then focused, in Chapter 4, in more detail on different clinical strains of C. 
glabrata and explored growth properties at different resource levels and the 
influence on evolution of antifungal resistance. C. glabrata is known to colonise 
multiple body sites and patients with different underlying risk factors, therefore 
different strains are likely exposed to different resource environments. As a 
consequence, different pathogen growth strategies may influence antifungal 
susceptibility and adaptability. We measured growth kinetic parameters across 
a set of C. glabrata clinical strains and compared the virulence of contrasting 
strains and their abilities to adapt to antifungal caspofungin treatment over 
laboratory experimental evolution. 
 
Finally, in Chapter 5, we explored the fitness costs and adaptations to 
antifungal treatment in C. glabrata. C. glabrata is known to develop antifungal 
resistance in the clinic but the dynamic process of adaptation and repeatability 
across replicate populations under controlled conditions is unknown. We 
studied phenotypic adaptations in experimentally-evolved populations of a lab 
reference strain of C. glabrata and investigated the presence of sub-population 
heterogeneity in resistant populations. 
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This thesis will end with a discussion in Chapter 6, describing the overall results 
of the thesis and their significance, as well as perspectives on future research 
directions.  
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2. Chapter 2: Population Dynamics of In vitro Resource 
Competition between C. glabrata and C. albicans in 
Clinically Relevant Environments 
 
2.1 Introduction 
 
The human body is host to several microbial communities, collectively known as 
the microbiota, consisting of bacterial and fungal commensals across sites 
including the gastrointestinal, oral and urino-genital tracts (Pelag et al. 2010; 
Saleem 2015). This community is vital in maintaining human health and 
performs several important functions of which “colonisation resistance”, a 
physical barrier against invading pathogens, is particularly important (Payne et 
al. 2003). Although studies of the human microbiota largely focus on bacterial 
species, there remains an important, largely under-studied part consisting of 
fungal commensals: the ‘mycobiota’ (Underhill and Iliev 2014), which colonise 
the skin, mucosal surfaces and a range of organs. Candida species make up a 
large component of the mycobiota, composing approximately 25% of all fungal 
genera in the colon and 50% in the vagina (Underhill and Iliev 2014; Figure 1) 
and fungal dysbiosis has also been attributed to diseases such as IBD 
(Inflammatory Bowel Disease) (Ott et al., 2008). The ecological dynamics of 
these mixed-species fungal communities remain to be fully characterised.  
 
It is important to study ecology and evolution of the human microbiome as 
competition for resources occurs during niche construction and dynamic 
community changes can predispose infection (Dethlefsen et al., 2006; Peleg et 
al., 2010). The microbiota differs between individuals due to various host-
related factors; recent studies have detected rapid changes in community 
structure due to diet (David et al., 2014). Community dynamics may not be 
stable over short and long-term timescales due to changes in resource supply 
and consequent selection for strains with growth advantages. Changes in 
communities can cause shifts in microbial species or abundances that can lead 
to disease (Marchesi et al., 2016).  
 
Previous studies to investigate microbial community dynamics in the lab have 
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focused on competition for resources between non-pathogenic strains of 
Escherichia coli (Turner et al., 1996; Elena and Lenski, 1997) or 
Saccharomyces cerevisiae (MacLean and Gudelj, 2006) in simple, resource-
limited environments. These experiments studied competition between 
genotypes on a single limiting resource in minimal media and described stable 
co-existence. This was possible in seasonal environments maintained in batch 
cultures, whereby resources are supplied and are then depleted throughout a 
defined competition period (Rainey et al., 2000).  
 
During competition for a limiting resource, selection can maintain diversity 
through a mechanism know as negative frequency dependence or balancing 
selection. Genotypes are selected when they are at low frequency in a 
population but are disadvantaged when common (Haldane and Jayakar, 1963; 
Feldgarden et al., 2003). Stable co-existence is predicted at the genotypic 
frequency at which fitness of the two genotypes is equal, a stable equilibrium 
point (Antonovics and Kareiva, 1988); this is presented graphically in Figure 
2.1. Several studies have described short-term negative frequency dependence 
as a predictor of long-term, stable co-existence (Ayala and Campbell, 1974; 
Rainey et al., 2000; Feldgarden et al., 2003; Vellend, 2010) and stable 
polymorphism maintenance has been experimentally verified over serial 
transfers (Turner et al., 1996) and in long-term experimental evolution (Elena 
and Lenski, 1997). It remains to be investigated whether negative frequency 
dependence allows stable co-existence of pathogenic species in clinically-
relevant environments. 
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Figure 2.1. Example plot of negative frequency-dependent selection and 
predicted species co-existence. Relative fitness of one competitor against another in 
a single resource environment is usually described by the ratio of the Malthusian 
parameters (logarithmic changes in densities of the two competitors) over a single 
season (24 hours) of competition (Lenski et al., 1991). This is calculated for 
competition mixtures of two competitors mixed together in different ratios. The 
relationship between fitness and competitor frequency is described by a negative linear 
relationship shown by the black line (Turner et al., 1996; Rainey et al., 2000) as 
competitors are selected for when rare but are less fit when common. Co-existence is 
predicted for the competitor frequency when neither competitor has a fitness 
advantage (relative fitness = 1.0; grey horizontal line), shown by the dotted grey line 
and red circle. It is predicted that competitor frequencies in mixed suspensions will 
converge towards the predicted stable co-existence point when serially transferred 
over multiple seasons. 
 
Species interactions and ecological dynamics are particularly important to study in 
Candida species infections due to the rise of multi-species infections. Multi-species 
candidemia (MSC) has been reported as representing 2.8-8.0% of all bloodstream 
candidemias, of which the most common species combination (37.5% of patients 
with MSC) was Candida albicans/ Candida glabrata (Nace et al., 2009). These 
infections pose a great threat to healthcare, particularly as they occur alongside 
serious pathologies such as cancer (Boktour et al., 2004) and HIV (Patel et al., 
2012). In addition, bloodstream infections can form polymicrobial communities 
including more than one Candida species alongside bacterial species (Klotz et al., 
2007). It is within these environments that competitive interactions occur that 
contribute to pathogenesis. Kirkpatrick et al. (2000) studied interactions between 
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clinical isolates of two similar species - C. dubliniensis and C. albicans- that occur 
together in oropharyngeal candidiasis, using in vitro broth and biofilm conditions. 
Another study (Thein et al., 2007) investigated competitive interactions between C. 
albicans and C. krusei in dual-species biofilms. These studies show that competitive 
interactions can be quantified in dual Candida species competitions, which can be 
applied to investigate the effect of resource levels on competition dynamics between 
C. glabrata and C. albicans.   
 
2.2 Aims of the Chapter 
 
In this chapter, we aim to extend the work of Nilsson (2012) and Beardmore et al. (in 
prep), which addressed short term in vitro resource competition between drug-
resistant C. glabrata and drug-sensitive C. albicans in a simple medium. We focus on 
resource competition between these two species at different glucose concentrations 
in the absence of drug and explore the population dynamics of short and long-term 
competition in clinically relevant media. We address three aims: 
 
1) To test whether variation in environmental resources in clinically relevant 
environments affects ecological dynamics within dual Candida species 
environments.  
 
2) To investigate whether short-term negative frequency-dependent changes in 
community composition are predictive of long-term population dynamics.  
 
3) To test whether competitive abilities for resources are ubiquitous across 
strains of a species.  
 
We studied in vitro competitions between C. glabrata and C. albicans for a 
range of limiting glucose concentrations and initial species ratios in Synthetic 
Urine media (Domergue et al., 2005; Uppuluri et al., 2009) over one-season to 
investigate competition dynamics in clinically-relevant media. Candida species 
are increasingly the cause of urinary tract infections in hospitals for which non-
albicans Candida species, particularly C. glabrata, compose approximately half 
of Candida urinary isolates (Fidel et al., 1999). Multi-species infections 
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containing C. glabrata and C. albicans are particularly prevalent, but the 
competitive dynamics within this environment have not been characterised.  
Whilst virulence of the individual species has been studied in SU media (Domergue 
et al., 2005; Uppuluri et al., 2009), here we study inter-specific competition in a 
“nutritionally poor medium supplemented with urine-specific salts and urea” 
(Domergue et al., 2005), in which the sole carbon source is glucose.  We compare 
short-term competitions with long-term competitions extended via serial transfers and 
also test for frequency and density dependence of competitive outcomes. Finally, we 
test a set of C. glabrata clinical strains in competition with C. albicans, for ubiquity of 
the species-specific resource responses.  
 
 
2.3 Materials and Methods 
 
2.3.1 Candida Strains and Growth Conditions 
 
Wild-Type reference strains used were Candida glabrata ATCC 2001 (Table 
A.1.2.S1) and Candida albicans ACT1-GFP (SBC153) (Milne et al., 2011) 
(Nilsson 2012, 12.1; Beardmore et al. (in prep)). C. albicans SBC153 has a 
GFP-tagged ACT1 gene and integrated nourseothricin resistance cassette but 
is otherwise isogenic to the clinical strain SC5314 from a “patient with 
disseminated candidiasis” (Gillum et al., 1984). See Table A.1.2.S1 for C. 
glabrata clinical strains. Glycerol stocks (15% v/v) of each strain were 
maintained at -80oC and were streaked on YPD (yeast peptone dextrose) agar 
plates (2% w/v bacteriological peptone, 1% w/v yeast extract, 1.8 % w/v agar, 
2% w/v glucose (A.1.1 Supplementary Materials and Methods)) and 
maintained at room temperature. Overnight cultures were prepared as 
previously described (Nilsson 2012, 12.1; Beardmore et al. (in prep)) via 
inoculation of a single colony into YPD broth per culture, and were grown in an 
orbital shaking incubator at 30oC and 180 rpm for 18-24 hours.  
Overnights were centrifuged and washed once in autoclaved distilled, de-
ionised water before re-suspension in the assay medium, to prepare growth 
assays. Synthetic Complete media (yeast nitrogen base (YNB) supplemented 
with amino acids: A.1.1 Supplementary Materials and Methods) was 
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sterilised by autoclaving and Synthetic Urine, as prepared previously (Griffith et 
al., 1976, cited by Martino et al., 2003; Domergue et al., 2005: Supplementary 
Materials; Uppuluri et al., 2009), was filter-sterilised. Filter-sterilised glucose in 
water was later added to media to prepare final glucose concentrations.  
2.3.2 One-Season Resource Competition in Synthetic Urine Media 
 
Competition between C. glabrata 2001 and C. albicans GFP in Synthetic 
Complete (SC) medium at 0.1% w/v glucose was performed as previously 
described (Nilsson, 2012, 12.3; Beardmore et al. (in prep)). We used ready-
plated CHROMagar Candida medium (BD Biosciences, Oxford, UK: Product 
code 257480; Nilsson, 2012, 12.6) for species identification (Figure A.1.2.S1).  
 
Synthetic Urine media (Griffith et al., 1976, cited by Martino et al., 2003; 
Domergue et al., 2005: SOM; Uppuluri et al., 2009), a “nutritionally-poor 
medium supplemented with urine-specific salts and urea” (Domergue et al., 
2005), was prepared as previously described but was supplemented with 
glucose at 6 different concentrations: 0.05, 0.1, 0.5, 1, 2 and 4% w/v. Overnight 
cultures of the reference strains were each diluted in the assay medium to 
approximately 6-8x106 cells/ml, estimated via haemocytometer colony counts. 
Initial cell densities were two times the desired starting density for competition, 
as cell suspensions were diluted by a factor of two within the assay medium in 
the 96-well plate.  Five species ratios were prepared as previously described for 
SC media: %C. glabrata: %C. albicans- 90:10, 70:30, 50:50, 30:70, 10:90 
(Nilsson, 2012, 12.3).  
 
Competition experiments were run in sterile 96-well flat-bottom polystyrene 
microtiter plates (Greiner BioOne; Product code: 655161) (see Figure 
A.1.2.S2a for details on plate set-up). The plate was sealed with transparent 
film with sterile holes punctured for aeration (Nilsson, 2012; 12.3) and was 
incubated in an orbital shaking incubator (180 rpm) for 24 hours at 30oC. 
Competition for ten times initial cell density was performed as above for 0.05, 1 
and 4% w/v glucose concentrations with initial cell density set to approximately 
6x107 cells/ml. Competition for one thousand times lower initial cell density was 
performed in 0.1% w/v glucose with initial cell density set to 6.5 x 103 cells/ml. 
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Initial C. albicans fractions were determined via dilution in PBS and plating on 
each of three CHROMagar plates (100-200 colonies per plate). After 24 hours, 
cells within triplicate wells were re-suspended and mixed via multi-channel 
pipetting, prior to dilutions. 9 CHROMagar plates were spread per species ratio 
(3 plates per replicate well). Plates were incubated at 30oC for 48-72 hours 
before colony counting and calculation of C. albicans fractions and viable 
CFU/ml counts. 
 
2.3.3 Long-Term Competition in Synthetic Urine Media 
 
2.3.3.1 Volumetric Serial Transfers 
 
Competition between C. glabrata and C. albicans was extended over time in low 
glucose (0.1% w/v) and intermediate glucose (1% w/v) for a high initial fraction 
(0.70) of C. albicans. Each species was diluted in the assay medium to 
approximately 5-6 x106 cells/ml. Long-term competitions were run in 
intermediate glucose (1% w/v), for initial C. albicans fractions of 0.20, 0.50 and 
0.80. For 0.20, three approximate initial densities were prepared: 3.25 x 106 
cells/ml, 6.50 x 106 cells/ml and 1.30 x 107 cells/ml. See Figure A.1.2.S2b for 
set-up. Growth conditions over the first season matched those of one-season 
competitions. After 24 hours, fresh media/ water was added to the subsequent 
row of the 96-well plate (Figure A.1.2.S2b). Overnight cells were re-suspended, 
mixed and serially diluted (1 in 30) for transfer to the next season (E. Cook, 
2014, pers.comm.). Monocultures and co-cultures were plated on CHROMagar 
(same replication as one-season) from initial until day 5, then approximately 
every 2 days until C. albicans was excluded. After 10 seasons, cell suspensions 
from the frequency/density-dependent experiment were frozen at -80oC in 15% 
v/v glycerol.  
 
2.3.3.2 Cell Density Serial Transfers 
 
Long-term competition in 1% w/v glucose was run in an independent 
experiment where initial cell density of each season was controlled via 
haemocytometer counts (total cell count). The same high initial fraction of C. 
albicans was set as in the volumetric transfers (0.70) and initial cell density of 
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each species was set to 6.5 x 106 cells/ml, prior to 2-fold dilution in the assay 
medium within the 96-well plate. The 96-well plate was set up in the same way 
as described above. After 24 hours of competition, the competition suspensions 
within the 3 replicate wells of the 96-well plate were thoroughly re-suspended 
and mixed via scraping the well bases with the pipette tip and pipette mixing. An 
appropriate aliquot of cells from each well was diluted in PBS, counted with the 
haemocytometer and diluted to a final concentration of 3.25 x 106 cells/ml within 
the assay medium in fresh wells of the plate for transfer to the next season. This 
protocol was repeated every 24 hours up until day 7 so that each season began 
with a constant density. As above, monocultures and co-cultures were plated on 
CHROMagar at the end of each season from days 1-5 and day 7. Viable end-
of-season colony counts were compared with haemocytometer cell counts.  
 
2.3.4 Clinical Strain Competitions 
 
One-season and serial transfer competitions were performed as above, but just 
for one initial species ratio. Competitors were diluted to an initial cell density of 
approximately 6.5 x 106 cells/ml. Initial and final competition suspensions were 
plated on CHROMagar as described above because all C. glabrata strains 
formed similar pink colonies, distinguishing them from C. albicans. 
 
One-season competitions involved all 5 strains in Table A.1.2.S1, paired with C. 
albicans GFP set to 10:90 initial ratio. The assay medium was 0.05% w/v 
glucose SC, instead of SU medium as strains were isolated from different host 
sites. C. glabrata NCPF 3605 and 3309 were competed against C. albicans 
GFP at 4% w/v glucose for five seasons of volumetric serial transfers.  
 
2.3.5 Competitions in Sterile Culture Tubes 
 
One-season and serial-transfer competitions in 0.05% w/v glucose SC and SU 
medias used 5-ml sterile culture tubes with two-position cap (Greiner BioOne; 
Product code 115 261). The tubes were incubated under the same conditions 
as for 96 well plates, with caps loosened. Change in C. albicans fraction was 
measured over one-season competition between the reference strains at 
different final tube volumes, representing fold increases in 96-well plate 
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volumes (Table 2.3). The tubes were set up as of wells of a 96-well plate 
(described above) using scaled volumes of the two species but with the same 
initial cell densities. Initial species ratio was set to 50:50. Long-term competition 
was run for 5 times the final 96-well plate volume over serial transfers (1 in 30 
dilution maintained).  
 
2.3.6 Data Analysis and Statistics  
 
Data was plotted in Excel and statistical analyses were completed in Excel or R 
(R version 3.3.2; R Core Team, 2016). C. albicans relative fitness in one-
season competitions was calculated as the log ratio of the strains’ Malthusian 
parameters as described previously using competition plating (Lenski et al., 
1991; Turner et al., 1996) by the following equation:  
 
Relative fitness of C. albicans =  
 
This was calculated for five initial fractions of C. albicans (competition ratios of 
the two species) using initial and final densities of each species calculated from 
colony counts on CHROMagar plates. Initial density was fixed as the average of 
the three initial CHROMagar plates, for each initial competition ratio. 
CHROMagar medium has previously been verified (Odds and Bernaerts, 1994) 
as a reliable method of detecting Candida species from clinical samples, due to 
differential enzymatic reactions with chromogenic substrates in the agar.  
 
We used a general linear model in R (R version 3.4.3; R Core Team, 2017) to 
test the main effects of C. albicans fraction, glucose concentration and their 
interaction on relative fitness of C. albicans, when in competition with C. 
glabrata in Synthetic Urine media, followed by model reduction to include only 
the significant effects. We used the R-package ‘plotrix’ (Lemon, 2006) to show 
all data in a single plot with fitted linear trendlines (Figure A.1.2.S3). We 
checked that the assumptions of normality and homoscedasticity were met by 
visualising the distribution of standardised residuals and plotting residuals 
against model fitted values. 
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The least-squares linear regression of relative fitness of C. albicans against 
initial fraction, was plotted in Excel and the slope and R-squared correlation co-
efficient were calculated for competition in each glucose concentration. Using 
the equation of the regression line, the C. albicans competitor fraction at which 
co-existence was predicted was calculated when relative fitness was equal to 
one. The significance of the regression slope was calculated in Excel (Zaiontz, 
2015). When co-existence was not predicted (the regression line did not 
intersect relative fitness = 1) the significance of C. albicans relative fitness 
above or below a relative fitness of 1 was calculated in one-sample tests in R. 
Samples were first tested for normality using a Shapiro-Wilk test and if found to 
be normally distributed then a one-sample t-test was used, otherwise a 
Wilcoxon signed-rank test was used. Both one sample tests were two-tailed to 
robustly test for changes in C. albicans relative fitness in either direction. 
 
To detect significant differences between initial and end C. albicans fractions in 
single-season competition experiments, two-sample, two-tailed unpaired t-tests 
were used (as in Beardmore et al. (in prep)) when initial and end fraction 
populations were normally distributed (Shapiro-Wilk test) and population 
variances were equal. When variances were not equal, Welch’s two-sample t-
test was run instead. When populations were non-normally distributed, non-
significant skew or kurtosis results justified use of t-tests (Crawley et al., 2007). 
Detection of significant skew in a small number of populations was due to 
random measurement error within small samples and would not be expected to 
occur in infinitely large populations. In addition, the t-test has been reported to 
be robust to non-normality (McDonald, 2014, pp.126-130).   
 
One-way ANOVA followed by Tukey’s post hoc test was used to deduce 
significant daily changes in C. albicans fraction in long-term competitions of C. 
glabrata and C. albicans at 1% w/v glucose. 
 
To test for significant differences in C. albicans relative fitness between different 
strains of C. glabrata, we used R (R version 3.4.3; R Core Team, 2017) and the 
package ‘plotrix’ (Lemon, 2006) to compare one-way ANOVA and Kruskal-
Wallis tests and to use Tukey’s HSD post hoc test to deduce significant pairwise 
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differences. The data was presented in box-plots with means and standard error 
bars overlain.  
 
 
 
2.4 Results  
 
2.4.1 One-Season Glucose Competitions in Mixed-Candida Species 
Environments 
 
Firstly, we replicated one-season competition between C. glabrata strain ATCC 
2001 and C. albicans ACT1-GFP in low glucose (0.1% w/v) Synthetic Complete 
(SC) medium, to ensure that we could replicate the results of Nilsson (2012) 
and Beardmore et al. (in prep). Previously, a significant increase in C. albicans 
frequency for five initial starting fractions was described over 24-hour 
competition. In support, we found that fitness of C. albicans relative to C. 
glabrata was significantly greater than 1 for all initial fractions (Figure 2.2(a); 
Table A.1.2.S2), meaning that C. albicans was consistently fitter than C. 
glabrata in short-term competition at this glucose concentration. The increase in 
C. albicans density in each competition mixture determined by CHROMagar 
plating (green colonies) is shown in Figure 2.2(b). We fitted a least-squares 
linear regression to the relative fitness data to see whether our data showed 
frequency-dependence and found that relative fitness was significantly 
negatively correlated with initial C. albicans fraction (Figure 2.2(a)), although 
co-existence was not predicted to occur at any species ratio.  
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Figure 2.2. One-season competition between C. glabrata and C. albicans at low 
glucose concentration in Synthetic Complete (SC) medium. (a) Fitness of C. 
albicans relative to C. glabrata over one season (24 hours) of competition in 0.1% w/v 
glucose SC is calculated as the ratio of their Malthusian parameters (Lenski et al., 
1991). Relative fitness assays were performed for mixtures of the two species at five 
different ratios (initial C. albicans fractions plotted). N = 9 for each initial fraction. The 
black continuous line is the best-fit least-squares linear regression, with the R-squared 
correlation coefficient shown. The slope of the line is significant (slope = -0.58, t = -
2.60, df = 43, P = 0.01279). The dotted line indicates a relative fitness of 1 and would 
predict stable co-existence if the regression line intersected this line at a specific 
fraction (see Figure 2.1). Relative fitness of C. albicans is significantly greater than 1 
for all species mixtures (Wilcoxon signed-rank test: P < 0.01; see Table A.1.2.S2 for 
full statistics). (b) CHROMagar plates showing change in C. albicans fraction for five 
initial frequencies. 1 plate is shown for each initial and final competition suspension. C. 
(a) 
(b) 
0.1% gluc SC 
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glabrata colonies are purple and C. albicans colonies are green. Mean frequencies (%) 
of C. albicans for initial populations are shown. 
 
 
2.4.2 Competition in SU Media: CHROMagar Plating 
 
To investigate whether these competitive outcomes are applicable to Candida 
species competitions in more clinically relevant environments, we completed 
competitions between C. glabrata and C. albicans in Synthetic Urine medium at 
each of six different glucose concentrations, starting with five initial fractions of 
C. albicans. We used CHROMagar plating to determine species densities. 
Firstly, we tested whether initial C. albicans fraction, glucose concentration and 
their interaction had a significant effect on relative fitness of C. albicans, using a 
general linear model. Overall, the model was significant (adjusted R2 = 0.2258, 
F3, 259 = 26.48, P = 5.699e-15) but the interaction term was non-significant (P = 
0.2090). This showed that the trend in C. albicans relative fitness across 
different initial fractions was not significantly influenced by glucose 
concentration (Figure A.1.2.S3). We removed the interaction term from the 
model to achieve an improved fit for the data (adjusted R2 = 0.2241, F2, 260 = 
38.84, P = 1.744e-15; AIC (main effects model) = 679.21, AIC (main effects and 
interaction model) = 679.61) and found significant independent effects of initial 
C. albicans fraction (P = 7.131e-10) and glucose concentration (P = 4.826e-09) 
on relative fitness of C. albicans (Figure 2.3).  
 
At low glucose concentrations (0.05% and 0.1% w/v), C. albicans relative 
fitness was significantly greater than 1 over one-season competition, for all 
initial fractions apart from the highest at 0.05% (Figure 2.3; Table A.1.2.S3), 
and at the lowest two fractions and the highest fraction at 0.1%. This shows that 
C. albicans was more fit than C. glabrata for competition at low glucose. 
Relative fitness was a significant negative function of C. albicans fraction at 
0.05%, but not at 0.1%, glucose. 
 
As glucose concentration was increased (0.5-2% w/v), C. albicans was less fit 
than C. glabrata, when starting from a high frequency in the population. Relative 
fitness was a significant decreasing function of C. albicans fraction for all three 
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glucose concentrations (Figure 2.3; Table A.1.2.S4) and species co-existence 
could be predicted for the C. albicans fraction at which the regression line 
intersected with a relative fitness of 1 meaning that both species were equally 
fit, as described previously (Turner et al., 1996). This C. albicans equilibrium 
fraction was 0.59 for 0.5% glucose, 0.49 for 1% glucose and 0.32 for 2% 
glucose (Figure 2.3). The fitted regression line shows that C. albicans is 
respectively more or less fit than C. glabrata at respective frequencies below or 
above the equilibrium fractions.  
 
At the highest glucose concentration (4% w/v), C. albicans relative fitness was 
significantly lower than 1 for the highest three initial fractions, meaning that C. 
glabrata was fitter than C. albicans in competition at these species ratios 
(Figure 2.3; Table A.1.2.S3). Relative fitness was significantly negatively 
correlated with C. albicans fraction.  
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Figure 2.3. One-season competitions between C. glabrata and C. albicans at 6 
different glucose concentrations in Synthetic Urine (SU) media. Single season 
competitions in glucose concentrations ranging 0.05-4% w/v were completed over 
single 24-hour periods for five mixtures of the two species (initial C. albicans fractions). 
Relative fitness of C. albicans is calculated as the ratio of the two species’ Malthusian 
parameters, as in Figure 2.2. N = 9 for each initial fraction at each glucose 
concentration. The black continuous line on each plot is the linear least-squares 
regression with the R-squared correlation coefficient shown for each. The slope of 
each regression is significant for all glucose concentrations, except 0.1% w/v (0.05%: P 
= 0.0009453; 0.1%: P = 0.5333; 0.5%: P = 3.005e-05; 1%: P = 1.696e-06; 2%: P = 
0.005566; 4%: P = 0.001166; Table A.1.2.S4). The dotted line on each plot indicates a 
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relative fitness of 1 and predicts stable species co-existence at 0.5 - 2% w/v glucose, 
when C. albicans has a relative fitness of 1 (see Figure 2.1). For plots in which co-
existence is not predicted: 0.05% glucose- relative fitness is significantly greater than 1 
(P < 0.05) for all initial C. albicans fractions, except 0.89; 0.1% glucose- relative fitness 
is significantly greater than 1 (P < 0.05) for the lowest two fractions and the highest 
initial fraction (P < 0.05); 4% glucose- relative fitness is significantly lower than 1 for the 
highest three initial fractions (P < 0.0001) (Table A.1.2.S3). 
 
2.4.3 Long-Term Competition Dynamics in Clinically Relevant SU Media 
 
We tested whether our short-term results, which show that C. albicans is fitter 
than C. glabrata at low glucose concentration, would lead to C. glabrata 
exclusion over long-term competition. We then investigated whether our 
predicted species co-existence, in an intermediate glucose concentration from 
one-season competition, resulted in stable equilibrium frequencies long-term. 
We selected a high initial fraction (0.70) of C. albicans for competitions with C. 
glabrata over daily transfers of a constant volume of cells into fresh media and 
plating of competition suspensions on CHROMagar. We found that C. albicans 
increased and excluded C. glabrata after 11 seasons at low glucose (0.1% w/v) 
(Figure 2.4(a) and (c)), as predicted from one-season data. At intermediate 
glucose (1% w/v), instead of reaching stable coexistence at a predicted C. 
albicans fraction of 0.49 (Figure 2.3), C. albicans rapidly decreased and was 
excluded from the population by C. glabrata after 11 days (Figure 2.4(b) and 
(d)).  
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Figure 2.4: Long-term competition of a high initial fraction of C. albicans with C. 
glabrata at low and intermediate glucose concentrations in Synthetic Urine 
media, via volumetric serial transfers. a) Low glucose concentration (0.1% w/v); b) 
Intermediate glucose concentration (1% w/v); c) Increase in C. albicans fraction on 
CHROMagar (1 replicate per day plated); d) Decrease in C. albicans fraction on 
CHROMagar. Initial C. albicans fraction was taken as the average of 3 CHROMagar 
plates, as for one-season competitions. End-of-season populations were plated daily 
a) b
) 
c) 
d
) 
        0                      1                   2                      3                      4                   5 
7                         9                          11 (Day of plating) 
0                            1                       2                       3                     4                      5 
7                              11 (Day of plating) 
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on CHROMagar (9 replicates) until day 5, after which plating was done every 2-4 days 
until day 11. SE bars are shown. Initial cell density at day 0 was 2.2 x 106 cells/ml for 
0.1% glucose and was 1.7 x 106 cells/ml for 1% w/v glucose. 
 
As C. albicans was excluded from the populations at 1% w/v glucose rather 
than co-existing with C. glabrata as predicted, we repeated the experiment with 
daily transfers of a constant density of cells. This was performed, as any 
deviation in initial cell density between seasons could have affected competitive 
pressures, meaning that initial season competition dynamics were not predictive 
of later seasons. Again, by starting with a high initial C. albicans fraction and 
plating end of season competition suspensions on CHROMagar, C. albicans 
was excluded from the populations after 7 days (Figure 2.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Long-term competition of a high initial fraction of C. albicans with C. 
glabrata at intermediate glucose concentration (1% w/v) in Synthetic Urine 
media, via cell density serial transfers. Initial C. albicans fraction was taken as the 
average of 3 CHROMagar plates, as for one-season competitions. End-of-season 
populations were plated daily on CHROMagar (9 replicates) until day 5 and then on 
day 7. Initial cell density at day 0 was 3.5 x 106 cells/ml. 
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2.4.4 Influence of Small Frequency and Density Changes on Long-Term 
Competition Dynamics 
 
Firstly, we selected three initial frequencies of C. albicans (approximately 0.20, 
0.50 and 0.80) to compete against C. glabrata in Synthetic Urine media at 1% 
w/v glucose over daily serial transfers of a constant volume of cells. C. albicans 
decreased in fraction and was excluded by C. glabrata from all 3 populations 
after 9 seasons of competition (Figure 2.6(a); Table A.1.2.S5). Next, we found 
that over small changes in initial cell density (a doubling and halving of that 
used above) for a low initial fraction, C. albicans was again excluded from the 
populations after 9 seasons of competition with C. glabrata (Figure 2.6(b); 
Table A.1.2.S5). These results support the long-term exclusion of C. albicans at 
intermediate glucose concentration.  
 
 
Figure 2.6: Long-term competitions between C. glabrata and C. albicans for 
different initial frequencies of C. albicans and co-culture initial densities. a) 
Competition at 3 different initial fractions. LF (triangles)=0.14 (initial density = 2.35 x 
106 cells/ml), IF (squares)= 0.41 (initial density = 1.9 x 106 cells/ml), HF (diamonds)= 
0.68 (initial density = 1.45 x 106 cells/ml): determined from viable counts on 3 
CHROMagar plates per ratio. One-way ANOVA tests on daily C. albicans fraction 
changes: HF: F7, 58 = 183.6, P < 2e-16 ***; IF: F7, 58= 134.3, P  < 2e-16 ***; LF: F7, 58 = 
27.23; P = 3.87e-16 ***. b) Competition at 3 different initial densities. LD (light orange, 
triangles) =9 x 105 cells/ml (initial frac = 0.20), ID (bright orange, squares) =2.35 x106 
cells/ml (initial frac = 0.14), HD (brown, diamonds) =5.05 x 106 cells/ml (initial frac = 
(a
) 
(
b
) 
  
(b)  
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0.15): determined from viable counts on CHROMagar. One-way ANOVAs: HD: F7, 58 = 
54.08; P < 2e-16 ***; ID (same as LF); LD: F7, 58 = 71.25; P < 2e-16 ***. Competition 
suspensions were plated on days 1 - 5, 7 and 9 in both experiments. Points plotted are 
averages from 9 CHROMagar plates with SE bars shown. See Table A.1.2.S5 for 
significant pairwise comparisons. 
 
 
2.4.5 Influence of Larger Density Changes on One Season Competition 
Dynamics   
 
Firstly, we investigated whether a ten-fold increase in initial cell density could 
affect one-season competition dynamics over the same set of five initial C. 
albicans fractions. By measuring the change in C. albicans and C. glabrata cell 
densities at the beginning and end of 24-hour competition, unexpectedly we 
found that at 0.05% glucose only, both species’ final densities were lower than 
their initial densities. This was likely due to error in dilution plating rather than 
cell death occurring during the experiment. This did not allow plotting of C. 
albicans relative fitness but we found that C. albicans decreased in frequency at 
all five initial fractions and this was significant for the lowest three fractions 
(Table 2.1), therefore C. albicans became less fit than C. glabrata in low 
glucose.   
 
A ten-fold higher cell density for competition at intermediate (1% w/v) (Figure 
2.7(a)) and high (4% w/v) (Figure 2.7(b)) glucose concentrations resulted in C. 
albicans relative fitness significantly lower than 1 (Table A.1.2.S3) for all initial 
C. albicans fractions, except for the lowest fraction in 1% glucose, so C. 
glabrata was more fit than C. albicans. For 1% glucose, these results contrast to 
those from ten times lower cell density (Figure 2.3), because relative fitness is 
not significantly negatively correlated with initial fraction and the regression line 
does not predict co-existence at any fraction, at ten times greater density 
(Figure 2.7(a); Table A.1.2.S4). The results at 4% glucose are similar to those 
at ten times lower density (Figure 2.3) and a significant negative frequency-
dependent effect is still observed, as the slope of the regression was significant 
(Figure 2.7(b)).  
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In contrast to a large increase in competitor density, we also tested whether 
one-thousand times decrease in initial competition density affected one season 
competition dynamics. Starting with an initial density of 103 cells/ml, C. albicans 
had a relative fitness significantly greater than 1 for all initial fractions (Figure 
2.7(c); Table A.1.2.S3), which was a stronger effect than that found at one- 
thousand times higher cell density (Figure 2.3) and C. albicans showed larger 
and more significant increases in frequency at lower density (Table 2.2). There 
was no significant negative frequency-dependent effect on relative fitness and 
the regression line did not predict co-existence (Figure 2.7(c); Table A.1.2.S4).  
 
Figure 2.7: One-season competition between C. glabrata and C. albicans at 
different glucose concentrations in Synthetic Urine medium, for large changes in 
initial cell densities of competition suspensions. Competition was tested at ten 
times the initial cell density used in Figure 2.3 and is shown for two different glucose 
concentrations: (a), intermediate (1% w/v) (b) high (4% w/v). Competition at one 
thousand times lower initial density was tested for 0.1% w/v glucose (c). Initial and end 
ratios were plated on CHROMagar. Initial cell densities (from viable colony counts) for 
all mixed species ratios were between 2.33 and 2.67 x 107 cells/ml for 0.05% w/v 
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glucose, between 2.32 and 2.71 x 107 cells/ml for 1% w/v glucose, and between 2.15 
and 2.52 x 107 cells/ml for 4% w/v glucose. Average initial cell density of co-cultures for 
one thousand times lower cell density for 0.1% glucose was 2.35 x 103 cells/ml. Data is 
plotted as relative fitness of C. albicans over 24 hours of competition and correlation 
coefficients are shown, as in Figure 2.3. The slope of each regression line is not 
significant, except for 4% glucose at ten times initial cell density (P = 0.01760; Table 
A.1.2.S4). Significance tests for C. albicans relative fitness significantly different from 1 
(Table A.1.2.S3): 1% glucose- lower than 1 for all initial fractions apart from the lowest 
(P < 0.0001); 4% glucose- lower than 1 for all initial fractions (P < 0.05); 0.1% glucose 
at one thousand times lower initial cell density- greater than 1 for all initial fractions (P < 
0.01). 
 
Table 2.1: Statistical comparisons of initial and final C. albicans fractions over 
one-season competition between C. glabrata 2001 and C. albicans GFP in 0.05 % 
w/v glucose Synthetic Urine medium at ten times greater competition density. 
Initial and final C. albicans fractions were determined from CHROMagar plating and 
averages are shown. Fractions are presented in ascending order. Values in bold show 
significance with asterisks indicating significance level: * = P < 0.05; ** = P < 0.01; P < 
0.001.  
 
0.05 % w/v glucose: 2-tailed, 2-sample t-tests 
 
Average 
initial C. 
albicans 
fraction 
 
Average 
final C. 
albicans 
fraction 
df t-value P-value 
0.136315176 0.080803335 10 2.6715 0.02343 * 
0.368573461 0.259124652 10 3.0119 0.01308 * 
0.583120393 0.398088425 10 3.0819 0.0116 * 
0.768867294 0.684041314 10 1.4942 0.166 
0.918357488 0.895937455 10 0.78295 0.4518 
 
 
Table 2.2: Statistical comparisons of initial and final C. albicans fractions over 
one-season competition between C. glabrata 2001 and C. albicans GFP in 0.1 % 
glucose Synthetic Urine medium, for initial competition cell densities of 
approximately 106 and 103 cells/ml. Initial and final C. albicans fractions were 
determined from colony counts on CHROMagar plates and averages are shown. 
Values in bold show significance with asterisks indicating significance level: * = P < 
0.05; ** = P < 0.01; P < 0.001.  
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0.1% w/v glucose: 2-sample, 2-tailed test: 106 cells/ml 
 
Initial C. 
albicans 
fraction 
Final C. 
albicans 
fraction 
df t-value P-value 
0.112864672 0.16459501 
 
10 -2.0833 0.06385 
0.2590261 0.3645866 10 -2.9794 0.01382 * 
0.4420522 0.5415211 10 -1.821 0.09862 
0.6883541 0.7164979 10 -1.0422 0.3219 
0.8499979 0.8944496 10 -1.2329 0.2458 
 
 
0.1% w/v glucose: 2-tailed, 2-sample t-tests: 103 cells/ml 
 
Average 
initial C. 
albicans 
fraction 
 
Average final 
C. albicans 
fraction 
df t-value P-value 
0.088525531 0.491319381 10 -13.605 8.899e-08 *** 
0.39497314 0.730916927 10 -10.81 7.748e-07 *** 
0.511993024 0.871003859 10 -16.552 1.353e-08 *** 
0.706162137 0.936851406 10 -8.0934 1.064e-05 *** 
0.920388091 0.987537691 10 -7.4151 2.275e-05 *** 
 
 
2.4.6 Influence of Larger Competition Volumes on One Season Population 
Dynamics 
 
To investigate the possibility of oxygen limitation causing downward shifts in C. 
albicans relative fitness, we reduced the surface area to volume ratio in the 
competition mixture by competing C. glabrata and C. albicans over single 
seasons in 5 ml culture tubes, in low glucose (0.05% w/v) SU (Table 2.3a) and 
SC (Table 2.3b) media (see Methods). This was used as a proxy for reduced 
oxygen availability with more competitors, occurring at ten times the initial cell 
density. Tubes with larger competition mixture volumes have a smaller surface 
area to volume ratio so have less capacity for gaseous exchange.  
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Measuring change in C. albicans frequency over a single season starting from 
0.50 fraction, the largest frequency increases were seen for the smallest 
competition suspension volumes with the biggest surface area to volume ratios. 
In SU media, C. albicans frequency increased by 13% for a 1.5-fold greater 
volume than in the microtiter plate whereas a 5-fold greater volume only 
resulted in a 7% increase (Table 2.3a). When the competition suspension 
volume was increased to 10 or 15 times the volume used in 96-well plate wells, 
C. albicans frequency decreased by 7%. These trends were also seen in SC 
media, as a 1.5-fold increase in volume resulted in a 19% increase in C. 
albicans frequency, compared with a 3% increase for a 3.5-fold greater final 
volume (Table 2.3b).  
 
We conclude that C. albicans is fitter in more aerobic environments, which is 
supported by the negative correlation we find between C. albicans relative 
fitness and culture tube volume in 0.05% w/v glucose media (Figure 2.8). Co-
existence is predicted when C. albicans fitness is equal to that of C. glabrata, 
which occurs in a competition volume of 1616 µl in SU (Figure 2.8a) and 545 µl 
in SC (Figure 2.8b), suggesting that C. albicans is fitter in the nutritionally 
poorer SU medium. 
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Table 2.3: Change in C. albicans fraction over one-season competition between 
C. glabrata 2001 and C. albicans GFP in 5-ml culture tubes. A range of final 
volumes was tested, representing fold increases in the final volume (150 µl) used in the 
96-well plate for competitions. A larger range was tested for SU media and the 3 
volumes with results most comparable to one-season 96-well plate data were selected 
for confirmation in SC media. Initial species ratio was set to 50:50 and initial cell 
density added to tubes was set to approximately 6.5 x 106 cells/ml (diluted 2-fold in 
media). Media glucose concentration was 0.05% w/v.  a) Competition in SU media. b) 
Competition in SC media. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fold 
increase in 
final volume  
C. albicans 
fraction 
change 
1.5 13% increase 
2.5 8% increase 
3.5 10% increase 
4 6% increase 
5 7% increase 
10 7% decrease 
15 7% decrease 
Final 
increase in 
final volume 
C. albicans 
fraction 
change 
1.5 19% increase 
2.5 8% increase 
3.5 3% increase 
a) 
b) 
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Figure 2.8. One-season competition between C. glabrata and C. albicans at a 
50:50 ratio in 0.05 % w/v glucose media, for different volumes of competition 
suspension in culture tubes. 5-ml culture tubes were used for competitions with 7 
different final volumes in SU media (a) and 3 different final volumes in SC media (b). N 
= 9 for each tube volume. Relative fitness of C. albicans is calculated as the ratio of the 
two species’ Malthusian parameters. The slope of the least-squares linear regression 
line on each plot is significant ((a) slope = -0.00053, t = -5.13, df = 61, P = 3.159e-06; 
(b) slope = -0.0018, t = -5.25, df = 25, P = 1.978e-05). Co-existence is predicted for 
competition volumes at which the regression line intersects with relative fitness of 1. 
 
2.4.7 Competitions between C. albicans and Clinical Isolates of C. glabrata 
 
To test whether C. albicans relative fitness in glucose competition is dependent 
on C. glabrata strain, we competed clinical strains of C. glabrata (Table 
A.1.2.S1) against the C. albicans reference strain in 0.05 % w/v glucose in 
microtiter plates over one season, plating the competition suspensions on 
CHROMagar. Using standard SC medium as strains were isolated from 
different host sites, we found that C. albicans relative fitness significantly varied 
in competition with different strains of C. glabrata (Figure 2.9; One-way 
ANOVA: F4, 40 = 11.94, P = 1.78e-06). C. albicans relative fitness was 
significantly greater in competition with C. glabrata strain 3605 (mean C. 
albicans relative fitness = 1.599 +/- 0.1275) than in competition with each of the 
other strains (Tukey HSD post hoc tests: 3605:2001, P = 0.0422; 3605:BG2, P 
= 0.000225; 3605:BG2Δssk2, P = 0.00231; 3605:3309, P = 0.0000007). This 
showed that C. glabrata 3605 was a poorer competitor than the other strains. C. 
albicans relative fitness was significantly greater in competition with strain 
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ATCC 2001 than NCPF 3309 (mean relative fitness: 1.273 +/- 0.1132; 0.8650 
+/- 0.0183 respectively; Tukey HSD post hoc test: P = 0.00614). C. albicans 
relative fitness was not significantly different between competitions with strains 
BG2 or BG2Δssk2, or between either of these strains and strain 2001 or 3309 
(Tukey HSD post hoc tests: P > 0.05). C. albicans was significantly more fit 
(relative fitness > 1.0) with all strains (one-sample, two-tailed t-tests: ATCC 
2001: t(8) = 2.412, P = 0.0424; BG2: t(8) = 2.4917, P = 0.0374; BG2Δssk2: t(8) 
= 5.2061, P = 0.000816; NCPF 3605: t(8) = 4.6975, P = 0.00155), except strain 
3309, with which C. albicans was less fit (relative fitness < 1.0) (one-sample, 
two-tailed t-test: t(8) = -7.3862, p = 7.721e-05).The two C. glabrata strains most 
contrasting in competitive abilities were NCPF 3605 as the poorest competitor 
(C. albicans mean relative fitness: 1.599 +/- 0.1275) and NCPF 3309 as the 
best competitor (C. albicans mean relative fitness: 0.8650 +/- 0.0183).  
 
 
Figure 2.9: One-season competition between C. glabrata clinical strains and C. 
albicans at low glucose concentration in SC medium. A set of 4 clinical isolates 
(Table A.1.2.S1), in comparison with the reference C. glabrata strain (ATCC 2001) 
were competed against a single high initial fraction of C. albicans GFP (~0.80 - 0.90). 
The assay medium was 0.05 % w/v SC medium. Relative fitness of C. albicans was 
calculated from the ratio of Malthusian parameters. N=9 for each species. The dotted 
line passing through relative fitness = 1.0 indicates no change in C. albicans fitness 
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during one-season competition. Box-plots show the median value as a horizontalline, 
1st and 3rd quartiles as box limits, whiskers marking 1.5 x interquartile range in both 
directions and empty plotted points as outliers. Red points and error bars overlaying 
each box represent mean and standard error. Relative fitness of C. albicans was 
significantly different in competition with different C. glabrata strains: One-way ANOVA 
(F4, 40 = 11.94, P = 1.78e-06) and Kruskal-Wallis test (χ2(4) = 33.743, P = 8.413e-07). 
Significant pairwise differences identified by Tukey HSD post hoc tests are shown by 
connecting lines. Asterisks represent significance level: * P < 0.05; ** P < 0.01; *** P < 
0.001. Mean (+/- SE) relative fitness of C. albicans in competition with each C. glabrata 
strain: ATCC 2001- 1.273 +/- 0.1132; BG2- 1.0674 +/- 0.027; BG2Δssk2- 1.153 +/- 
0.0294; NCPF 3309- 0.8650 +/- 0.0183; NCPF 3605- 1.599 +/- 0.1275.   
  
 
To determine whether differing strain competitive abilities were also present at 
high glucose and maintained long-term, we individually competed strains NCPF 
3605 and NCPF 3309 with C. albicans in high glucose (4% w/v) SC media (see 
Methods; data not shown). C. albicans greatly decreased in frequency in 
competition with each strain over five seasons (initial-end: 0.47 - 0.06 for 3605; 
initial-end: 0.72 - 0.02 for 3309). This equated to an 87% proportional decrease 
in C. albicans fraction in competition with strain 3605 compared with a 97% 
proportional decrease in C. albicans in competition with strain 3309. These 
results support the decrease in C. albicans fraction in long-term competition 
seen with strain 2001 in SU media at intermediate glucose (1% w/v: Figure 
2.4b), suggesting that long-term outcomes in this in vitro system are broadly 
conserved across strains. 
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2.5 Discussion 
 
The human microbiota is composed of a diversity of bacterial species, but 
fungal species also have an important role in health and disease, often 
interacting in mixed-species communities (Underhill and Iliev, 2014). The eco-
evolutionary dynamics of standard bacterial (Turner et al., 1996) and yeast 
(MacLean and Gudelj, 2006) laboratory species have been studied in in vitro 
simple nutrient environments, but competitive interactions between clinical 
fungal species have not been explored in depth. It is important to understand 
the ecological dynamics in clinical environments, as mixed-species infections 
make up a significant proportion of Candida species infections (Nace et al., 
2009). We investigated short and long-term resource competition between C. 
albicans and C. glabrata in clinically relevant environments, testing different 
species frequencies, densities and clinical strains. We found that outcomes of 
species competition were dependent on resources and that discrepancy 
occurred between short and long-term outcomes. These findings contribute to 
understanding fungal interactions that underlie mixed-species clinical infections. 
 
During short-term competitions in Synthetic Urine (SU) media, we found that C. 
albicans had a greater fitness than C. glabrata in low glucose concentrations 
(0.05 - 0.1% w/v) but was less fit in high glucose (4% w/v). This correlates with 
the findings of Nilsson (2012) and Beardmore et al. (in prep), who described a 
shift from C. albicans to C. glabrata with increasing glucose concentration, over 
competitions in the standard Synthetic Complete (SC) minimal medium. These 
results are similar to those from glucose competition between Saccharomyces 
cerevisiae and Candida utilis (Postma et al., 1989a) in which C. utilis dominated 
under glucose-limited conditions due to the presence of high affinity 
transporters, compared with low affinity transporters in S. cerevisiae. Similar to 
C. utilis, C. albicans may dominate in low glucose due to its high affinity glucose 
sensor encoded by HGT4 (Brown et al., 2006) and efficient glucose utilisation 
from transcriptomic regulation of respiratory genes (Rodaki et al., 2009). C. 
glabrata may dominate under glucose excess due to lower affinity glucose 
transport and less-efficient utilisation for growth, due to up-regulation of 
fermentative genes, as described for S. cerevisiae.  
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The shift towards C. glabrata with increasing glucose is consistent with 
detection of C. glabrata infections in diabetics (Fidel et al., 1996; Malani et al., 
2011) and is of clinical concern as multi-drug resistant C. glabrata infections are 
common (Farmakiotis et al., 2014).  The glucose concentrations we use are 
physiologically relevant as glucose is not normally present in the urine of 
healthy patients, but can be detected at concentrations of 11 mmol/l (0.2 % w/v) 
in the urine or blood of diabetics (WHO Committee on Diabetes Mellitus, 1980; 
Gibson et al., 1990). 
 
In short-term competitions in SU media at intermediate glucose concentrations 
(0.5-2% w/v) we found that C. albicans relative fitness was a decreasing 
function of its initial frequency, such that species co-existence occurred at an 
intermediate species frequency. C. albicans was fitter than C. glabrata when at 
low frequency but was less fit than C. glabrata when common. Negative 
frequency-dependent selection has been observed in single-season competition 
between two different Eschericia coli metabolic genotypes in single resource 
environments (Turner et al., 1996) and in glucose competition between socially 
interacting co-operator and cheat S. cerevisiae strains (MacLean and Gudelj, 
2006). In these systems, co-existence via negative frequency dependence 
occurred due to temporal heterogeneity in resource levels during the season: 
resources change from high to low (Levin, 1972; Rainey et al., 2000). Under 
competition for a single resource, if one competitor grows faster at higher 
resource concentrations and the other grows faster at lower resource levels 
then a balance between the two strategies will result in stable co-existence 
(Stewart and Levin, 1973). This may be the mechanism for co-existence in our 
system as it is likely that C. albicans grows faster at lower resources and C. 
glabrata grows faster at higher resources.  
 
Our work shows that negative frequency-dependent selection can occur in 
competition for a single carbon source between clinical species in more 
complex clinically-relevant media. By using synthetic urine medium, we could 
mimic Candida species interactions that occur in urinary tract infections, which 
are commonly composed of C. glabrata and C. albicans (Fidel et al., 1999). SU 
is a “nutritionally poor medium supplemented with urine-specific salts and urea” 
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(Domergue et al., 2005) and it is possible that amino acid deficiencies or 
differential species abilities to utilise nitrogen (a large component of the media) 
could also influence competition dynamics, as these have previously affected 
virulence and drug resistance in biofilms (Domergue et al., 2005; Uppuluri et al., 
2009).  
 
We implemented growth conditions that encouraged the two competitors to 
grow as single yeast cells (non-adherent microplates, 300C and orbital 
agitation), rather than allowing C. albicans to form hyphae, which would have 
complicated evaluation of species competitive abilities via colony counts. This 
allowed us to better study interactions amongst fungal commensals (existing in 
yeast form) within the human microbiota, an area lacking in research (Krom et 
al., 2014), and to predict interactions that may occur in multi-species infections. 
We do not claim that the outcomes of our competition experiments will match 
species interactions in host infections, particularly as fungi naturally co-exist 
with bacterial species in human environments (Jenkinson and Douglas, 2002) 
and context-dependent competition can alter competitive outcomes (de Muinck 
et al., 2013).  
 
CHROMagar plating has been used to measure competition dynamics between 
C. albicans and C. dubliniensis in in vitro broth and biofilm studies and C. 
albicans dominated in both environments (Kirkpatrick et al., 2000). In contrast, 
another biofilm study showed that C. albicans could be inhibited by C. krusei 
(Thein et al., 2007). Support for antagonistic C. glabrata-C. albicans interactions 
was provided in a recent study by Rossoni et al. (2015) who found a 77% 
reduction in C. albicans density in dual-species compared with single species 
biofilms.  Alternatively, co-existence and apparent lack of competition between 
C. glabrata and C. albicans has been described in vitro, likely due to 
biochemical and morphological differences between the two species (Silva et 
al., 2011) and may occur in vivo due to spatial structuring. Co-existence 
between S. cerevisiae strains has been described in spatially structured 
environments (MacLean et al., 2010).  
 
For longer term competitions in SU media extended via seasonal batch 
culturing, C. albicans dominated the populations at low glucose (0.1% w/v) but 
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was excluded at intermediate glucose (1% w/v) concentration. In one-season 
competition at 0.1% glucose, as C. albicans was significantly fitter than C. 
glabrata for most initial fractions and fitness was not a significant decreasing 
function of C. albicans fraction, our long-term results supported our prediction 
that C. albicans would dominate over time. In contrast, at 1% glucose we 
predicted from one-season competition that stable co-existence would occur 
long-term for a C. albicans fraction of approximately 0.49, but instead C. 
albicans was excluded. 
 
Previous studies have commonly described negative frequency dependence as 
a predictor of long-term stable co-existence in bacterial and yeast studies 
(Stewart and Levin, 1973; Ayala and Campbell, 1974; Lunzer et al., 2002; 
MacLean et al., 2006), in the absence of experimental verification. Some 
studies have verified that negative frequency dependence maintains stable co-
existence via serial batch culturing, for example in competition between E. coli 
genotypes (Turner et al., 1996) or in stable maintenance of polymorphisms in 
Lenski’s long-term E. coli evolution experiment (Lenski et al., 1991; Elena and 
Lenski, 1997). These studies used a constant daily volumetric transfer of cells in 
order to maintain the same environment each season. In our work, we 
employed this volumetric transfer method and conducted an independent 
experiment in which we transferred an approximately equal competition cell 
density per day in an attempt to more closely replicate the initial season 
conditions. We found that C. albicans was excluded in both experiments, rather 
than stably co-existing with C. glabrata. This shows that negative frequency 
dependence cannot always predict stable co-existence in in vitro competition. It 
remains to be found whether this would occur for other microbial species in 
different environments.  
 
Detection of genetic adaptations in C. glabrata that allowed it to exploit the 
niche of C. albicans during long-term competition would support previous 
studies that have described evolutionary changes over ecological timescales 
(Odling-Smee et al., 2013), due to short generation times of microbes 
(Feldgarden et al., 2003). Studies of yeast adaptation to limiting glucose 
identified gene duplication of high affinity hexose transporters HXT6 and HXT7, 
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which resulted in greater glucose transport, cell yield and relative fitness (Brown 
et al., 1988).  
 
Long-term exclusion of C. albicans at intermediate glucose concentration was 
robust to different initial competitor frequencies and for a doubling and halving 
of an initial competition cell density containing C. albicans at low initial fraction. 
In all cases, C. albicans was completely excluded after 9 days. These results 
contrast with the outcome of long-term co-existence of E. coli genotypes in 
seasonal batch cultures, whereby transfers with different competitor starting 
frequencies all converged on the stable equilibrium fraction (Levin, 1972; Turner 
et al., 1996). These studies did not test whether differences in initial competition 
density altered long-term outcomes.  
 
Ten-fold increases in competition cell density over a single season resulted in 
C. glabrata being fitter than C. albicans at low (0.05%), intermediate (1%) and 
high (4%) glucose concentrations, whereas a one-thousand-fold decrease in C. 
albicans at low glucose (0.1%) did not change competitive outcomes. C. 
glabrata is a Crabtree-positive species so produces ethanol (Van Urk et al., 
1990) and grows well under anaerobic conditions like its close relative, S. 
cerevisiae (Roetzer et al., 2011; Rozpedowska et al., 2011). In contrast, C. 
albicans is Crabtree-negative and relies on aerobic conditions for growth 
(Rozpedowska et al., 2011).  
 
We tested for oxygen limitation favouring C. glabrata by competing C. glabrata 
and C. albicans in a range of different volumes in larger culture tubes. We found 
that C. albicans fitness was negatively correlated with competition volume for 
single season competition in low glucose SU and SC media, supporting our 
hypothesis. This indicates that SA/V ratio is important for oxygen uptake, as the 
smaller ratio for larger tube volumes created oxygen limitation and favoured C. 
glabrata. Ethanol production could be measured in the competition cultures 
(Verduyn et al., 1984). Previously, ten times increases in inoculum size of C. 
glabrata and C. albicans in isolation created additive effects on seasonal 
biomass and longer exponential growth (Cuenca-Estrella et al., 2001), but the 
effect on growth in co-culture was not tested. Studying differences in 
competition density is relevant for better understanding infections, as antifungal 
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resistance is greater at higher densities in biofilms (Perumal et al., 2007). 
Quorum sensing may be a relevant mechanism of growth suppression of C. 
albicans through farnesol production (Weber et al., 2010) but this remains to be 
explored.  
 
In contrast, lowering initial cell densities by one thousand times in low glucose 
still resulted in C. albicans having greater fitness than C. glabrata, although 
larger increases in C. albicans frequencies occurred at the lower cell density. 
This was likely due to the increased number, rather than rate, of doublings over 
the single season as the populations were further away from carrying capacity. 
It remains to be tested whether lower cell densities would change C. albicans 
relative fitness at higher glucose concentrations and whether co-existence 
would still be predicted. Using lower competition densities is relevant for 
understanding niche establishment and commensal interactions of Candida 
species prior to pathogenic overgrowth. 
 
C. albicans relative fitness significantly varied across one-season competitions 
when in competition with different C. glabrata clinical strains at low glucose 
concentration. C. albicans was most fit in competition with C. glabrata strain 
NCPF 3605, showing that this strain was the poorest competitor in low glucose. 
This correlates with strain 3605’s isolation from a diabetic patient (Table 
A.1.2.S1) and its likely preferential adaptation to higher blood glucose 
concentrations, as strain 3605 could outcompete C. albicans over long-term 
competition in high glucose. In contrast, we found that clinical strain 3309 
isolated from the gastrointestinal tract was more competitive than C. albicans. In 
comparison, C. albicans had a greater relative fitness when in competition with 
strain BG2 that was isolated from the vagina, a higher glucose environment 
than the gastrointestinal tract (Karabocuoglu et al., 1994; Owen and Katz, 
1999). This indicates that the species composition of infections could vary 
between different body sites and patients. Antifungal resistance is likely to be 
greater in infections in which C. glabrata is a better competitor, due to its 
intrinsic drug resistance (Fidel et al., 2009). Candida species colonise a 
diversity of host sites (Underhill and Iliev, 2014) and differences in C. glabrata 
clinical isolate genetics (Healey et al., 2016) could influence strain competitive 
abilities. In a previous study of clonal types of the bacterial opportunistic 
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pathogen MRSA (methicillin-resistant Staphylococcus aureus), it was found that 
clones with a greater competitive fitness were also more drug-resistant (Knight 
et al., 2012). By designing treatments that manipulate the metabolic 
environment (Allison et al., 2011), for example by reducing glucose availability, 
there is potential to reduce the frequency of C. glabrata strains that have 
adapted as better competitors in infection sites with greater glucose 
concentrations.  
 
 
2.6 Conclusions of the Chapter 
 
In conclusion, our results are threefold:  
1) The outcome of in vitro Candida species competition in clinically relevant 
environments is dependent on resources.  
 
2) Short-term negative frequency-dependent dynamics cannot always 
predict long-term competitive outcomes, as shown in mixed Candida 
species competitions. 
 
3) C. glabrata competitive abilities differ across clinical strains. 
 
Interactions between C. albicans and C. glabrata will be explored in a model 
invertebrate host in Chapter 3, in which we explore the effect of strain virulence 
on host immunity.  
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3. Chapter 3: Dual Candida Species Interactions in the 
Host Model Galleria mellonella 
 
3.1 Introduction 
 
Dual species fungal infections, particularly those consisting of Candida species, 
compose a significant proportion of all fungal infections and are more difficult to 
treat than single species infection (Boktour et al., 2004). This has stemmed from 
the rise of non-albicans species in infections, with C. glabrata second most 
commonly isolated after C. albicans (Odds et al., 1996). Multi-species infections 
are responsible for 2-10% of Candida species bloodstream infections and the 
most common combination reported is C. glabrata and C. albicans, resulting in 
a high mortality rate (Boktour et al., 2004; Nace et al., 2009). In addition, 
approximately 15% of biofilms in oral Candida infections are dual species, 
notably C. albicans with C. glabrata or C. krusei (Samaranyake et al., 1987). 
Multi-species infection (candidemia) can occur in patients with cancer (Boktour 
et al., 2004) or HIV (Patel et al., 2012) and is more difficult to treat with single 
antifungal therapy due to the presence of intrinsically drug-resistant species. 
Candida species also interact with Aspergillus species in the respiratory tract 
(Peleg et al., 2010) and with bacteria in one quarter of bloodstream 
candidemias (Klotz et al., 2007).  
 
Mixed-species interactions in infections lack detailed characterisation and their 
nature can be highly diverse (Harrison, 2007). Some studies describe one 
Candida species enhancing the invasion of another in epithelial infections (Silva 
et al., 2011; Alves et al., 2014), whereas others have found that co-infection can 
lead to out-competition (Kirkpatrick et al., 2000; Henry-Stanley et al., 2005; 
Thein et al., 2007), resulting from competition for common resources (Harrison, 
2007). Species may directly inhibit each other via toxin release or over-
stimulation of the immune response (Brown et al., 2009), but often it is difficult 
to elucidate the mechanism in in vivo systems (Henry-Stanley et al., 2005; 
Tampakakis et al., 2009).  Quorum sensing, the cell density-dependent 
chemical regulation of gene expression (Miller and Bassler, 2001), can also 
have a role in inter-species interactions. This can cause inhibition of competitor 
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growth in mixed infections (Peleg et al., 2008) or stimulation of virulence factor 
production to enhance infection virulence (Asad and Opal, 2008).  
 
Species interactions in dual infections are often described as synergistic (Harrison, 
2007). Silva et al. (2011) and Alves et al. (2014) described synergism between C. 
albicans and C. glabrata in in vitro epithelium as greater fungal invasion and tissue 
damage in dual compared to single species infections. Synergism has also been 
described between Pseudomonas aeruginosa and oropharyngeal bacterial species 
isolates (Sibley et al., 2008) in the Drosophila melanogaster invertebrate model, 
resulting in increased expression of virulence genes in P. aeruginosa and altered 
host immune antimicrobial peptide production. Synergistic interactions were defined 
by greater host mortality in dual compared with single species P. aeruginosa 
infections, when the bacterial species co-infecting with P. aeruginosa was non-
pathogenic in single infection. Synergism also occurred between P. aeruginosa 
clinical strains and Streptococcus species strains in the Galleria mellonella wax moth 
larval model (Whiley et al., 2014), measured by decreased survival in dual compared 
with single species infection of either species, when total infection dose was equal in 
single and dual infections. Synergism is also described in mixed-species biofilms 
whereby Streptococcus species can increase growth of Candida species (Pereira-
Cenci et al., 2008) or increase invasion of mucosal tissue (Diaz et al., 2012).  
 
Alternatively, microbial species interactions in infections can be described as 
antagonistic (Harrison, 2007). A dual species infection of the nematode worm 
Caenorhabditis elegans with the bacterium Acinetobacter baumannii and Candida 
albicans revealed direct reciprocal antagonistic interactions (Peleg et al., 2008) by 
production of molecules that inhibited growth. In biofilms, antagonistic interactions 
occur between P. aeruginosa and C. albicans through physical interactions, 
production of quorum sensing molecules and immunomodulatory factors by the host 
and pathogen (Fourie et al., 2016).  Antagonism has also been described as a 
reduction in host fungal burden (colony forming units) of a Streptococcus species 
strain in co-culture with a Pseudomonas aeruginosa clinical strain, compared with 
monoculture in in vitro biofilms (Whiley et al., 2014).  
 
To study host-pathogen interactions in fungal infections, a range of in vivo 
infection models are used to mimic pathological symptoms that occur in human 
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infection environments (MacCallum, 2012). In vivo murine models can be used 
to study virulence of mucosal, host site-specific and systemic infections, 
although immunosuppression is sometimes required to establish infection with 
C. glabrata (Fidel et al., 1999). Genetic analysis of host immunity is possible 
and mice have highly conserved innate and adaptive immune systems with 
humans, however higher costs and ethical constraints reduce sample sizes and 
repeatability (Buer and Balling, 2003). Alternatively, the minihost vertebrate 
zebrafish (Danio rerio) and the invertebrate nematode (Caenorhabditis elegans) 
models can be used to study virulence-associated fungal morphological 
changes non-invasively in transparent larvae (Pukkila-Worley et al., 2009; 
Brothers and Wheeler, 2012). The zebrafish has both innate and adaptive 
immunity (MacCallum, 2012) and genetic tools are available in both models 
(Brothers and Wheeler, 2012; Desalermos et al., 2012). These minihosts are 
however limited, as they cannot be incubated at 37oC to truly replicate the 
mammalian infection environment (MacCallum, 2012).  
 
To better understand dose-dependent pathogen virulence, the fruit fly 
(Drosophila melanogaster) has proved a useful host. Precise inoculum doses 
can be injected into the haemolymph (Glittenberg et al., 2011b), whilst 
gastrointestinal specific infections have been studied by ingestion from food 
(Glittenberg et al., 2011a). Genetic tools are available to probe host immunity 
(Kounatidis and Ligoxygakis, 2012). In contrast, the fruit fly is limited as it has 
innate but not adaptive immunity and cannot be incubated at human 
physiological temperature (MacCallum, 2012) and is not widely used as an 
infection model as specialist equipment (incubators and “fly room” (Desalermos 
et al., 2012)) are required.  
 
An insect model that has successfully been used to study host-pathogen 
interactions is Galleria mellonella, larvae of the greater wax moth, which can be 
easily maintained in the laboratory (Cotter et al., 2000; Desalermos et al., 
2012). Virulence of C. albicans (Cotter et al., 2000; Brennan et al., 2002; 
Borman et al., 2013), C. tropicalis (Mesa-Arango et al., 2013), C. krusei 
(Scorzoni et al., 2013) and C. glabrata (Junquiera et al., 2011; Borghi et al., 
2014; Santos et al., 2017; Ames et al., 2017) has been described. Larval 
infection can be studied at both 30oC and 37oC, precise inoculum injections into 
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the haemolymph are easier as the larvae are larger and large sample sizes are 
possible due to low costs and fewer ethical constraints (Cotter et al., 2000; 
MacCallum, 2012). 
 
Strain virulence is correlated between G. mellonella and mouse models 
(Brennan et al., 2002; Amorim-Vaz et al., 2015). This makes it a useful model of 
mammalian systemic infection. This model does present limitations as 
differences in larval health can occur between batches and inter-laboratory 
variation can restrict comparability of results (Cook and McArther, 2013), for 
example if larvae are fed different diets or differ in genetics or microbiota 
composition. This has been addressed by development of TruLarv™ 
(Champion, 2016), research grade G. mellonella which have been in-bred from 
a genome sequenced stock and will allow understanding of host genetics, in 
addition to transcriptomic tools for analysis of host immunity and stress 
response (Vogel et al., 2011).  
 
Dual Candida species interactions in the host have recently been studied in G. 
mellonella (Rossoni et al., 2015). Interestingly, the authors found that dual 
infection of C. albicans (with C. glabrata or C. krusei) with a doubled total 
infection dose (2 x 106 CFU/larva) compared with a C. albicans single species 
infection (1 x 106 CFU/larva), increased larval survival in dual infection beyond 
that of single C. albicans infection. Whilst larvae infected only with C. albicans 
did not survive beyond 18 hours post-injection, larvae survived up until 72 hours 
in C. albicans-C. glabrata infection and 96 hours in C. albicans-C. krusei 
infection. C. albicans fungal burden and hypha formation were also lower in 
dual infection than in single infection. The authors concluded that competitive 
(antagonistic) interactions occurred in mixed-Candida species infections, 
whereby C. glabrata or C. krusei were better competitors than C. albicans and 
increased larval survival in dual infection due to their lower virulence. These 
experiments only tested a single strain of each species and the interactions 
between different species clinical strains remain to be explored. 
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3.2 Aims of the Chapter 
 
In this chapter, we aim to further explore interactions in dual species fungal 
infections and the interaction with host immunity, after establishing Galleria as a 
model to study dose-dependent Candida species virulence as described 
previously (Brennan et al., 2002; Borghi et al., 2014). We selected G. mellonella 
as the infection model to study mixed-species interactions due to the ability to 
infect larvae with precise inocula, incubate at 37oC and study large sample 
sizes (Cotter et al., 2000; MacCallum, 2012). We address three aims: 
 
1) To establish G. mellonella as a model for studying host-pathogen 
interactions by testing single species virulence and temperature-
dependent virulence of C. albicans and C. glabrata. 
 
2) To determine whether dual species interactions in mixed Candida 
species infection of G. mellonella described by Rossoni et al. (2015) can 
be replicated using similar species lab strains. 
 
3) To further explore dual Candida species interactions across a range of 
clinical strains to determine whether the type of interaction is strain-
dependent.  
 
We extended our work from Chapter One on in vitro competition assays 
between C. glabrata and C. albicans, to investigate species interactions within 
the environmental complexity of a host and interaction with the immune system. 
We studied single species dose-dependent virulence of C. albicans and C. glabrata 
in G. mellonella at two different temperatures that mimic commensal and pathogenic 
interactions, to confirm previous findings (Cotter et al., 2000; Brennan et al., 2002; 
Scorzoni et al., 2013; Borghi et al., 2014; Ames et al., 2017). Candida species have 
shown dose-dependent virulence in G. mellonella infection, with C. albicans being 
more virulent than C. glabrata (Cotter et al., 2000; Rossoni et al., 2015; Ames et al., 
2017). Temperature-dependent virulence with single Candida species inoculum 
doses has previously been described in Candida species (Mesa-Arango et al., 2013; 
Scorzoni et al., 2013).  
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We replicated the experiments of dual species Candida infection of G. mellonella 
described by Rossoni et al. (2015) and tested for antagonistic or synergistic 
interactions or lack of interaction across different clinical strains of C. albicans and C. 
glabrata, measuring larval survival. We injected equal doses of C. albicans in 
combination with C. glabrata or C. krusei in dual infections, with the doses of the 
non-albicans species being non-pathogenic in single species infection. Similar to 
previous studies (Sibley et al., 2008; Whiley et al., 2014), we define interactions as 
synergistic or antagonistic if we observe a respective decrease or increase in larval 
survival in dual compared with single species C. albicans infection. We report no 
species interaction if larval survival is not significantly different between dual and 
single species C. albicans infection. Lack of species interaction has previously been 
observed as a lack of increase in host mortality (Sibley et al., 2008) or biofilm cell 
concentration (Whiley et al., 2014) in dual infections with a non-pathogenic bacterial 
species strain and a virulent strain. We further evaluate differences in species strain 
interactions by comparing host melanisation, a hallmark of the insect immune 
response (Scorzoni et al., 2013) in different strains.   
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3.3 Materials and Methods 
 
3.3.1 Galleria mellonella Larvae 
 
G. mellonella larvae were ordered from Live Foods Direct (Sheffield, UK: 
Waxworms (15-25 mm); Product Code-W1000) and were stored in wood 
shavings in a 15oC incubator for 7-10 days before use to reduce the possibility 
of using immune-primed larvae resulting from stress of transportation (Browne 
et al., 2014; 2015). Larvae were kept for 3-4 weeks from this date. 16 larvae (for 
dual infections) of uniform colour and size (approximately 0.25-0.35 g) were 
selected per infection group and were stored in 90 mm petri dishes containing a 
single 90 mm filter paper disc. Larvae were inoculated with 10 µl of cell 
suspension using a 50 µl Hamilton Gastight syringe (Hamilton, Bonaduz, 
Switzerland; Product No: 1705), into the top left proleg for single injections. The 
second left proleg was used as a second site when two injections were given 
for dual infections. 20 larvae were used per infection group for single species 
infection experiments. Larvae were discarded if any leakage of the inoculum or 
larval haemolymph occurred. In all assays, an extra group of larvae injected 
only with PBS was used as a control against the stress of injection. In all 
experiments, PBS controls survived the duration of the experiment, or 
experiments were discarded when greater than 2 larvae of an infection group 
died. Larvae were removed from the experiments (censored) when they began 
to pupate. 
 
3.3.2 Single Candida Species Infection in G. mellonella 
 
Candida strains used were C. glabrata ATCC 2001 and C. albicans SBC153 
(Milne et al., 2011) (see Chapter 2). Overnights were prepared in YPD media 
and incubated with shaking at 180 rpm in 30oC. After 24 hours, cultures were 
removed, washed twice in 1 x PBS solution then re-suspended in PBS. Each 
species was diluted in PBS and cell concentration was counted with the 
haemocytometer. 
 
Doses of C. albicans used for infection were 1, 2 and 4 x 107 cells/ml for C. 
albicans and 1.25, 2.5 and 5 x 108 cells/ml for C. glabrata (Ames et al., 2017). 
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As 10 µl of each concentration was injected into larvae, the final dosages were 
1, 2 and 4 x 105 cells/larva for C. albicans and 1.25, 2.5 and 5 x 106 cells/larva 
for C. glabrata. Larvae were incubated in static, dark conditions at 30oC or 37oC 
and survival was recorded every 24 hours for seven days. Each infection assay 
was repeated three times independently. 
 
3.3.3 Dual Candida Species Infection in Galleria mellonella: Replication of 
Experiments Described by Rossoni et al. (2015)  
 
The methods of Rossoni et al. (2015) were used with modifications as follows. 
The Candida strains used were C. albicans ATCC 18804, C. krusei ATCC 6258 
(Table 3.1), C. albicans SBC153 (isogenic to clinical isolate SC5314 with 
ACT1p-GFP-NAT1 insertion (Milne et al., 2011)) and C. glabrata ATCC 2001; 
the latter two strains were described in Chapter 2. Strains were streaked onto 
SDA (Sabouraud Dextrose Agar) plates and incubated at 37oC for 24-48 hours 
until colonies were visible. Overnight cultures were prepared by inoculation of a 
single colony into YPD medium and incubating at 37oC for 18 hours. Cells were 
washed three times in 1xPBS solution then were re-suspended in PBS and 
diluted for cell enumeration with a haemocytometer. For preparation of infection 
inocula, strains were diluted in PBS to cell densities of 1 x 108 and 2 x108 
cells/ml, resulting in final concentrations of 1 x 106 and 2 x 106 CFU/larva.  
 
Dual infections were performed by single or dual site inoculation. For dual site 
inoculation, 1 x 106 CFU/larva of C. albicans was inoculated into one proleg and 
1 x 106 CFU/larva of C. glabrata or C. albicans was inoculated into the second 
proleg (Rossoni et al., 2015). For single site inoculation, 2 x 106 CFU/larva of 
each species were vortex mixed in a 50:50 ratio and 10 µl of the cell 
suspension was inoculated into the top left proleg. Single species infections 
were run alongside, by injecting 1 x 106 or 2 x 106 CFU/larva. 
 
Larvae were incubated at 37oC in the dark for five days and survival was 
recorded daily (including at 18 hours) for 5 days, based on reaction to physical 
stimulation. Each experiment was replicated independently three times. 
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3.3.4 Dual Species G. mellonella Infection with Different Doses and Strains 
 
The methods used were as above with modifications. Strains were streaked on 
SDA plates and incubated at 37ºC and overnight cultures were incubated at 
37ºC for 18-22 hours. Firstly, the total dual species infection dose was 
maintained at 2 x 106 CFU/larva but the ratio of species concentrations (C. 
albicans: C. glabrata) mixed together and inoculated at a single site, was 
altered from 50:50 (1 x 106 CFU/larva each species) to each of 30:70 (6 x 105 
CFU/larva: 1.4 x 106 CFU/larva) and 10:90 (2 x105 CFU/larva: 1.8 x 106 
CFU/larva).  
 
A set of clinical strains of C. glabrata, C. albicans and C. krusei were tested in 
different combinations in dual infections and larval survival was measured 
(Table 3.1). The total dual species infection dose was 4 x 105 CFU/larva, 
consisting of 2 x 105 CFU/larva of each species. Single species infections with 2 
x 105 CFU/larva were also tested. Each species strain combination in dual 
infections was tested in one independent experiment, then independent 
experiments were repeated for a selection of strains showing contrasting 
species interactions: C. glabrata strains BG2, 1184, NCPF 3605 and 3309, C. 
krusei ATCC 6258 and C. albicans strain SBC153 and 18804. We then tested a 
range of doses of C. glabrata BG2 and 1184 in single species infections to find 
the infective dose of each with equal virulence as a C. albicans SBC153 
infection with 2 x 105 CFU/larva. 
 
 
Table 3.1. Candida strains used in single and dual species infections. See 
Chapter 2 for description of strains C. albicans ACT1-GFP (SBC153 (Milne et al., 
2011); lab-derived strain isogenic to clinical isolate SC5314 with GFP insertion) and C. 
glabrata strains ATCC 2001, BG2, BG2Δssk2, NCPF 3605, NCPF 3309. All strains 
listed below are clinical isolates of Wild-Type genotype. 
 
Strain Reference 
C. albicans strains 
ATCC 18804 Reference strain isolated from human 
skin infection (American Type Culture 
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Collection). Used by Rossoni et al. 
(2015) and received as kind gift from 
Donna MacCallum, University of 
Aberdeen 
ATCC 90028 Reference strain isolated from blood 
(American Type Culture Collection).  
Quality control for antifungal 
susceptibility testing (NCCLS, 2002). 
B311/ ATCC 32354 Lab reference strain (Sokol-Anderson 
et al., 1988) 
NCPF 3302 Isolated from chronic mucocutaneous 
candidosis and is azole-resistant 
(UKNCC; Haynes and Westerneng, 
1996) 
C. glabrata strains 
85/038 Zhou and Thiele, 1991 
11088A Haynes and Westerneng, 1996 
1184 Kind gift from Ken Haynes, University 
of Exeter. Origin unknown. 
C. krusei strains 
ATCC 6258 Isolated from bronchomycosis 
(American Type Culture Collection). 
Reference strain used in antifungal 
susceptibility testing (NCCLS, 2002). 
Used by Rossoni et al. (2015). 
 
 
3.3.5 Host Melanisation Response 
 
The methods used are as described in Ames et al. (2017) and Scorzoni et al. 
(2013), with modifications. Larvae in groups of three were injected with PBS, 2 x 
105 CFU/larva of C. glabrata BG2 or C. glabrata 1184 in a single experiment. In 
a separate experiment, the same infectious doses were used but C. glabrata 
BG2 and C. krusei ATCC 6258 were compared. At 2 and 6 hours post-injection, 
three larvae per infection group were put on ice. Haemolymph was collected in 
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a micro-centrifuge tube by removing the final tip of the body. Haemolymph was 
diluted in IPS (Insect Physiological Saline: 150 mM sodium chloride, 5 mM 
potassium chloride, 10 mM Tris-HCl pH6.9) and melanin production was 
quantified in a plate reader at OD 415 nm. This assay is robust for reporting 
melanin biosynthesis as a similar absorbance wavelength was used to measure 
laccase activity (the oxidative enzyme involved in melanin synthesis) via 
production of an intermediate product of melanin biosynthesis (Williamson, 
1994; Alvarado-Ramírez et al., 2008).   
 
3.3.6 Statistical Analyses 
 
Survival data collected from three independent experiments (biological 
replicates) were analysed for significant between-replicate differences using 
pairwise log rank tests with OASIS 2 software (Han et al. 2016; Ames et al., 
2017). If no significant differences occurred, then experiments were pooled. 
Kaplan-Meier survival curves were plotted using the ‘survfit’ function in the R-
package ‘Hmisc’ (Harrell et al., 2016) using R version 3.3.2 (R Core Team, 
2016). Significant differences between survival curves in the probability of death 
over the measured time points were deduced from pairwise log-rank tests with 
Bonferroni correction for multiple comparisons, using OASIS 2 software (Han et 
al., 2016; Ames et al., 2017). Mean survival times and standard errors were 
also computed. Larvae that pupated during the experiment and those that were 
alive at the end of the experiment were censored. One-way ANOVA tests and 
Tukey post hoc tests were used to deduce between-group differences in host 
melanisation. 
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3.4 Results 
 
3.4.1 Single Candida Species Infection of G. mellonella: Dose and 
Temperature-Dependent Effects 
 
In order to test the dual species interactions described by Rossoni et al. (2015), 
we firstly investigated single Candida species virulence and temperature 
dependency in G. mellonella, to establish the model to measure dose-
dependent virulence of reference strains in our laboratory. We picked three 
different infective doses for each of C. glabrata ATCC 2001 and C. albicans 
SBC153 (Ames et al., 2017) and measured larval survival over seven days at 
two different temperatures. C. glabrata virulence showed significant dose-
dependent effects at both 37oC and 30oC (Figure 3.1a and b; Table A.2.1.S1). 
For example, at 30oC mean larval survival was 3.93 +/- 0.36 days for 1.25 x 106  
CFU/larva compared with 1.75 +/- 0.19 days with 5 x 106 CFU/larva. At 37oC 
mean survival was 4.90 +/- 0.25 days for 1.25 x 106 CFU/larva and 1.95 +/- 0.09 
days for 5 x 106 CFU/larva. There were no significant differences in larval 
survival time between the two temperatures for any of the three doses of C. 
glabrata. These results contrast with the temperature effects described in Ames 
et al. (2017), likely due to variation in the health of different larval batches.  
 
C. albicans also showed significant dose-dependence at both temperatures 
(Figure 3.1c and d; Table A.2.1.S1). At 30oC mean larval survival was 6.54 +/- 
0.16 days for 1 x 105 CFU/larva compared with 1.26 +/- 0.12 days for 4 x 105 
CFU/larva. At 37oC mean larval survival time was 5.59 +/- 0.20 days for 1 x 105 
CFU/larva compared with 1.06 +/- 0.03 days for 4 x 105 CFU/larva. C. albicans 
showed significant temperature-dependent virulence at low and intermediate 
doses (1 x 105 CFU/larva: p = 0.00; 2 x 105 CFU/larva: p = 4.20E-6) but not at 
the highest dose (4 x 105 CFU/larva) at which percentage survival was reduced 
below 10% at both temperatures, on the first day post-injection. Overall, 
approximately ten times greater infective doses of C. glabrata, compared with 
C. albicans, were required for similar virulence (Ames et al., 2017).  
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Figure 3.1. Survival of G. mellonella infected with C. glabrata or C. albicans at 
two different temperatures. Kaplan-Meier survival plots show virulence of C. glabrata 
strain ATCC 2001 at 37oC (a) and 30oC (b), similar to results of Ames et al. (2017). 
Infective doses are 1.25 x 106 CFU/larva (squares), 2.5 x 106 CFU/larva (triangles) and 
5 x 106 (upside-down triangles). Data is pooled from 3 biological replicates. Virulence 
plots of C. albicans strain SBC153 (isogenic to NGY152 with ACT1-GFP insertion) at 
37oC (c) and 30oC (d) are presented. Infective doses are 1 x 105 CFU/larva (squares), 
2 x 105 CFU/larva (triangles) and 4 x 105 CFU/larva (upside-down triangles). Data is 
pooled from 4 biological replicates. See Table A.2.1.S1 for statistical results from Log-
rank tests. 
 
 
3.4.2 Dual Candida Species Infection in Galleria mellonella: Replication of 
Experiments from Rossoni et al. (2015) 
 
We firstly tested repeatability of the antagonistic species interaction from 
Rossoni et al. (2015), whereby an increase in larval survival occurred with dual 
(c) (d) 
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Candida species infection at double the total infection inoculum as a single 
species C. albicans infection. Following the same methods with minimal 
modifications, a dual infection with 1 x 106 CFU/larva of each of C. albicans 
strain SBC153 and C. glabrata strain ATCC 2001 did not produce a significant 
increase in larval survival (Figure 3.2b), in contrast to Rossoni et al. (2015). 
Larval survival time for infection with 1 x 106 and 2 x 106 CFU/larva of C. 
albicans SBC153 did match previous results as all larvae had died at 18 hours, 
but mean survival time in the dual species group was 18.63 +/- 0.63 hours 
(Table A.2.1.S2). For single species infections with 1 x 106 CFU/larva, C. 
albicans was significantly more virulent than C. glabrata (P = 0.00); mean larval 
survival time was 71.75 +/- 4.48 hours with C. glabrata and 18 hours with C. 
albicans (Figure 3.2a). 
 
Secondly, we tested whether similar antagonistic interactions between C. 
albicans and C. krusei described in Rossoni et al. (2015) could be replicated, 
using the same strains from the paper. Again, no increase in larval survival was 
observed in dual species infection compared with C. albicans infections of 1 
and 2 x 106 CFU/larva, resulting in death of all larvae in the three infection 
groups at 18 hours (Figure 3.2d). No significant mortality was seen in PBS 
injection controls, controlling against stress of injection. As seen in Rossoni et 
al. (2015), C. krusei had significantly lower virulence than C. albicans with 1 x 
106 CFU/larva infection (P < 0.001) (1 biological replicate: Figure 3.2c). C. 
krusei had a mean survival time of 46.88 +/- 7.73 hours (Table A.2.1.S2). 
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(a)
(b)
(c)
(d)
 
Figure 3.2. Survival curves for single and dual Candida species G. mellonella 
infection. Survival of G. mellonella infected with single species C. albicans, C. glabrata 
and C. krusei in comparison with dual C. albicans/ non-albicans infections. Methods of 
Rossoni et al. (2015) were replicated. (a) and (b): strains used were C. albicans ACT1-
GFP (SBC153) and C. glabrata ATCC 2001. (c) and (d): strains used were C. albicans 
ATCC 18804 and C. krusei ATCC 6258 (same strains as Rossoni et al. (2015)). Data 
were pooled from 3 biological replicates in (a) and (b) and from 2 biological replicates 
in (d). Data in (c) is from 1 biological replicate. Significant differences between survival 
curves were determined with log-rank tests and mean survival times were calculated 
and results are presented in Table A.2.1.S2. 
 
 
3.4.3 Dual Candida Species Infection of G. mellonella: Manipulating 
Species Ratio, Total Infective Dose and Species Strains 
 
We extended the work of Rossoni et al. (2015) to determine whether species 
interactions in G. mellonella were dependent on species inoculum ratio in dual 
infection. Firstly, maintaining the total dose of 2 x 106 CFU/larva, a dual infection 
with a species ratio of 30:70 (0.6 x 106 C. albicans SBC153/ 1.4 x 106 CFU/larva 
C. glabrata ATCC 2001) showed no significant difference in survival (P = 1.00; 
1 biological replicate- data not shown) compared with a single species C. 
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albicans infection (2 x 106 CFU/larva). A dual infection with a 10:90 species 
ratio (0.2 x 106 CFU/larva C. albicans/ 1.8 x 106 CFU/larva C. glabrata) showed 
a small increase in larval survival (mean 25.5 +/- 3.88 hours) compared with 2 x 
106 C. albicans (mean 18.38 +/- 0.36 hours) but this was not significant 
(Bonferroni-corrected P = 0.137; 1 biological replicate- data not shown). This 
indicates that C. albicans showed higher virulence in our work than in the 
experiments of Rossoni et al. (2015), such that antagonistic species interactions 
were not seen. 
 
As the dose of C. albicans used in Rossoni et al. (2015) was much higher than 
doses required for virulence in our experiments (Figure 3.1c), for all future 
single-dual species experiments we used a dose of 2 x 105 CFU/larva of C. 
albicans, which showed intermediate virulence (Figure 3.1c). In combination 
with 2 x 105 CFU/larva of C. glabrata (below virulent dose: Figure 3.1a), we 
found no significant difference in larval survival between dual infection and 
single 2 x 105 CFU/larva C. albicans infection (P = 0.0799; 1 biological replicate- 
data not shown). In dual infections, with C. albicans dose maintained at 2 x 105 
CFU/larva and C. glabrata dose increased above 2 x 105 CFU/larva, larval 
survival decreased in dual compared with single C. albicans infection.    
 
We then built on the work of Rossoni et al. (2015) by testing whether species 
interactions were strain-dependent. We compared larval survival between a 
single species C. albicans infection of 2 x 105 CFU/larva and dual infection of C. 
albicans with different strains of C. glabrata or C. krusei (2 x 105 CFU/larva of 
each species), in one independent experiment. In single species C. glabrata 
and C. krusei infections, a dose of 2 x 105 CFU/larva was too low to cause 
infection (Table 3.2). In addition, no significant differences in larval survival with 
2 x 105 CFU/larva of C. albicans occurred across four clinical strains tested (P = 
0.7277; Table 3.3). No difference in survival (no interaction) occurred in dual 
infections of C. albicans SBC153 with C. glabrata strains ATCC 2001, NCPF 
3605, BG2, BG2Δssk2, 85/038 and 11088A (Table 3.4), compared with single 
species C. albicans infection. In contrast, significant decreases in larval survival 
in dual compared with single species C. albicans infections (synergistic 
interactions) occurred with C. albicans SBC153 and C. glabrata NCPF 3309, 
1184 and C. krusei ATCC 6258. No interaction was seen between C. albicans 
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ATCC 90028 and the lab reference C. glabrata strain ATCC 2001. In dual 
infections with C. krusei ATCC 6258, synergistic interactions occurred with C. 
albicans strains ATCC 90028 and B311, but there was no interaction in dual 
infection with C. albicans strain NCPF 3302. 
 
In all dual Candida species strain infections of G. mellonella described above, 
we did not see an increase in larval survival in dual compared with single 
species C. albicans infections as found in Rossoni et al. (2015). Importantly, we 
did, however, see potential synergistic interactions between some species 
strains and no interaction between others. We explored these contrasting 
interactions and influence on larval immunity in further experiments described in 
the next section.  
 
 
Table 3.2. Comparison of G. mellonella survival between single species C. 
glabrata and C. krusei strain infections. Infections had an inoculum dose of 2 x 105 
CFU (strains described in Table 3.1). G. mellonella larval survival was measured daily 
over 96 hours in one experiment for each species strain pairing. N = 16 in infection 
groups. Data was analysed in R (version 3.3.2; R Core Team, 2016) using the survival 
package ‘Hmisc’ to calculate mean survival times and log-rank comparison of larval 
survival across the strains. Log-rank test chi-squared = 7.11, P = 0.5244. 
 
Strain Mean survival time +/- SE (hours) 
C. glabrata 11088A 96.00 +/- 0.00 
C. glabrata 1184 91.13 +/- 4.88 
C. glabrata 85/038 96.00 +/- 0.00 
C. glabrata ATCC 2001 96.00 +/- 0.00 
C. glabrata BG2 96.00 +/- 0.00 
C. glabrata BG2Δssk2 93.00 +/- 3.00 
C. glabrata NCPF 3309 96.00 +/- 0.00 
C. glabrata NCPF 3605 96.00 +/- 0.00 
C. krusei ATCC 6258 96.00 +/- 0.00 
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Table 3.3. Comparison of G. mellonella survival between single species C. 
albicans strain infections. Infections had an inoculum dose of 2 x 105 CFU (strains 
described in Table 3.1). G. mellonella larval survival was measured daily over 96 hours 
in one experiment for each species strain pairing. N = 16 in infection groups. Data was 
analysed in R (version 3.3.2; R Core Team, 2016) using the survival package ‘Hmisc’ 
(Harrell et al., 2016) to calculate mean survival times and log-rank comparison of larval 
survival across the strains. Log-rank test chi-squared = 1.31, P = 0.7277. 
 
C. albicans strain Mean survival time +/- SE (hours) 
ATCC 90028 37.88 +/- 7.60 
B311 48.75 +/- 6.59 
NCPF 3302 38.25 +/- 6.15 
SBC153 37.13 +/- 4.46 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4. Comparison of G. mellonella survival between single species strain C. 
albicans infections and dual infection of C. albicans with different strains of C. 
glabrata and C. krusei. Single species infections of C. albicans had an inoculum dose 
of 2 x 105 CFU; dual species infections consisted of 2 x 105 CFU/larva C. albicans and 
2 x 105 CFU/larva of a strain of C. glabrata or C. krusei (described in Table 3.1). G. 
mellonella larval survival was measured daily over 96 hours in one experiment for each 
species strain pairing. N = 16 in dual and single species infection groups. Data was 
analysed in R (version 3.3.2; R Core Team, 2016) using the survival package ‘Hmisc’ 
(Harrell et al., 2016) to calculate mean survival times and log-rank comparison of larval 
survival between the dual and single C. albicans species infection groups. 
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C. 
albicans 
strain 
C. glabrata 
or C. 
krusei 
strain 
Dual 
infection: 
Mean 
survival 
time +/- SE 
(hours) 
Single 
infection 
(2 x 105 
CFU/larva 
C. 
albicans): 
Mean 
survival 
time +/- SE 
(hours)  
Log-rank 
test chi-
squared 
value: 
dual 
versus 
single 2 x 
105 
CFU/larva 
C. 
albicans 
infection 
p value 
from log-
rank test 
SBC153 C. krusei 
ATCC 6258 
18.38 +/- 
0.38 
27.00 +/- 
3.19 
7.68 0.00558 
SBC153 C. glabrata 
ATCC 2001 
21.75 +/- 
2.56 
30.00 +/- 
4.24 
3.36 0.06694 
SBC153 C. glabrata 
NCPF 3605 
26.25 +/- 
3.94 
27.00 +/- 
3.19 
0.02 0.8929 
SBC153 C. glabrata 
NCPF 3309 
38.25 +/- 
4.83 
54.00 +/- 
7.10 
4.64 0.03129 
SBC153 C. glabrata 
BG2 
48.38 +/- 
8.75 
54.00 +/- 
7.10 
0.49 0.4829 
SBC153 C. glabrata 
BG2Δssk2 
39.38 +/- 
5.50 
54.00 +/- 
7.10 
2.68 0.1015 
SBC153 C. glabrata 
1184 
20.63 +/- 
1.89 
37.12 +/- 
4.46 
14.78 0.0001209 
SBC153 C. glabrata 
85/038 
28.13 +/- 
3.50 
37.13 +/- 
4.46 
3.32 0.06844 
SBC153 C. glabrata 
11088A 
27.75 +/- 
4.17 
37.13 +/- 
4.46 
2.7 0.1006 
ATCC 
90028 
C. krusei 
ATCC 6258 
19.89 +/- 
1.88 
37.89 +/- 
7.60 
7.85 0.005079 
ATCC C. glabrata 24.38 +/- 37.89 +/- 1.82 0.1773 
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90028 ATCC 2001 3.26 7.60 
B311 C. krusei 
ATCC 6258 
19.13 +/- 
0.60 
48.75 +/- 
6.59 
21.61 3.341e-06 
NCPF 
3302 
C. krusei 
ATCC 6258 
36.38 +/- 
6.61 
38.25 +/- 
6.15 
0.06 0.799 
 
 
 
3.4.4 Strain-Dependent Dual Candida Species Interactions in G. mellonella 
 
We replicated dual Candida species infection of G. mellonella with C. albicans 
strain SBC153 in combination with two C. glabrata strains that did not appear to 
interact with C. albicans (strains NCPF 3605 and BG2) (Table 3.4), and two C. 
glabrata strains with proposed synergistic interactions (NCPF 3309 and 1184). 
To deduce lack of interaction or synergistic interaction between C. albicans and 
different strains of C. glabrata in individual dual-species infections, we 
compared larval survival between single species infections of 2 x 105 and 4 x 
105 CFU/larva of C. albicans and C. glabrata, with a dual species infection of 2 
x 105 CFU/larva of each species. For all four strains of C. glabrata, there was no 
significant decrease in larval survival in the single infections (Figure 3.3). As a 
result, a dual infection with 2 x 105 CFU/larva of any C. glabrata strain in 
combination with 2 x 105 CFU/larva of C. albicans would be expected to show 
no significant difference in larval survival compared with a single infection of 2 x 
105 CFU/larva of C. albicans. A significant decrease in larval survival in dual 
species infection compared with 2 x 105 CFU/larva of C. albicans in single 
infection would signify a synergistic interaction. 
  
Across three independent experiments, there was no significant difference in 
larval survival between single (2 x 105 CFU/larva) C. albicans infection and dual 
infection with C. glabrata NCPF 3605 (P = 1; Figure 3.3(b); Table A.2.1.S3), 
supporting a lack of species interaction. Larval survival was significantly greater 
in dual than single species infection with a total infection dose of 4 x 105 
CFU/larva C. albicans (P < 0.0001; Table A.2.1.S3). 
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In contrast, larval survival was significantly lower in dual infection compared 
with single C. albicans infection (2 x 105 CFU/larva), for C. albicans SBC153 in 
combination with C. glabrata strain BG2 (P = 0.0269; mean survival time- dual: 
37.5 +/- 3.98 hours, single- 50.75 +/- 3.73 hours) (Figure 3.3(a); Table 
A.2.1.S3) or C. glabrata strain NCPF 3309 (Figure 3.3(d); Table A.2.1.S3) (P = 
0.0003; mean survival times: 30.63 +/- 2.65 hours and 48.63 +/- 4.42 hours), 
suggesting synergistic species strain interactions. Larval survival was greater in 
dual infections than in single species infections with 4 x 105 CFU/larva C. 
albicans (p < 0.01; Figure 3.3(a) and (d); Table A.2.1.S3). In dual infection with 
C. glabrata strain 1184, larval survival was significantly lower compared with 2 x 
105 CFU/larva C. albicans (P = 4.80e-07; mean survival times: 21.75 +/- 1.80 
hours, 41.88 +/- 3.85 hours) (Figure 3.3c; Table A.2.1.S3) and larval survival in 
dual infection was equal to that of 4 x 105 CFU/larva of C. albicans in single 
infection (P = 1.00), suggesting a stronger synergistic response with this strain. 
 
We then tested the effects of C. albicans and C. krusei species strain 
interactions on larval survival over independent experiments. When single 
species infections of C. krusei were included in the same experiment that tested 
dual species infection of C. albicans SBC153 with C. krusei, we found no 
significant decrease in larval survival with 2 x 105 CFU/larva of C. krusei 
compared with the sterile PBS control (Figure 3.4(a)). We did, however, see a 
significant decrease in larval survival with 4 x 105 CFU/larva of C. krusei (mean 
survival time = 87.25 +/- 2.90 hours) but survival was still much greater than in 
single species C. albicans infections (Figure 3.4(a); Table A.2.1.S4). Dual 
infection of C. albicans SBC153 with C. krusei resulted in a significant decrease 
in larval survival relative to a single C. albicans infection of 2 x 105 CFU/larva (P 
= 0.0003; mean survival times 22.00 +/- 1.59 hours and 36.25 +/- 3.57 hours) 
(Figure 3.4(a); Table A.2.1.S4). Larval survival in dual infection was equal to 
that of a single infection of 4 x 105 CFU/larva of C. albicans (P = 1.00). Similarly, 
dual infection with C. albicans strain 18804 and C. krusei, the strains used in 
Rossoni et al. (2015), resulted in lower larval survival than a single infection of 2 
x 105 CFU/larva C.albicans strain 18804, (P = 8.50e-9) and mean survival time 
for dual infection was 18.75 +/- 0.29 hours (Figure 3.4(b); Table A.2.1.S4). 
This indicated strong synergistic interactions between C. albicans and C. krusei. 
It is, however, important to note that both C. krusei single species infections that 
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were run alongside the dual infection with C. albicans strain 18804 and C. 
krusei caused significant decreases in larval survival (Figure 3.4(b)), so the 
extent of the dual species synergistic interaction could not be unambiguously 
determined. Our results suggested a synergistic interaction as larval survival in 
dual infection was not significantly different from that of single infection with 4 x 
105 CFU/larva of C. albicans, despite the higher larval survival with 2 x 105 
CFU/larva of C. krusei (mean survival time = 55.75 +/- 5.13 hours) than with C. 
albicans (mean survival time = 40.38 +/- 4.05 hours) (Figure 3.4(b)). 
 
 
Figure 3.3. Survival curves for single species C. albicans and C. glabrata 
infections and dual C. albicans-C. glabrata infection of G. mellonella,  with 
different C. glabrata strains. Larval population survival (%) is plotted every 24 hours 
up until 96 hours. Each plot shows C. albicans strain SBC153 infection at 2 x 105 
(larger circles) and 4 x 105 (larger squares) CFU/larva, C. glabrata infection at 2 x 105 
(small diamonds) and 4 x 105 (small circles) and the dual species infection (2 x 105 
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CFU/larva of each species; larger triangles). Different C. glabrata strains tested in 
single and dual infections: (a) BG2; (b) NCPF 3605; (c) 1184; (d) NCPF 3309. Data 
was pooled from three biological replicates (N = 16 per infection group per biological 
replicate) for each plot, apart from (b) which was pooled from four biological replicates. 
Single species C. glabrata infections caused no significant decreases in larval survival 
for any strains compared with PBS control infections (Log-rank tests: P > 0.800). See 
Table A.2.1.S3 for statistical results from Log-rank tests comparing larval survival in 
single species C. albicans infections with dual species infection. 
 
 
 
Figure 3.4. Survival curves for single species C. albicans and C. krusei infections 
and dual C. albicans-C. krusei infection of G. mellonella. Larval population survival 
(%) is plotted every 24 hours up until 96 hours.  Each plot shows C. albicans infection 
at 2 x 105 (larger circles) and 4 x 105 (larger squares) CFU/larva, C. krusei infection at 2 
x 105 (small diamonds) and 4 x 105 (small circles) and the dual species infection (2 x 
105 CFU/larva of each species; larger triangles). (a) Infections are with C. albicans 
strain SBC153 and C. krusei ATCC 6258. C. krusei infection of 2 x 105 CFU/larva did 
not significantly affect larval survival (Log-rank test: P = 1.00) but 4 x 105 CFU/larva 
significantly decreased survival (P = 0.0062; mean survival time = 87.25 +/- 2.90 
hours). (b) Infections are with C. albicans strain ATCC 18804 and C. krusei ATCC 
6258, the same strains used in Rossoni et al. (2015). Unexpectedly, C. krusei 
infections caused significant decreases in survival compared with the PBS control 
(Log-rank test: P < 0.001) and survival was dose-dependent (Log-rank test: P = 
0.0208; mean survival time = 73.38 +/- 4.99; 55.75 +/- 5.13 hours, for 2 x 105 and 4 x 
105 CFU/larva respectively). Data was pooled from three independent experiments for 
each plot (N = 16 per infection group per biological replicate). See Table A.2.1.S4 for 
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statistical results from Log-rank tests comparing larval survival in single species C. 
albicans infections with dual species infection. 
 
 
3.4.5 Comparative Virulence and Host Melanisation Response across C. 
glabrata Strains 
 
To investigate potential causes of differences in the strength of the synergistic 
response between C. albicans and C. glabrata strains BG2 and 1184, we 
compared strain virulence and G. mellonella immune response as we observed 
qualitative differences in host melanisation response. After testing a range of 
doses of the two C. glabrata strains we found that, 5 x 106 CFU/larva of strain 
BG2 whereas 1.25 x 106 CFU/larva of strain 1184 resulted in comparable larval 
survival to an infection with 2 x 105 CFU/larva of C. albicans (Figure 3.5(a) and 
(b) respectively; Table A.2.1.S5). 
Figure 3.5. Survival curves of G. mellonella infection for doses of C. glabrata 
strains BG2 and 1184 with comparative virulence to C. albicans. (a) Comparative 
survival of 5 x 106 CFU/larva of C. glabrata BG2 (circles) and 2 x 105 CFU/larva of C. 
albicans SBC153 (squares) over 168 hours (7 days). (b) Comparative survival of 1.25 x 
106 CFU/larva of C. glabrata 1184 (circles) and 2 x 105 CFU/larva of C. albicans 
SBC153 (squares). Each plot represents pooled data from three independent 
experiments and statistical analyses are presented in Table A.2.1.S5.   
 
 
To quantify differences in G. mellonella melanisation responses induced by 
different C. glabrata strains, we injected larvae with 2 x 105 CFU/larva in single 
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species infections and measured melanin levels in the larval haemolymph, 
similarly to the methods of Scorzoni et al. (2013) and Ames et al. (2017)). We 
also tested melanisation response with C. krusei strain 6258 as this strain 
showed a similar level of synergism as C. glabrata strain 1184 when in dual 
infection with C. albicans SBC153 (Figures 3.3 and 3.4). Larval melanisation 
was significantly greater with C. glabrata strain 1184 infection than the PBS 
control or C. glabrata BG2 infection at 2 and 6 hours (Figure 3.6(b)). At 2 hours 
post-inoculation, larval melanisation with C. krusei infection was approximately 
two-fold greater than in PBS-injected control larvae (P = 0.04651) (Figure 
3.6(a)) whereas C. glabrata BG2 infection caused equal melanisation to the 
PBS control (Figure 3.6(a); (b)). At 6 hours, melanisation from C. krusei 
infection was significantly greater than with strain BG2 infection (P = 0.001650).  
  
* * ***
**
***
*****
(a) (b)
 
Figure 3.6. Melanisation response in G. mellonella with single species C. glabrata 
strain or C. krusei infection. G. mellonella were infected with 2 x 105 CFU/larva of C. 
glabrata BG2 (light grey bars) and C. krusei (a) or C. glabrata BG2 and 1184 (b) and 
melanisation (OD415) was measured at 2 and 6 hours, relative to PBS-injected controls 
(blue bars). Columns represent means +/- SE bars. Bars labelled with asterisks 
represent significant differences from Tukey’s post hoc test following one-way ANOVA: 
* = P < 0.05; ** = P < 0.01; *** = P < 0.001. (a) 2 hours: F2, 6 = 6.192; P = 0.0348 (PBS-
C. krusei: P = 0.04651; PBS-C. glabrata BG2: P = 0.9845; C. glabrata BG2-C. krusei: 
P = 0.05707). 6 hours: F2, 6 = 20.57; P = 0.00206 (PBS-C. krusei: P = 0.03517; C. 
glabrata BG2-C. krusei: P = 0.001650; PBS-C. glabrata BG2: P = 0.05089). (b) 2 
hours: F2, 6 = 32.93; P = 0.0005820 (PBS-C. glabrata 1184: P = 0.0005782; C. glabrata 
BG2-C. glabrata 1184: P = 0.002620; PBS- C. glabrata BG2: P = 0.2137). 6 hours: F2, 6 
= 47; P = 0.0002160 (PBS-C. glabrata 1184: P = 0.0003750; C. glabrata BG2-C. 
glabrata 1184: P = 0.0003879; PBS-C. glabrata BG2: P = 0.9986). 
 
 
 91 
 
 
3.5 Discussion 
 
 
In this chapter, we investigated dual Candida species interactions in the in vivo 
model Galleria mellonella and the influence of different C. glabrata clinical 
strains on the nature of the interactions. We tested dual species infection of C. 
albicans with C. glabrata or C. krusei and measured host survival during 
infection, for different species strain combinations. Importantly, we found that 
interactions between Candida species do not uniformly influence host survival, 
indicating that the type and strength of the interaction is dependent on the 
clinical strain. We also found that host immune response quantitatively varied 
across C. glabrata strains. These findings have implications for characterising 
the virulence of mixed-Candida species fungal infections in different host 
patients. 
 
Firstly, we sought to replicate the experiments of Rossoni et al. (2015) that 
described antagonistic interactions of Candida species in G. mellonella, but we 
could not replicate the increase in larval survival in dual species compared with 
single C. albicans infection using lab strains. This suggested that C. glabrata or 
C. krusei could not outcompete C. albicans or did not trigger an effective host 
response (I. Gudelj and S.Bates, pers. comm., April 2016). It is unclear why 
these differences occurred and is likely due to variation in larval batches, 
supplier or laboratory environmental conditions. We found that both C. glabrata 
and C. krusei showed a much greater decrease in larval survival by 96 hours 
than described by Rossoni et al. (2015) (C. glabrata: 66% (ours), 19% (Rossoni 
et al., 2015); C. krusei: 94% (ours), 34% (Rossoni et al., 2015)).  The infection 
dose of C. albicans (1 x 106 CFU/larva) used by Rossoni et al. (2015) was 
highly virulent as all larvae were dead at 18 hours, therefore we could not 
deduce whether the two species interacted synergistically or no interaction 
occurred in dual infection. In our experiments, lower doses of 1-4 x 105 
CFU/larva of C. albicans in single infection were sufficient to cause a decrease 
in larval survival at 37oC.  
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We extended the experiments of Rossoni et al. (2015) by testing dual infections 
with different clinical Candida species strains at lower infective doses and 
identified synergistic interactions or absence of interaction dependent on strain 
combination. No species interaction occurred in dual infection of C. albicans 
SBC153 with C. glabrata NCPF 3605, but larval survival decreased to varying 
degrees with three C. glabrata strains (BG2, NCPF 3309 and 1184) and C. 
krusei (ATCC 6258), suggesting synergistic interactions. Due to significant 
decreases in larval survival with single species infections of C. krusei, it was 
difficult to unambiguously determine synergism in the dual infection. Our 
method for deducing synergistic species interactions could be made more 
robust by combining doses of two Candida species with equal virulence in dual 
infection and comparing larval survival with single species infections of the 
same dose of each species that were used in dual infection. Synergism would 
be deduced if larval survival was lower in dual infection than in either of the 
single species infections. Our described synergistic species interactions 
contrast with studies showing competitive interactions in in vitro biofilms, 
whereby C. glabrata or C. krusei exerts an antagonistic influence on C. albicans 
(El-Azizi et al., 2004; Henry-Stanley et al., 2005; Thein et al., 2007; Rossoni et 
al., 2015; Santos et al., 2016). Alternatively, competitive interactions may not 
necessarily occur due to niche differentiation based on morphological or 
biochemical differences (Silva et al., 2011).  
 
Our results contribute to studies (Silva et al., 2011; Alves et al., 2014; Tati et al., 
2016) that have described dual-Candida species synergistic interactions and 
identified strain differences that impact on strength of interaction. In both 
Drosophila (Sibley et al., 2008) and Galleria (Whiley et al., 2014), the strength 
of synergistic interactions between Pseudomonas aeruginosa and Streptococci 
depended on the species strain combination and interaction with the immune 
system. Increased tissue invasion and damage was observed in dual C. 
glabrata-C. albicans infection in in vitro oral and vaginal epithelium (Silva et al., 
2011; Alves et al., 2014) across strains, potentially caused by increased C. 
glabrata nutrient acquisition via C. albicans tissue damage (Brunke and Hube, 
2013). In an immunosuppressed murine model of oral candidiasis (Tati et al., 
2016), synergism was characterised by increased colonisation and biofilm 
density in dual infections of C. glabrata and C. albicans, and C. glabrata was 
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found to adhere to C. albicans hyphae. C. glabrata strains showed differing 
degrees of synergism characterised by dual infection burden and our results 
support these findings by describing differences in host survival across C. 
glabrata strains in G. mellonella. 
 
Of particular interest is the strongly synergistic response we find in dual 
infections of C. albicans with C. glabrata 1184 or C. krusei ATCC 6258. C. 
krusei may form synergistic interactions with C. albicans due to hyphal 
attachment in co-infection, as described for C. glabrata (Tati et al., 2016). 
Understanding the interaction mechanism in vivo has medical significance as C. 
krusei is associated with a high mortality rate and intrinsic antifungal azole 
resistance (Scorzoni et al., 2013) and is often co-isolated with C. albicans in 
HIV patients (Rossoni et al., 2015). In the case of C. glabrata 1184, there are 
no previous studies that describe the origin of this strain or characterise its 
virulence (apart from Ames et al. (2017)) or dual species interactions. This 
highlights the need for better characterisation of the virulence properties and 
growth kinetics of fungal strains in dual species clinical infections.  
 
We found no synergistic interaction  between the species’ strains C. albicans 
SBC153 and C. glabrata NCPF 3605 as there was no significant difference in 
G. mellonella survival between single infection with 2 x 105 CFU/larva of C. 
albicans and dual infection with 2 x 105 CFU/larva of each species. Lack of 
synergistic interaction between species has been described in C. glabrata-C. 
albicans infection in a type 1 diabetic murine vaginal infection model (Nash et 
al., 2016). C. glabrata BG2 (a vaginal isolate) showed no significant increase in 
tissue invasion, biofilm formation or immune response in dual compared with 
single species C. albicans infection. Our results showed that absence of 
synergistic interaction between species (with C. glabrata strain 3605) was 
possible in systemic G. mellonella infection. Interestingly, NCPF 3605 was 
isolated from a diabetic patient (UKNCC, 2000) so the lack of synergistic 
interaction between species could be linked to C. glabrata strain adaptations to 
a high glucose environment rather than infection site. In our work, C. glabrata 
BG2 showed weak synergism with C. albicans and synergism was also 
described for this strain in murine oral infection (Tati et al., 2016). Alternatively, 
lack of synergistic interaction between species in our work could be correlated 
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with strain virulence level, as NCPF 3605 is highly attenuated compared with 
other C. glabrata strains (Ames et al. (2017)). Virulence differences across C. 
glabrata strains could explain the gradation in synergistic responses. We 
showed that a four times greater dose of BG2 than 1184 was required for equal 
virulence, which supports the greater virulence of strain 1184 described in 
Ames et al. (2017).  
 
We identified differences in the extent of host immune melanisation during early 
stages of infection across C. glabrata strains BG2 and 1184 and C. krusei, 
despite injecting avirulent doses of each strain. Dose-dependent melanisation 
has occured in C. glabrata strain ATCC 2001 (Ames et al., 2017) and in C. 
krusei (Scorzoni et al., 2013). Melanisation across clinical strains was only 
tested for C. krusei and did not quantitatively vary, unlikely the strain differences 
we observed in C. glabrata. Fast melanisation caused by C. krusei may be due 
to the larger rod-shaped cells and clumps of filaments causing greater immune 
stimulation (Scorzoni et al., 2013). Similarly, C. glabrata strain 1184 may cause 
greater host melanisation than strain BG2 due to greater cell agglutination. 
Differences in melanisation could explain the differences in strain virulence and 
interactions in dual infections, as over-activation of the host immune response 
can be detrimental to the host (Sibley et al., 2008).  
 
Single species infections showed that C. albicans had dose- and temperature-
dependent virulence at lower infective doses (1 x 105 – 4 x 105 CFU/larva), 
correlating with previous studies (Cotter et al., 2000; Scorzoni et al., 2013). A 
significant temperature effect was shown for a single dose of C. albicans 
(Scorzoni et al., 2013) and C. tropicalis (Mesa-Arango et al., 2013), although no 
temperature effect occurred for C. krusei (Scorzoni et al., 2013). One possible 
determinant of temperature-dependent virulence is the change in growth 
kinetics. C. albicans has a two-fold greater growth rate at 37oC than 30oC and 
reaches a higher population density in stationary phase (Scorzoni et al., 2013). 
In contrast, C. krusei has a slightly greater growth rate at 37oC but no difference 
in final population density.  
 
Temperature-dependent effects may also be due to changes in growth 
morphology between 30oC and 37oC. C. albicans forms hyphae during infection 
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at 37oC in G. mellonella, which contributes to virulence due to tissue invasion 
and biofilm formation (Fuchs et al., 2010). Studies have described this 
morphogenetic switch to occur at 37oC (Shen et al., 2008), due to regulation by 
the heat-shock protein Hsp90 (Shapiro and Cowen, 2012). In contrast, C. krusei 
only forms pseudohyphae (elongated cells) rather than true hyphae, which may 
decrease its invasive capacity (Samaranayake and Samaranayake, 1994). 
Alternatively, temperature may impact on host immune response through 
altered expression of invertebrate immune genes (Linder et al., 2008) and 
lowered phagocytosis (Ratcliffe, 1985; Mesa-Arango et al., 2013) at higher 
temperatures, or host and pathogen responses could both be altered. 
 
3.6 Conclusions of the Chapter 
 
In conclusion, our results are threefold: 
 
1) Competitive interactions do not always occur in dual-Candida species in 
vivo infections; species can interact synergistically or form no interaction 
and the strength of interaction is strain-dependent. 
 
2) Differences in C. glabrata strain virulence and host immune melanisation 
are correlated with the degree of synergistic interaction with C. albicans 
in dual infection. 
 
3) Virulence is temperature-dependent for low and intermediate doses of C. 
albicans. 
 
These results build on our experiments from Chapter 2 which investigated in 
vitro short and long-term competition dynamics between C. glabrata and C. 
albicans and identified differences in competitive interactions between C. 
glabrata strains. Chapter 4 will explore differences in growth kinetics of C. 
glabrata strains in in vitro glucose-limited cultures and comparative strain 
abilities to evolve antifungal resistance.  
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4. Chapter 4: Growth Kinetics of C. glabrata Clinical 
Strains and the Evolution of Antifungal Resistance 
 
4.1 Introduction 
 
 
Candida species inhabit many different body sites in which resource levels vary, 
so they must adapt their metabolism in order to survive and grow in these 
complex environments (Brown et al., 2014a). Carbon sources, particularly 
glucose, are important energy sources for growth, although S. cerevisiae can 
also sense and uptake nitrogen, phosphorus and trace nutrients (Gagiano et al., 
2002). Host niches are glucose-limited and concentrations vary between sites; 
glucose levels are normally present at 0.06-0.1% in the bloodstream (Barelle et 
al., 2006), 0.5% in the vagina (Owen and Katz, 1999) and up to 0.25% in faeces 
(Karabocuoglu et al., 1994). Glucose is not normally present in the urine but 
can be detected at concentrations of 11 mmol/l (0.2% w/v) in the urine or blood 
of diabetics (WHO Committee on Diabetes Mellitus, 1980; Gibson et al., 1990). 
 
Differential regulation of metabolic gene expression in C. albicans has been 
described in environmental adaptation and in the transition between commensal 
and pathogenic forms (Brown et al., 2014a). This allows efficient nutrient uptake 
and assimilation. Nutrient sensing and transport have been well characterised 
in Saccharomyces cerevisiae, including the description of low and high affinity 
glucose sensors and transporters (Ozcan et al., 1996) that are tuned to the 
environment (Lagunas, 1993) and control expression of respiratory or 
fermentative genes (Gagiano et al., 2002). A glucose sensor and transporters 
have also been described in C. albicans (Brown et al., 2006). S. cerevisiae and 
C. albicans are highly sensitive to a range of glucose concentrations resulting in 
changes in gene expression (Yin et al., 2003; Rodaki et al., 2009). C. glabrata 
shares a close evolutionary relation to S. cerevisiae and can switch from 
respiration to fermentation in the transition from low to high glucose (Postma et 
al., 1989b; Van Urk et al., 1990; Roetzer et al., 2011), unlike C. albicans which 
retains respiratory activity at high glucose (Rozpedowska et al., 2011). This 
raises the question as to whether C. glabrata strains that colonise different body 
sites with contrasting resource levels (Cataldi et al., 2016), show different 
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growth properties on glucose and adaptations to host-imposed stresses and 
antifungal treatment. 
 
Growth of microbial populations in the laboratory is typically quantified in 
seasonal resource environments (batch cultures) in which defined growth 
phases occur over time, described by a growth curve (Monod, 1949; 
Cunningham et al., 2010). The lag phase characterises initiation of enzymatic 
reactions and is followed by an increase in microbial growth rate that remains 
constant during the exponential phase of growth. Growth rate slows as 
microbial density approaches the maximum that the environment can sustain, 
due to nutrient limitation or accumulation of toxic metabolites. Cells enter 
stationary phase as the population growth rate decreases to zero and the 
carrying capacity is reached. This pattern of growth has been described in batch 
cultures of bacteria (Thornton, 1922; Schmidt et al., 1985) and in Candida 
species (Cuenca-Estrella et al., 2001). Thus, density-dependence exerts a 
control on intrinsic (per capita) growth rate such that a logistic model of 
population growth best describes change in population density over time in 
resource-limited microbial cultures (Vandermeer, 2010). This is described by 
the Verhulst equation (1) (Verhulst, 1845; Murray, 1990; Vandermeer, 2010) 
and is shown diagrammatically in Figure 4.1. In relation to the logistic equation, 
the parameters r (growth rate) and K (carrying capacity) can be calculated from 
microbial data to describe growth properties on limiting resources (Reding-
Roman et al., 2017).  
 
 = rN ( ); (1),  
where  represents population growth rate (change in size over time), r is 
exponential per capita growth rate (h-1), N is population size, K is population 
size at carrying capacity and r( ) represents intrinsic per capita growth rate 
(h-1). 
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Figure 4.1. Logistic population growth described by the Verhulst equation. This 
figure is adapted from Figure 1 in Murray (1990) and describes change in population 
size over time when controlled by density-dependent factors over seasonal growth. 
Population sizes shown are as follows: N0 is initial, Nt is size at time, t, K is size at 
carrying capacity of the environment and K/2 is half carrying capacity. Intrinsic growth 
rate (r( )) is controlled by how far the population size (N) is away from carrying 
capacity (K) (term ( ) which decreases growth rate as N approaches K). Growth rate 
is lower when N0 is below K/2 and population growth takes a sigmoidal form. 
Populations with different starting densities (N0 values) will converge on K, the stable 
population density maintained by environmental controls. 
 
 
The ability of microbes to take up and assimilate nutrients and to possess 
metabolic flexibility is important for stress adaptation and virulence (Barelle et 
al., 2006; Brown et al., 2014a). In C. albicans, gene regulatory networks link 
metabolism with stress resistance, virulence and cell wall remodelling in 
different host niches (Brown et al., 2014a). When glucose is limiting in host 
niches, flexibility to switch to metabolism of alternative carbon sources can aid 
oxidative and osmotic stress adaptation, virulence and antifungal resistance 
(Ene et al., 2012; Brown et al., 2014a, b; Miramón and Lorenz, 2017). In 
addition, switching between glycolytic, gluconeogenic and glyoxylate pathways 
in different host niches is important for virulence in C. albicans (Lorenz and 
Fink, 2001; Barelle et al., 2006; Miramón and Lorenz, 2017).  
 
exponential phase: r = 
intrinsic growth rate 
lag phase 
stationary phase 
Pop. 
density 
K= Pop. density at 
carrying capacity 
K/2 
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Variation in glucose levels differentially affects regulation of stress responses 
across yeast species, indicating adaptation to environments with different levels 
of nutrient availability (Roetzer et al., 2011). Whilst both C. albicans and S. 
cerevisiae are sensitive to low levels of glucose, C. albicans up-regulates 
oxidative and cationic stress genes over a range of glucose concentrations 
whereas S. cerevisiae down-regulates homologous genes (Rodaki et al., 2009). 
Both S. cerevisiae and the closely evolutionarily related pathogenic yeast C. 
glabrata show an environmental stress response whereby conserved stress 
protective genes are induced in response to a range of stresses (Roetzer et al., 
2008; Roetzer et al., 2011). For example, oxidative stress response genes are 
upregulated in response to glucose starvation. C. glabrata shows greater stress 
resistance due to the stressful environments it encounters in competition with 
other microbes on mucosal surfaces and from host immune defences during 
phagocytosis (Roetzer et al., 2011). 
 
Glucose also upregulates antifungal stress resistance genes in C. albicans 
(Rodaki et al., 2009) and in C. glabrata (Ng et al., 2016). Antifungal resistance 
is increasing in Candida species, particularly in C. glabrata (Pfaller et al., 2012; 
Sanglard, 2016), but current antifungal susceptibility testing is limited in 
predicting clinical resistance (Sanglard and Odds, 2002). Intrinsic resistance 
occurs naturally and is likely to have arisen from frequent toxin exposure within 
the host microbiota, prior to administration of antifungals (Roetzer et al., 2011). 
Acquired resistance has evolved with antifungal usage (Fidel et al., 1999) and 
for C. glabrata, this has occurred against all antifungal classes: azoles, 
echinocandins, polyenes (amphotericin B) and nucleoside analogues 
(flucytosine) (Pfaller et al., 2012). Standardised antifungal susceptibility testing 
(Clinical and Laboratory Standards Institute (CLSI), 2008; European Committee 
on Antimicrobial Susceptibility Testing (EUCAST), (Arendrup et al., 2012)) are 
commonly used to detect antifungal activity via growth inhibition defined by the 
MIC (minimum inhibitory concentration) of drug that is required to substantially 
inhibit growth (Sanglard, 2016). This measure can be a poor predictor of in vivo 
resistance and clinical outcomes, as it does not take into account host immune 
status, strain virulence and fitness and other environmental parameters such as 
nutrient concentrations at different host sites (Sanglard and Odds, 2002; 
Anderson, 2005; Kanafani and Perfect, 2008).  
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Whilst research into antibiotic adaptation dynamics in bacterial infections is 
increasing (Palmer and Kishony, 2013), few studies have investigated the 
evolutionary dynamics of antifungal adaptation (Cowen et al., 2002; Anderson, 
2005). Experimental in vitro evolution of antifungal resistance allows real-time 
dynamics of changing pathogen fitness and resistance mechanisms to be 
studied and replicated under controlled conditions, such that the specific effects 
of selection pressure and environment on adaptation can be determined 
(Cowen et al., 2002; Anderson, 2005). Evolutionary dynamics such as rates of 
adaptation (Hegreness et al., 2008), growth kinetics and mechanisms of 
resistance in parallel-evolved replicate populations have been studied in 
bacteria (Toprak et al., 2011; Lindsey et al., 2013; Oz et al., 2014). In fungi, in 
vitro evolution of antifungal resistance has been studied in C. albicans with 
fluconazole and amphotericin B (Cowen et al., 2000; Vincent et al., 2013) and in 
S. cerevisiae with fluconazole (Anderson et al., 2003), but real-time in vitro 
dynamics of C. glabrata resistance and fitness adaptations across different 
clinical strains have not been characterised.   
 
 
4.2 Aims of the Chapter 
 
In this Chapter, we focus on growth kinetics of C. glabrata strains in different 
glucose level environments and explore the influence on virulence and 
antifungal resistance adaptation. We address three main aims: 
 
1) To compare growth rate, carrying capacity and yield (efficiency of 
biomass production per unit of resource (Pfeiffer et al., 2001)) across C. 
glabrata strains in different glucose environments.  
 
2) To investigate whether differences in strain growth kinetics are related to 
different virulence levels. 
 
3) To determine whether strain growth kinetics are correlated with 
differential abilities to adapt to antifungal treatment. 
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We measured logistic growth parameters and yield of C. glabrata in single-
season (24-hour) batch cultures in minimal medium supplemented with a range 
of physiologically relevant glucose concentrations. This expanded the work of 
Ng et al. (2016) who found differences in growth rates across three different 
strains of C. glabrata over a small range of glucose concentrations, but did not 
characterise the relationship with carrying capacity or yield. We then selected 
strains with the most contrasting growth kinetics and determined whether these 
traits correlated with differences in virulence in the G. mellonella infection 
model.  
 
Finally, we compared the ability of strains with contrasting growth kinetics to 
adapt to treatment with the antifungal caspofungin. We selected caspofungin, a 
cell wall-targeting echinocandin class antifungal that is fungicidal as it destroys 
cell wall integrity (Kartsonis et al., 2003). Caspofungin is often used as the 
primary therapy for C. glabrata infections due to common resistance to 
fluconazole, however C. glabrata is increasingly becoming caspofungin-
resistant and resistance rate more than doubled in a recent 10-year study 
(Alexander et al., 2013). Although common mechanisms of resistance are well 
described (Sanglard, 2016), only one study has looked at the evolution of 
resistance over time in C. glabrata (Singh-Babak et al., 2012). The authors 
studied resistance evolution through serial isolation of patient samples rather 
than in controlled in vitro evolution so the influence of selection environment 
and dynamics of pathogen fitness could not be measured. We measured 
evolution of the caspofungin dose response inhibition profile via serial transfers 
of replicate populations in a range of constant drug concentrations. This allows 
for dynamic comparison of changing population fitness at different drug 
concentrations and was described by Peña-Miller et al. (2014) for characterising 
bacterial resistance evolution. 
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4.3 Materials and Methods 
 
 
4.3.1 Cell Growth in Synthetic Complete Medium at Different Glucose 
Concentrations 
 
These methods are as described in Reding-Roman et al. (2017), but are 
provided in more detail below.  
 
4.3.1.1 Media and Stock Solutions 
 
Overnight cultures of each strain were prepared in YPD medium (Yeast 
Peptone Dextrose with 20 mg ml-1 glucose (2% w/v)) in 4 ml volumes in 
universal tubes, via inoculation of a single colony per tube. Following 18-24 
hours incubation at 30oC and 180 rpm, overnights were centrifuged and washed 
once in PBS solution prior to re-suspension in SC (Synthetic Complete) minimal 
medium at the appropriate glucose concentration. 
 
SC medium was prepared at 14 different glucose concentrations ranging 0.25-
32 mg ml-1 by autoclaving media components (excluding glucose and 10% of 
the final media volume) prior to addition of filter-sterilised glucose solution. D-
Glucose was dissolved in distilled, de-ionised water to reach a final 
concentration of 320 mg ml-1 (32% w/v) and sterilised through a 0.22 μm filter 
unit. Glucose was diluted appropriately in autoclaved SC media and by addition 
of water to make up the final volume where necessary, to prepare SC medias 
with 4, 12, 20, 24 and 32 mg ml-1 final glucose concentrations. All other SC 
media were prepared from a 200 mg ml-1 (20% w/v) glucose stock solution. 
 
4.3.1.2 Candida glabrata Strains 
 
All strains used were the clinical strains and the osmotic stress-signalling 
mutant of the BG2 strain (BG2 Δssk2) described in Table A.1.2.S1 (ATCC 
2001, BG2, BG2Δssk2, NCPF 3605 and NCPF 3309). Strains were preserved 
in glycerol at -80oC and were streaked on YPD agar and incubated at 30oC for 
48 hours then maintained at room temperature prior to preparation of overnight 
cultures. 
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4.3.1.3 Single Season Cell Growth Assays 
 
Overnight cultures of each strain were split into separate universal tubes based 
on the number of glucose concentrations to be tested. Each was centrifuged 
and re-suspended in equal volume in 1 x PBS. A 1:7 dilution of each was 
prepared in PBS and one universal of overnight culture per strain was further 
diluted for cell enumeration with a haemocytometer, to calculate cell 
concentration in cells/ml. Cultures were centrifuged and re-suspended in equal 
volumes of the appropriate glucose concentration SC media, per strain. All 
universals were diluted in their SC media to reach a concentration of 6.49 x 106 
cells/ml and cell suspensions were diluted in PBS and plated on YPD to verify 
viable cell concentration (CFU/ml).  
 
Cell growth per strain, per glucose concentration was measured in 96-well clear 
flat-bottom, non-adherent polystyrene microtiter plates (Greiner Bio-One; 
Product code: 655161) via inoculation of wells containing 75 µl of the 
appropriate glucose concentration SC medium, with 75 µl of diluted cells to 
reach a final volume of 150 µl per well (final cell concentration within wells 
approximately 3.25 x 106 cells/ml). Background controls containing 150 µl of 
media were included for each SC media used in the plate. The outer border 
wells were filled with 150 µl of distilled, DI water to reduce edge effects of 
evaporation. Each of the five strains were grown in triplicate cultures within a 
96-well plate over the 14 different glucose concentrations and experiments 
were repeated over three independent biological replicates, resulting in a 
sample size of 9 replicates per strain and glucose concentration. 
 
96-well plates were sealed with transparent film and 2 holes were punctured in 
the film over the centre of each well via a sterile needle, for aeration. Plates 
were incubated at 30oC over 24 hours with orbital shaking at 182.6 rpm 
(amplitude 4 mm) in a Tecan M200 microtiter plate reader, with OD (Optical 
Density) readings at 650 nm wavelength taken every 20 minutes. OD is used as 
a proxy for total biomass (number of cells and cell size), which indicates the 
total carbon assimilated over time and can easily be tracked during growth 
(Reding-Roman et al., 2017).  
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4.3.1.4 Data Analysis and Statistics 
 
Data for each strain and glucose concentration condition was compiled across 
biological replicates and imported into MATLAB for analysis and fitting of a four-
parameter growth model, which is a modified solution of the logistic equation 
that includes lag phase (equation (9); Reding-Roman et al. (2017)). The model-
estimated blank OD (optical density) readings of the media-only wells were 
subtracted from microbial growth data of all culture wells. Yield (efficiency of 
glucose conversion into biomass) was calculated as K (carrying capacity) 
divided by glucose concentration (mg ml-1). 
 
In order to achieve mechanistic descriptions of the data, we fitted growth kinetic 
equations that incorporated yield (efficiency of biomass production) as a 
variable function of glucose concentration, to growth rate (r), carrying capacity 
(K) and yield data measured at different glucose concentrations (Meyer et al., 
2015; Reding-Roman et al., 2017). Yield was modelled as a variable function 
due to a proposed switch from respiration to fermentation at higher glucose 
concentrations that is predicted to decrease efficiency of biomass production 
through incomplete respiration and production of waste metabolites (Pfeiffer et 
al., 2001; MacLean and Gudelj, 2006; Meyer et al., 2015; Reding-Roman et al., 
2017). Final data plots, statistical analyses of model fits and t-tests to compare 
growth parameters were produced in MATLAB and were completed by Carlos 
Reding-Roman, University of Exeter. 
 
Barplots of growth kinetic parameters (r, K and yield) across C. glabrata strains 
were plotted for low (1 mg ml-1) and intermediate (10 mg ml-1) glucose 
concentrations in Excel. R version 3.4.3 (R Core Team, 2017) was used for two-
way ANOVA tests to analyse the effects of C. glabrata strain, glucose 
concentration and their interaction on each of growth rate, carrying capacity and 
yield. Tukey post hoc tests were used to deduce significant pairwise 
differences. We tested for the asumptions of normality and homoscedasticity for 
the ANOVA model by visualising the distribution of the standardised residuals 
and the relationship with model-fitted values.  
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4.3.2 Comparative Virulence of C. glabrata Strains 
 
Galleria mellonella larval survival assays (as described in Chapter 3) were used 
to compare virulence of C. glabrata strains 2001 and 3605 at an intermediate 
inoculum dose (2.5 x 106 CFU/larva). Methods from Ames et al. (2017) were 
used with modifications. 20 larvae per C. glabrata strain were injected with the 
inoculum dose in the top left proleg and experiments were repeated twice 
independently. Using OASIS 2 software (Han et al., 2016), the log-rank test 
confirmed that there were no significant differences in larval survival for each C. 
glabrata strain between the two independent experiments so the data was 
pooled. Data was analysed in R (R Core Team, 2016) using the package 
‘Hmisc’ (Harrell Jr et al., 2006) to plot Kaplan-Meier survival plots, calculate 
mean survival times and compare survival between strains using the log-rank 
test. Ames et al. (2017) tested larval survival at the mammalian physiological 
temperature of 37oC, whereas we incubated larvae at 30oC as we measured in 
vitro growth kinetics of C. glabrata at this temperature (described above). 
 
4.3.3 In vitro Experimental Evolution of Populations of C. glabrata Strains 
2001 and 3605 on a Gradient of Caspofungin Concentrations  
 
To compare the abilities of C. glabrata strains 2001 and 3605 to evolve 
caspofungin resistance in the laboratory, we tested for growth adaptation in 
replicate populations of each strain that were grown across a gradient of 
caspofungin concentrations in 10 mg ml-1 glucose Synthetic Complete medium, 
an intermediate glucose concentration to allow for sufficient growth of C. 
glabrata strains 2001 and 3605 (see Figure 4.2 for experimental design). A 
single overnight culture of each strain founded all replicate populations at the 
eight different caspofungin concentrations and the drug-free growth control. 
Replicate populations were serially transferred every 24 hours to fresh media 
and drug conditions, maintaining the same environmental conditions for each 
population in subsequent seasons. A total of 14 serial transfers of all 
populations were completed in the evolutionary experiment and the whole 
experiment was repeated on three separate 14-day periods. We used this as a 
high-throughput approach to test adaptation of populations at a range of 
clinically-relevant caspofungin concentrations (Espinel-Ingroff et al., 2013) over 
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time. The highest caspofungin concentration used was approximately 8 times 
the MIC50 recorded previously for C. glabrata isolates (Espinel-Ingroff et al., 
2013) and that found in our pilot experiments. We tracked real-time growth of all 
populations during each season via OD (optical density) measurement in a 
Tecan M200 microtiter plate reader. The 96-well plate was sealed with 
transparent film and 2 holes were punctured over the centre of each well via a 
sterile needle, for aeration. Plates were incubated at 30oC over 24 hours with 
orbital shaking at 182.6 rpm (amplitude 4mm), with OD (Optical Density) 
readings at 650 nm wavelength taken every 20 minutes. In Experiment 1, day 6 
and 13 cells were grown in an orbital shaking incubator with only a single 
reading taken at 24 hours (after 60 seconds shaking) on the Tecan reader. 
 
 
 
Figure 4.2. Experimental design for populations of C. glabrata strains 2001 and 
3605 evolving on a gradient of caspofungin concentrations. Experimental 
populations were evolved in 96-well plates. Eight different caspofungin concentrations 
representing a 1.75-fold dilution series from 2.4 µg/ml were prepared separately in 10 
mg ml-1 glucose Synthetic Complete medium. Aliquots of 75 µl of a single drug 
concentration were added to 6 replicate wells from rows B to G in a single column of 
the 96-well plate. The prepared plate contained a decreasing gradient of caspofungin 
concentrations from columns 2 to 9. The 6 replicate wells in column 10 contained 75 µl 
aliquots of 10 mg/ml SC medium alone and represented growth controls. Column 11 
contained 6 replicate wells of 150 µl of 10 mg ml-1 SC medium alone as media controls. 
75 µl aliquots of diluted cells of strain 2001 were added to all wells in rows B - D in 
columns 2 - 10 of the plate. Diluted cells of strain 3605 were added to all wells in rows 
E – G in columns 2 – 10 of the plate. The outer border wells of the plate were filled with 
150 µl of distilled, DI water to reduce edge effects of evaporation. On each subsequent 
day, a new 96-well plate was prepared with the same caspofungin concentration 
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gradient and identical layout, but 145 µl aliquots of each drug concentration were 
added to the plate wells. Following 24 hours of incubation and measurement of C. 
glabrata growth in the previous day’s 96-well plate, cells in all wells were re-suspended 
and a 5 µl aliquot from each well was pipette-transferred to the corresponding well in 
the newly-prepared 96-well plate. Identical daily transfers were completed for a total of 
14 days. The entire experiment was repeated over 3 separate 14-day periods with a 
separate overnight culture of the ancestral stock of strains 2001 and 3605 used for 
each experiment. 
 
A working caspofungin stock solution was prepared from powder stock 
(provided by Christopher Thornton, University of Exeter, UK) stored at -80oC, 
which was diluted in sterile distilled, de-ionised water to reach a final 
concentration of 5 mg ml-1 and stored at -20oC. Caspofungin concentrations 
required for the evolutionary experiment were prepared by appropriate dilutions 
of the 5 mg ml-1 stock solution in SC medium. Eight drug concentrations were 
separately prepared from the 5 mg ml-1 caspofungin stock, diluted in 1% w/v 
glucose SC and vortex-mixed in Eppendorf tubes. Prepared caspofungin 
concentrations differed by 1.75-fold, ranging 0.1 – 4.8 µg/ml (final 
concentrations following 2-fold dilution with cell suspension in the 96-well plate 
were 0.05- 2.4 µg/ml). The two C. glabrata strains were each diluted to a final 
concentration of 6.49 x 106 cells/ml (2 x final concentration in 96-well plate) in 
SC medium before adding to the plate.  
 
In subsequent seasons, caspofungin concentrations prepared in Eppendorfs 
matched the final concentrations (0.05- 2.4 µg/ml) in the plate wells, added in 
145 µl aliquots to wells. Serial transfer of 5 µl aliquots to these wells from the 
previous season’s populations did not alter the caspofungin concentration in the 
final 150 µl per well. Following daily transfers, remaining volumes of all cell 
populations were frozen at -80oC in a final concentration of 15% v/v glycerol 
(Fisher Scientific UK, Loughborough, UK; Product Code: G/0650/17) within 
each plate well by adding appropriate volumes of 50% v/v glycerol stock to 
each well and pipette mixing.  
 
Data was imported into MATLAB (MATLAB and Statistics Toolbox Release, 
2012a) for analysis and model fitting of the four-parameter logistic growth 
equation to daily growth profile data at each drug concentration. The data was 
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blank-corrected by subtracting the OD at time 0 predicted from the logistic 
model fit, from all other time points in each growth curve. This best-fit model 
was used to compute growth rate (r) and carrying capacity (K). Growth profile 
data was used to calculate final OD at 24 hours and AUC (area under the 
growth profile curve) as extra measures of microbial fitness (Roemhild et al., 
2015).  
 
We measured the daily dose response profile of each strain via final OD (at 24 
hours) measurement across populations at different drug concentrations. As 
described in Roemhild et al. (2015), growth inhibition in daily dose responses 
was measured as % relative growth, the OD at 24 hours of each drug-treated 
population as a percentage of the mean OD of the no drug-treated populations. 
We used IC50 as a measure of drug sensitivity, similar to the IC75 measure 
used in Roemhild et al. (2015) and analogous to the caspofungin MIC described 
in clinical studies (Espinel-Ingroff et al., 2013). In a large inter-lab comparison of 
C. glabrata isolates, caspofungin MICs ranged between 0.031-0.5 µg/ml 
(Espinel-Ingroff et al., 2013). A four-parameter logistic dose response model 
was fitted to the growth data across populations evolving on the gradient of 
caspofungin concentrations. The model was used to predict IC50 and slope 
(gradient of inhibition: Hill coefficient) using R package ‘drc’ and to compare 
parameters between dose response profiles (Ritz et al., 2015; R Core Team, 
2016). Plots show all data points (Figure 4.9; Figure A.3.1.S8-S11) or the best 
fit of the model with associated 95% confidence region (Figure A.3.1.S6).  
 
We used the lme4 package (Bates et al., 2015) with R version 3.4.3 (R Core 
Team, 2017) to conduct a linear mixed effects analysis of the effect of 
caspofungin concentration on relative growth of C. glabrata. We tested the 
influence of C. glabrata strain, day of the evolutionary experiment and 
caspofungin concentration as fixed effects and also tested for 2-way or 3-way 
interactions. The individual 14-day evolutionary experiments were treated as a 
random effect with a random intercept, to account for variation between 
separate experimental runs. We checked the distribution of the standardised 
residuals from the fitted model for normality and checked for homoscedasticity 
in the standardised residuals with the Fligner-Killeen test, which showed lack of 
significant heteroscedasticity (Fligner-Killeen:med chi-squared = 93.808, df = 
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161, P = 1). We started with a full model including the three main effects and all 
possible interactions and obtained P-values from likelihood ratio tests 
comparing the full model with alternative models with individually-removed 
interactions. These tests showed the significance of individual interactions. 
 
 
 
4.4 Results 
 
4.4.1 Resource-Dependent Growth Kinetic Relationships across and 
within C. glabrata Strains 
 
We grew five clinical strains of C. glabrata in minimal medium at 14 different 
glucose concentrations over single seasons, measuring optical density and 
calculating growth rate (r), carrying capacity (K) and yield (efficiency of biomass 
production) per glucose concentration for each strain (Reding-Roman et al., 
2017). Growth rate increased with glucose concentration across all strains of C. 
glabrata, reaching a maximum at intermediate glucose concentrations (Figure 
4.3(a); Figure A.3.1.S1). Further increases in glucose concentration above this 
level resulted in saturation of growth rate followed by a decrease for all strains. 
Population size at carrying capacity (K) also increased with glucose 
concentration across all C. glabrata strains (Figure 4.3(b); Figure A.3.1.S2), 
but saturated above intermediate glucose concentrations. Efficiency of biomass 
conversion (yield) rapidly declined at low glucose concentrations for C. glabrata 
(Figure 4.3(c); Figure A.3.1.S3) then saturated at a low level (below 0.05 OD 
mg ml-1) for further increases in glucose concentration. A model that described 
a non-linear relationship between yield and glucose concentration for E. coli 
(Meyer et al., 2015) was a good fit to the data for each C. glabrata strain 
(Figure 4.3(c); Figure A.3.1.S3). 
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Figure 4.3. Growth kinetics of five C. glabrata strains measured over a range of 
glucose concentrations. These data plots were taken from Figure 1 of Reding-
Roman et al., (2017). Growth kinetic data is shown for 5 clinical strains of C. glabrata 
(see Methods) plotted along the z-axis. Growth parameters were measured over 14 
glucose concentrations for each C. glabrata strain and N = 9 for each concentration. 
Glucose concentrations are plotted in ascending order along the x-axis in (a) and (c) 
and in descending order in (b). Growth parameters measured on the y-axis: (a) per 
capita growth rate (h-1) (r), (b) population size (OD) at carrying capacity (K) and (c) 
yield (OD/ mg ml-1 glucose). Separate 2-dimensional plots for each strain were 
constructed for each of the datasets in (a) (Figure A.3.1.S1), (b) (Figure A3.1.S2 with 
glucose concentrations plotted in ascending order on the x-axis) and (c) (Figure 
A.3.1.S3). Growth parameters were estimated from best fit of a logistic equation to 
growth profile data (Reding-Roman et al., 2017). Dots represent experimental data 
whereas solid lines are model predictions based on mechanistic equations derived in 
Meyer et al., (2015) and Reding-Roman et al., (2017), which incorporate yield 
(efficiency of glucose conversion to biomass) to vary as a function of glucose 
concentration. The fitted model relationship between yield and glucose concentration 
(c) is a robust fit to the data for all C. glabrata strains (adjusted R2 = 0.995, 0.98, 0.99, 
0.95, 0.98) (Reding-Roman et al., 2017). In (c), the last solid line fitted on the z-axis 
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shows the predicted lack of relationship if yield was not glucose concentration-
dependent. Data plots and model fitting were completed by Carlos Reding-Roman, 
University of Exeter. 
 
We investigated whether relationships existed between growth rate (r), carrying 
capacity (K) and yield within each C. glabrata strain. We found that a parabolic 
profile robustly described the r/K relationship for each strain across all glucose 
concentrations (Figure 4.4; Reding-Roman et al., 2017). A mechanistic model 
(Reding-Roman et al., 2017), which described growth rate as a product of 
glucose-dependent yield and uptake, was a robust fit to the data. Growth rate 
and carrying capacity were positively correlated (“trade-up”) between low and 
intermediate glucose concentrations and negatively correlated (‘trade-off”) 
between intermediate and high glucose concentrations. Similarly, growth rate (r) 
and yield were also described by a parabolic relationship for each strain of C. 
glabrata across glucose concentrations (Figure 4.5). As yield is negatively 
correlated with K (Figure 4.3), the glucose concentration-dependent 
correlations were reversed: rate and yield were positively correlated (“trade-up”) 
at higher glucose and negatively correlated (“trade-off”) at lower glucose 
(Figure 4.5). Growth rates were maximised at intermediate glucose 
concentrations (Figure 4.4 and 4.5). 
 
We then compared the rate versus carrying capacity and rate versus yield 
parabolic profiles across C. glabrata strains and found that the shapes differed 
(Figure 4.6; top panels). Strain 3605, isolated from a diabetic patient, showed 
profiles that were noticeably skewed towards higher growth rate, with lower 
carrying capacities and yields compared with all other strains. We compared 
mean growth rate, carrying capacity and yield, measured across all glucose 
concentrations, between strains 2001 (lab reference strain) and 3605 and found 
that strain 3605 had a significantly higher growth rate but lower carrying 
capacity and yield than strain 2001 (Figure 4.6; bottom panels).  
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Figure 4.4. Relationship between growth rate (r) and carrying capacity (K) in five 
C. glabrata strains. These plots are taken from Supplementary Figure S5 in Reding-
Roman et al. (2017). Data points are plotted from all 14 glucose concentrations (N = 9 
per glucose) with the colour gradient from light to dark blue indicating increasing 
glucose concentration. Plots from left to right, top to bottom show strains 2001, 3309, 
3605, BG2 and BG2Δssk2. The black solid lines represent a fit of a model equation 
that describes growth rate as a product of yield (glucose concentration-dependent) and 
Glucose concentration (mg ml-1) 
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glucose uptake rate (Meyer et al., 2015; Reding-Roman et al., 2017). Carrying capacity 
(K) is equal to yield multiplied by glucose concentration (mg ml-1). 
 
 
 
Figure 4.5. 
Relationship between growth rate (r) and yield (OD mg ml-1 glucose) in five C. 
glabrata strains. These plots were generated by Carlos Reding-Roman, University of 
Exeter, using data described in Reding-Roman et al., (2017). Data points are plotted 
from all 14 glucose concentrations (N = 9 per glucose) with the colour gradient from 
dark to light blue indicating decreasing glucose concentration. Plots from left to right, 
Glucose concentration (mg ml-1) 
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top to bottom show strains 2001, 3309, 3605, BG2 and BG2Δssk2. The black solid 
lines represent a model fit, describing growth rate as a product of yield (glucose 
concentration-dependent) and glucose uptake rate (Meyer et al., 2015; Reding-Roman 
et al., 2017).  
 
3605
2001
3605
2001
 
 
Figure 4.6. Comparison of r/K and r/yield relationships across C. glabrata strains. 
r/K plots (left panels) were taken from Reding-Roman et al., (2017) and r/yield plots 
(right panels) were created by Carlos Reding-Roman, University of Exeter. The top two 
panels compare the parabola model fits across all five strains (shown by blue colour 
gradient) taken from data presented in Figure 4.4 and 4.5. Strains 3605 (diabetic 
patient) and 2001 (lab reference) with contrasting parabola shapes are labelled. The 
bottom left panel compares C. glabrata strain 2001 (light blue) with strain 3605 (dark 
blue), contrasting in growth rate and carrying capacity (t-test for r: t = -4.52, df = 250, P 
< 10-5; for K: t = 7.72, df = 250, P < 10-12). The solid blue lines show the model fits 
(adjusted R2 = 0.982, 0.878) (Reding-Roman et al., 2017). The bottom right panel 
compares C. glabrata strain 2001 (light blue) with strain 3605 (dark blue), contrasting in 
yield (Kruskal-Wallis rank sum test: chi-squared = 78.658, df = 1, P < 2.2e-16). The 
solid blue lines show the model fits (Reding-Roman et al., 2017).  
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We then tested for glucose concentration-specific differences in mean growth 
rate, K and yield across C. glabrata strains through further analysis of the strain 
data collected at intermediate (10 mg ml-1) and low (1 mg ml-1) glucose 
concentrations. We used two-way ANOVA tests to analyse the effect of C. 
glabrata strain, glucose concentration and their interaction on growth rate, 
carrying capacity and yield.  
Growth rate significantly differed across C. glabrata strains (2-way ANOVA: F4, 
80 = 37.11, P < 2e-16) and glucose concentrations (2-way ANOVA: F1, 80 = 
246.36, P < 2e-16), and the magnitude of the strain differences varied with 
glucose concentration (strain x glucose concentration interaction, 2-way 
ANOVA: F4, 80 = 76.70, P < 2e-16) (Figure 4.7(a)). Strain 3605 had a 
significantly greater growth rate than strains BG2, 3309 and 2001 at 
intermediate glucose concentration (10 mg ml-1) (Tukey HSD post hoc test- 
3605:BG2, P < 0.01; 3605:3309, P < 0.001; 3605:2001, P = 0.000), but a 
significantly lower growth rate than each of these strains and BG2Δssk2 at low 
glucose concentration (1 mg ml-1) (Tukey HSD post hoc test- P = 0.000). 
Additionally, strains 2001 and 3309 had significantly lower growth rates than 
strains BG2 and BG2Δssk2 in intermediate glucose (Tukey HSD post hoc test- 
2001: BG2, P < 0.001; 2001: BG2Δssk2, P = 0.000; 3309: BG2, 3309: 
BG2Δssk2, P < 0.001). Strains 2001 and 3309 only had significantly lower 
growth rates than strain BG2Δssk2 in low glucose (Tukey HSD post hoc test- 
2001: BG2Δssk2, P = 0.000; 3309: BG2Δssk2, P < 0.01). Growth rate was 
significantly greater at intermediate (I) than low (L) glucose concentration for 
strains 3605 and BG2 only (Tukey HSD post hoc test- 3605 (I): 3605 (L), P = 
0.000; BG2 (I): BG2 (L), P < 0.001).  
 
Carrying capacity significantly varied across C. glabrata strains (2-way ANOVA: 
F4, 80 = 441.57, P < 2e-16) and glucose concentrations (2-way ANOVA: F1, 80 = 
5299.65, P < 2e-16) (Figure 4.7(b)). The difference in carrying capacity 
between strains significantly varied between low and intermediate glucose 
concentrations (strain x glucose concentration interaction, 2-way ANOVA: F4, 80 
= 35.48, P < 2e-16). 
 116 
Strain 3605 had a significantly lower carrying capacity than all of the other four 
strains at intermediate and low glucose concentrations (Tukey HSD post hoc 
test- P = 0.000). Additionally, strains 2001 and BG2 had significantly lower 
carrying capacities than strains 3309 and BG2Δssk2 in intermediate glucose 
(Tukey HSD post hoc test- 2001: 3309, BG2: 3309, P = 0.000; 2001: 
BG2Δssk2, BG2: BG2Δssk2, P < 0.001). The carrying capacity of strain 
BG2Δssk2 was significantly lower than that of strain 3309 in intermediate 
glucose (Tukey HSD post hoc test- P = 0.000). Carrying capacity was 
significantly greater at intermediate (I) than low (L) glucose concentration for all 
five strains (Tukey HSD post hoc test- P = 0.000).    
 
Yield significantly varied across C. glabrata strains (2-way ANOVA: F4, 80 = 
218.1, P < 2e-16) and glucose concentrations (2-way ANOVA: F1, 80 = 1627.5, P 
< 2e-16) (Figure 4.7(c)). The difference in yield between strains significantly 
varied between low and intermediate glucose concentrations (strain x glucose 
concentration interaction, 2-way ANOVA: F4, 80 = 124.9, P < 2e-16). Strain 3605 
had a significantly lower yield than strains 2001, 3309 and BG2Δssk2 at 
intermediate glucose concentration (Tukey HSD post hoc test- 3605: 2001, P < 
0.05; 3605: 3309, P < 0.001; 3605: BG2Δssk2, P < 0.01). Strain 3605 had a 
lower yield than all four of the other strains at low glucose concentration (Tukey 
HSD post hoc test- P = 0.000). Strain BG2Δssk2 had a significantly lower yield 
than strain 3309 in low glucose (Tukey HSD post hoc test- P < 0.01). Yield was 
significantly greater at low than intermediate glucose for all strains except strain 
3605 (Tukey HSD post hoc test- P = 0.000). 
 
We concluded that strains 2001 and 3605 had most contrasting growth 
strategies as all three growth parameters significantly differed between the 
strains at both glucose concentrations (Figure 4.7). At low glucose, strain 2001 
compared with strain 3605 had a 6.3-fold higher growth rate and a 12.8-fold 
greater carrying capacity and yield. Figure A.3.1.S4 (left panels) show example 
growth profile plots and model fits, indicating a flat growth profile for strain 3605.  
At intermediate glucose, strain 2001 compared with strain 3605 had a 1.8-fold 
lower growth rate and 1.8-fold greater carrying capacity and yield. Figure 
A.3.1.S4 (right panels) show logistic growth profile shapes for each strain and 
the balance between growth rate (r) and carrying capacity (K). Between glucose 
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concentrations, strain 3605 had a 13.9-fold greater growth rate at intermediate 
than low glucose whereas strain 2001 had no difference (Figure 4.7). Carrying 
capacity was 2.3-fold greater for strain 2001 at intermediate glucose and 17.2-
fold greater for strain 3605. Yield was 4.3-fold greater for strain 2001 at lower 
glucose but there was no significant change for strain 3605. 
 
 
 
Figure 4.7. Growth rates, carrying capacities (K) and yields across C. glabrata 
strains at low and intermediate glucose concentrations. Figures are plotted from 
data collected at 1 and 10 mg ml-1 presented in earlier plots. Growth parameters were 
measured across all strains and both glucose concentrations (low and intermediate) (a) 
Growth rate (r) per capita (h-1); (b) K (OD at carrying capacity); (c) Yield (OD per mg 
ml-1 glucose). Bar plots show mean value +/- SE.  
 
 
 
 
 
 
4.4.2 Comparative Virulence of C. glabrata Strains 2001 and 3605 
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To determine whether contrasting growth kinetics of C. glabrata strains 2001 
and 3605 correlated with differences in virulence, we measured survival of 
Galleria mellonella wax moth larvae over single strain infection at 30oC. Over 10 
days, we found that strain 2001 caused a significantly greater decrease in larval 
survival, with a negligible change in survival of strain 3605 (Figure 4.8). Mean 
survival time (+/- SE) of strain 2001 was 5.65 +/- 0.53 days, compared with 9.63 
+/- 0.25 days for strain 3605. 
 
Figure 4.8. Survival of Galleria mellonella infected with C. glabrata strain 2001 or 
3605 at 30ºC. Survival was measured daily for 10 days following infection with a 
moderate dose of either strain. Data was pooled from two independent experiments 
that showed no significant differences in survival and N = 40 for each strain. Kaplan-
Meier survival curves were plotted: Log rank test = 40.56, df = 1, P = 1.907e-10. 
 
 
4.4.3 Experimental Evolution of Populations of C. glabrata Strains 2001 
and 3605 Across a Gradient of Caspofungin Concentrations 
 
For each C. glabrata strain, we measured the daily growth density relative to the 
no-drug treated control for triplicate populations evolving at each of eight 
caspofungin concentrations. The experimental evolution was repeated over 
three 14-day experiments (E1-3), using a separate overnight culture of each 
strain per experiment to found all replicate populations. Both strains were 
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evolved at drug concentrations diluted in SC medium at intermediate glucose 
concentration (10 mg ml-1) as strains 2001 and 3605 were greatly contrasted in 
growth rate and carrying capacity at this glucose concentration (Figures 4.3-
4.7) (Reding-Roman et al., 2017).  
 
By treating variation between independent experiments as a random effect, we 
found that relative growth of C. glabrata over time between the start, mid and 
end-points of the evolutionary experiment (across days 1, 7 and 14) was 
significantly influenced by strain (effect of strain x day interaction, likelihood 
ratio test: χ2(2) = 11.77, P = 0.00278), but this effect was not significantly 
dependent upon caspofungin concentration (effect of strain x day x caspofungin 
concentration interaction, likelihood ratio test: χ2(2) = 2.97, P = 0.226). The 
average relative growth percentage of strain 2001 increased by 19.9 between 
days 1 and 7 and a by a further 5.4 between days 7 and 14 (Figure A.3.1.S5 
(a)). In contrast, average relative growth percentage of strain 3605 only 
increased by 6.7 between days 1 and 7, followed by a decrease of 3.9 between 
days 7 and 14 (Figure A.3.1.S5(b)). The inhibitory influence of higher 
caspofungin concentrations on relative growth was reduced over time (effect of 
day x caspofungin concentration interaction, likelihood ratio test: χ2(2) = 10.48, 
P = 0.00530), signifying C. glabrata growth adaptation to caspofungin.  
 
Higher caspofungin concentrations had a greater inhibitory effect on relative 
growth for strain 3605 than strain 2001, but overall the effect of caspofungin on 
growth was not influenced by strain (effect of strain x caspofungin concentration 
interaction, likelihood ratio test: χ2(1)  = 3.25, P = 0.0716). Caspofungin had a 
minimal inhibitory effect on relative growth of both strains between 0 and 0.15 
µg/ml and could stimulate growth of strain 3605 above that of the no-drug 
treated control (Figure A.3.1.S5(b)). Independently, caspofungin concentration 
had an inhibitory effect on growth (effect of caspofungin concentration, 
likelihood ratio test: χ2(1) = 425.35, P < 2.2e-16), strain 2001 had greater 
growth than strain 3605 (effect of strain, likelihood ratio test: χ2(1) = 5.22, P = 
0.0223) and C. glabrata relative growth increased over time (effect of day, 
likelihood ratio test: χ2(2) = 21.73, P = 1.999e-05).  
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For each strain, we fitted a single four-parameter logistic dose response model 
to daily growth data across all populations evolving on the gradient of 
caspofungin concentrations. To test for caspofungin adaptation over time, we 
compared the dose response model fit across evolving populations on days 1, 7 
and 14 of the evolutionary experiments. For strain 2001, we found that the 
gradient of sensitivity (slope) of the profile significantly decreased over time in 
Experiments 2 and 3, resulting in flatter dose response profiles as populations 
evolving at higher caspofungin concentrations increased their relative growth 
(Figure 4.9; left panels; Table A.3.1.S1). Interestingly, in populations 
transferred at the third highest caspofungin concentration (0.78 µg/ml), relative 
growth was initially very low or non-detectable, but adaptation occurred over 
serial transfers, with relative growth above 50% at day 14 in all three 
independent experiments (Figure 4.9; left panels).  
 
By tracking real-time growth by automated optical density (OD) measurement, 
in Experiment 3 that was representative of the three experiments, we identified 
logistic growth in strain 2001 populations grown at 0 – 0.26 µg/ml on day 1 
(Figure A.3.1.S14), and at 0.45 µg/ml on days 7 (Figure A.3.1.S15) and 14 
(Figure A.3.1.S18). On day 7, low growth occurred at 0.78 µg/ml with standard 
error across replicates (Figure A.3.1.S19) and a similar profile was observed at 
1.37µg/ml by day 14 (Figure A.3.1.S18). Detectable growth by day 14 in 2.4 
µg/ml caspofungin was not consistently identified across the technical 
replicates.  
 
Strain 2001 adaptation to caspofungin measured by the IC50 (50% inhibitory 
concentration) significantly increased between days 1 and 14 in all three 
experiments (Figure 4.9; left panels; Table A.3.1.S2), but the fold increase in 
IC50 varied: experiment 1: 2.1-fold; experiment 2: 6.4-fold; experiment 3: 3.6-
fold. Fluctuation in the increasing trend in IC50 value was shown at 
intermediate time points in the three experiments (Figures A.3.1.S8, 10, 12). In 
Experiments 1 and 3, significant increases in the concentrations of caspofungin 
inhibiting between 15 and 50% of relative growth (IC15 - IC50 values) occurred 
between days 1 and 7, shown by non-overlapping 95% confidence intervals of 
dose response model prediction (Figure A.3.1.S5 (left panels); Figure 
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A.3.1.S7). In all three experiments, significant increases in caspofungin IC45 - 
IC60 values of relative growth occurred between days 1 and 14.  
 
For strain 2001, relative growth varied between replicate populations evolving at 
post-IC50 concentrations (Figure 4.9; left panels; Figures A.3.1.S8, 10, 12), 
particularly during the early stages of growth adaptation. At 0.78 µg/ml 
caspofungin, the standard error of relative growth between technical replicate 
populations was 37% on day 7 in the first and second biological replicates 
(Figure 4.9; left panels). Across all nine replicate populations relative growth 
ranged from 3-115% and relative growth became greater than 50% in all 
populations by day 11 (Figures A.3.1.S8, 10, 12). At 1.37 µg/ml, adaptation 
was lower as relative growth was not consistently greater than 50% by day 14 
across all replicate populations. Standard error of relative growth was greater 
than 21% at day 7 and after (Figures A.3.1.S8, 10, 12). At 2.4 µg/ml, relative 
growth was not above 50% by day 14 in any of the replicate populations in 
Experiments 2 and 3.  
 
Strain 3605 did not show significant evolution of the caspofungin dose response 
profile across populations evolving across the gradient of caspofungin 
concentrations in the three independent experiments (Figure 4.9; right panels; 
Figure A.3.1.S6, left panels). The slope of the dose response profile did not 
change over time, apart from a slightly significant decrease in gradient between 
day 1 and 14 for Experiment 2 (Table A.3.1.S3), indicating a lack of consistent 
adaptation across replicate populations and at higher drug concentrations over 
time.  The change in caspofungin susceptibility over time (IC50) in Experiment 3 
was intermediate to the response in the other two experiments (Figure 4.9; right 
panels). In Experiment 3, logistic growth occurred in populations adapted to 0-
0.26 µg/ml caspofungin concentration on day 1 (Figure A.3.1.S15), growth 
occurred at 0.45 µg/ml by day 7 (Figure A.3.1.S17) and at 0.78 µg/ml by day 14 
(Figure A.3.1.S19).  
 
At 0.78 µg/ml caspofungin, standard error of relative growth of strain 3605 was 
greater than 40% by day 14 in Experiments 1 and 3, but relative growth was not 
consistently above 50% across technical replicate populations (Figure 4.9; right 
panels). Sensitivity to caspofungin (IC50) did not significantly change between 
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days 1 and 14, apart from an increase in IC50 between days 1 and 7 in 
Experiment 3 (Table A.3.1.S5). IC50 varied across the three independent 
experiments (Figure 4.9; right panels; Figures A.3.1.S9, 11, 13) and in 
Experiment 2, daily IC50 was consistent and no growth occurred in populations 
transferred at 0.45 µg/ml and above (Figure A.3.1.S11). Experiment 2 had 
highly overlapping dose response profiles on days 1, 7 and 14, whereas a small 
(non-significant) increase in IC50 between days 1 and 7 occurred in 
Experiments 1 and 3 (Figure 4.9; right panels; Figure A.3.1.S6, left panels). 
Relative growth was not consistently greater than 50% across technical 
replicates at 1.37 and 2.4 µg/ml in all three experiments. 
 
 
 123 
 
Figure 4.9. Evolution of populations of C. glabrata strains 2001 and 3605 on a 
gradient of caspofungin concentrations in three independent experiments. Left 
panels show evolution of populations of strain 2001; right panels show evolution of 
populations of strain 3605. The three separate plots per strain represent independent 
14-day evolutionary experiments, each started from a separate overnight culture. In 
each independent experiment, three replicate populations of each strain were grown at 
eight different caspofungin concentrations and a drug-free environment, in 10 mg ml-1 
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Synthetic Complete medium within a 96-well plate (see Methods). The plate was 
incubated for 24 hours with OD readings taken and all replicate populations were 
transferred to identical fresh drug conditions every 24 hours, respectively for each set 
of three replicate populations evolving at each drug concentration (see Figure 4.2 for 
experimental design). Relative growth was calculated from OD measurement of all 
populations at 24 hours, as % growth relative to the no drug control. The plots show 
changes in the dose response profile shape across populations evolving on the 
gradient of drug concentrations over time, with all replicate populations plotted as data 
points. The solid line curves represent 4-parameter logistic model fits (R-package ‘drc’; 
Ritz et al., 2015). Days 1, 7 and 14 dose responses are plotted (black, green, blue 
respectively) and IC50 estimates with their standard errors predicted from the logistic 
model are presented for each curve. Comparison of IC50 parameters- 2001 E1: Day 1 
compared with Day 7,14, P < 0.01; 2001 E2: Day 1 compared with Day 14, P = 0.00; 
2001 E3: Day 1 compared with Day 7,14, P < 0.001; 3605 E1, E2, E3: no significant 
differences apart from E3: Day 1 and Day 7, P < 0.05. Comparison of slopes/ gradients 
of profiles (Hill coefficient)- 2001 E1: no significant differences; 2001 E2: Day 1 and 
7,14, P < 0.01; 2001 E3: Day 1 and 14, P < 0.01; 3605 E1, E2, E3: no significant 
differences apart from E2: Day 1 and 14, P < 0.05.  
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4.5 Discussion 
 
Candida species occupy diverse host sites that vary in nutrient concentrations, 
to which they must adapt in order to grow and resist other environmental 
stresses (Brown et al., 2014a). Metabolic adaptations to glucose in the yeasts 
C. albicans (Rodaki et al., 2009) and S. cerevisiae (Yin et al., 2003) have been 
described, but growth kinetic adaptations over a range of glucose levels in C. 
glabrata strains, and relationships with virulence and antifungal susceptibility 
have not been characterised. It is, therefore, important to investigate the 
influence of environment-dependent growth kinetics on antifungal adaptation to 
gain a better understanding of susceptibility and evolution of resistance in 
infections. We measured growth parameters of different strains of C. glabrata 
over a range of glucose concentrations (Reding-Roman et al., 2017) and 
compared evolution of antifungal adaptation between the strains most 
contrasting in growth kinetics. We identified conserved relationships between 
growth parameters across the strains, but found differences in virulence and 
evolution of the antifungal susceptibility response in two strains that were most 
contrasting in average growth rates, carrying capacities and yields. Our results 
contribute to understanding C. glabrata metabolic adaptation in different 
infection environments and identify growth traits associated with antifungal 
adaptation, which could improve characterisation and susceptibility testing of 
fungal infections.  
 
During growth of five strains of C. glabrata in minimal medium, we found that 
growth rate (r) and carrying capacity (K) non-linearly increased with glucose 
concentration and that yield (efficiency of biomass production per mg ml-1 of 
glucose) sharply decreased at higher glucose (Reding-Roman et al., 2017). 
These trends are similar to those described by Monod (1949) for growth of 
bacterial cultures over increasing concentrations of a single limiting resource. In 
contrast to Monod kinetics, we found that K was non-linearly correlated with 
glucose and saturated at high concentrations, rather than continuously 
increasing (Reding-Roman et al., 2017). Whilst Monod (1949) described growth 
rate saturation at high glucose concentrations, we found that C. glabrata growth 
rate decreased at the highest glucose concentrations, a trend also observed in 
E. coli (Reding-Roman et al., 2017).  
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The growth kinetic trends on glucose that we observe were consistent with prior 
mechanistic models that rely on glucose metabolism proceeding via a ‘branched 
pathway’ (MacLean and Gudelj, 2006; Meyer et al., 2015; Reding-Roman et al., 
2017). Glucose can be completely respired via glycolysis and the TCA 
(tricarboxylic acid cycle) producing a high yield of ATP, or incompletely respired 
to produce a much lower yield of ATP via glycolysis and excretion of 
metabolites (a separate metabolic ‘branch’ resulting in faster ATP production) 
(MacLean and Gudelj, 2006). Complete respiration occurs at low glucose 
whereas glycolysis is the dominant form of metabolism at high glucose, 
resulting in decreasing yield that we observe with increasing glucose (Reding-
Roman et al., 2017). As growth rate is the product of yield and glucose uptake 
rate (Beardmore et al., 2011; Reding-Roman et al., 2017) and K is the product 
of yield and glucose concentration (Reding-Roman et al., 2017), a large 
decrease in yield at high glucose concentration is linked to decreasing growth 
rate and saturation in K.  
 
These observations correlate with changes in metabolic gene expression 
described in the yeasts S. cerevisiae and C. albicans during the transition from 
low to high glucose (Yin et al., 2003; Rodaki et al., 2009) as central metabolic 
genes (TCA cycle) and glycolytic genes were alternatively up-regulated at very 
low (0.01%) and high (> 0.1%) glucose respectively. This correlates with the 
switch from respiration to fermentation in the transition from low to high glucose 
in S. cerevisiae, which shares a close evolutionary relation with C. glabrata 
(Postma et al., 1989b; Van Urk et al., 1990; Roetzer et al., 2011). Our work also 
fits with a recent study that described the ability of C. glabrata to grow on 
glucose concentrations ranging 0.1-20 mg ml-1, due to upregulation of high or 
low affinity glucose sensors at low or high glucose respectively, indicating its 
tuned nutrient adaptations (Ng et al., 2015). 
 
Due to incorporation of variable yield into models predicting growth rate and 
carrying capacity at different glucose concentrations, we observed parabolic 
relationships between growth rate and K and between growth rate and yield in 
all five strains of C. glabrata (Reding-Roman et al., 2017). At low glucose 
concentrations, r and K were positively correlated which matches the trend 
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described by Monod (1949) at resource-limiting concentrations of substrate and 
correlates with results in E. coli (Meyer et al., 2015). Rate and yield were 
positively correlated at high glucose and negatively correlated at low glucose 
concentrations (Reding-Roman et al., 2017). Pfeiffer et al. (2001) theoretically 
described a similar parabolic profile in heterotrophic organisms due to 
thermodynamic and biochemical constraints on the rate of glucose utilisation 
and yield of ATP production, resulting in a balance between fermentation and 
respiration (Pfeiffer et al., 2001; MacLean, 2008).  
 
Rate and yield are theoretically predicted to trade off during microbial growth on 
limited resources (Beardmore et al., 2011) and a trade-off between rate of 
glucose metabolism and biomass yield has been found in S. cerevisiae in a 
glucose-limited chemostat (Postma et al., 1989b; MacLean, 2008) and across 
Crabtree-positive yeast species (Merico et al., 2007; MacLean, 2008). Following 
experimental evolution of rate and yield of ATP production in E. coli 
populations, these two traits were only negatively correlated within but not 
between populations (Novak et al., 2006). The rate-yield trade-off in microbial 
cultures has also evolved with environmental spatial structure that provides an 
advantage for a high yield strategy, otherwise fast growth rate is preferred as 
resource uptake is faster (Bachmann et al., 2013). We show that rate and yield 
can trade off between high and low glucose and that this transition in growth 
kinetics is predicted to occur in seasonal environments that experience 
temporal changes in resource availability, as described for S. cerevisiae 
(MacLean and Gudelj, 2006). 
 
Previous work has described a positive correlation between rate and yield as a 
‘maintenance’ strategy whereby growth rate and biomass yield concurrently 
decrease under starvation or stressful conditions and energy is allocated for 
stress protection (Pirt, 1965; Lele and Watve, 2014; Lipson, 2015). This has 
been seen in experimental evolution of E. coli in oscillating environments in 
which starvation is experienced and led to poor adaptation to nutrient-rich 
environments (Ying et al., 2015). We observed decreasing rate and yield in C. 
glabrata under high glucose environments and show that a mechanistic model 
can capture both positive and negative relationships between rate and yield for 
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a single organism, dependent on a switch from respiration to fermentation 
(Meyer et al., 2015; Reding-Roman et al., 2017). 
 
In comparison of the rate-K and rate-yield parabolae across C. glabrata strains, 
strain 3605 had a significantly greater average growth rate but lower K and 
growth yield than the lab reference strain 2001 (Reding-Roman et al., 2017). 
These results indicate that C. glabrata strains show host patient or host site-
specific adaptations, particularly as strain 3605 was isolated from a diabetic 
patient whereas strain 2001 was from the gastrointestinal tract of another 
patient (Table A.1.2.S1). Exposure to higher glucose concentrations (greater 
than 0.2% w/v typically in diabetics (WHO Committee on Diabetes Mellitus 
1980; Gibson et al. 1990)) may cause genetic changes resulting in a higher 
growth rate, perhaps due to increased fermentation associated with low yield 
(Pfeiffer et al., 2001) or mutations that increase expression of low affinity 
glucose sensors (Ng et al., 2015). Recently, a study compared growth rates of 
three different C. glabrata strains including ATCC 2001 used in our work 
(isolated from faeces with up to 0.25% glucose (Karabocuoglu et al., 1994)) and 
two strains isolated from very low glucose sites (Ng et al., 2016). Whilst the low 
glucose-adapted strains had higher growth rates than strain 2001 at very low 
glucose concentration in lab media, there were no significant differences in 
growth rates at higher glucose. This indicates that strains from different host 
sites can have different growth adaptations and highlights the need to better 
characterise C. glabrata strains in infections as growth properties may be linked 
to stress resistance (Ng et al., 2016).  
 
A lower average growth rate and higher carrying capacity (K) and yield of strain 
2001 compared with 3605 (Reding-Roman et al., 2017) correlated with higher 
virulence of strain 2001 in the G. mellonella wax moth model. We tested 
virulence at 30oC as we measured in vitro growth kinetics at this temperature, 
but results support those comparing virulence of the two strains at 37oC (Ames 
et al., 2017). Growth rate is traditionally described to positively correlate with 
pathogen fitness and virulence (Anderson and May, 1982), due to debilitation of 
the host (Perlman, 2008). Alternatively, growth rate can be negatively correlated 
with virulence in human pathogens (Leggett et al., 2017), which indicates that 
other pathogen life-history traits, virulence factors or host immunological 
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response contribute to virulence (Day et al., 2007; Frank and Schmid-Hempel, 
2008; Perlman, 2009; Ames et al., 2017). In our experiments, we show that a 
higher carrying capacity or yield may be responsible for greater virulence. 
 
C. glabrata strain 2001, but not strain 3605, showed significant adaptation to 
daily caspofungin dosing in three independent 14-day experiments, evidenced 
by an increase in its IC50 measured across populations evolving on a gradient 
of caspofungin concentrations, due to greater relative growth of populations 
evolving at higher caspofungin concentrations. As evolution was performed at 
intermediate glucose concentration (10 mg ml-1), a greater carrying capacity 
and yield but lower growth rate of strain 2001, compared with strain 3605, 
correlated with caspofungin adaptation. During batch cultures, resource 
concentrations change from high to low (Levin, 1972; Rainey et al., 2000) and 
we found that at low glucose (1 mg ml-1), strain 2001 had a higher growth rate 
and higher carrying capacity and yield than strain 3605. This suggests that a 
higher carrying capacity and yield of strain 2001 facilitated caspofungin 
adaptation and that strain growth rate and yield likely engage in a trade-off 
during the seasonal transition to low glucose. Rate-yield trade-offs have 
influenced community functions (Lipson, 2015) and adaptation to variable 
environments in nature (Lele and Watve, 2014).  
 
In S. cerevisiae, the rate-yield trade-off has been found in chemostat cultures, in 
which it is possible to manipulate the nutrient dilution rate to control growth rate 
(Zakrzewska et al., 2011). At lower growth rates, full respiration occurred 
leading to a higher biomass / ATP yield that provided energy for increased 
resistance to oxidative, acid and heat stresses. This may explain adaptation to 
caspofungin, another stress inflicted on the cell, in C. glabrata strain 2001 due 
to conservation of stress responses between these evolutionarily conserved 
yeasts (Roetzer et al., 2011). A slower growth rate has also been implicated in 
increased antibiotic tolerance or resistance in bacteria (Gilbert et al., 1990; 
Claudi et al., 2014), but it is unclear whether this is due to the rate-yield trade-
off or counteraction of the mode of drug action.  
 
C. albicans, a solely respiratory yeast, showed up-regulation of genes related to 
azole antifungal, oxidative and osmotic stress resistance upon exposure to 1% 
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glucose (same concentration as our work), due to co-regulation of metabolic 
and stress response pathways (Rodaki et al., 2009). In addition, high glucose 
concentrations can induce oxidative stress resistance in C. glabrata, whereas 
low glucose concentrations (0.01-0.2%) could promote biofilm formation and 
amphotericin B stress resistance (Ng et al., 2016). Overall, this highlights that 
different nutrient levels in host environments affect pathogen growth kinetics 
and/or metabolic-stress regulatory networks (Brown et al., 2014a) which in turn 
influence in vivo antifungal susceptibility. In vitro standardised susceptibility 
testing is limited, as it does not test susceptibility under a range of physiological 
conditions that model host environment, immunity and strain-specific growth 
and virulence in infections (Kanafani and Perfect, 2008).  
 
Across and within independent evolutionary experiments, differences in relative 
growth occurred between technical replicate populations that adapted to high 
caspofungin concentrations, particularly at 0.78 µg/ml. This could indicate 
differences in adaptive mechanisms or their time of acquisition across 
populations, although there was a significant increase in IC50 across all 
replicate populations, which suggests parallel evolution of phenotype across 
independent evolutions (Bailey et al., 2015). Studies of in vitro experimental 
evolution of antifungal resistance are limited and lack dynamic growth kinetic 
measurement of replicate populations. In 2000, Cowen et al. tested parallelism 
of evolution across six populations of C. albicans evolving in the antifungal drug 
fluconazole at high inhibitory doses that were tuned to double the MIC 
(Minimum Inhibitory Concentration) of the adapting populations. Variation in 
MIC changes over time, overexpression of resistance genes and competitive 
fitness occurred across the populations, which was not seen in media-adapted 
replicate populations (Cowen et al., 2001). This variation may have been due to 
the emergence of different resistant mutations in different populations by 
chance, as population sizes were small (Cowen et al., 2002).  
 
In contrast, evolution of S. cerevisiae with stepwise increases in fluconazole 
across replicate populations showed very similar increases in competitive 
fitness adaptations across three replicate populations (Anderson et al., 2003; 
Anderson et al., 2005). Environmental conditions and selection pressure 
(Lindsey et al., 2013) are likely to be important in determining the parallelism of 
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evolution (Bailey et al., 2015). The method of antifungal dosing that we employ 
is similar to that described by Peña-Miller et al. (2014), who tested resistance 
adaptation in the dose-response profile across E. coli populations evolving at 
different concentrations of the bacteriostatic antibiotic erythromycin. Eight 
replicate populations were evolved at each drug concentration and after five 
days of transfers, standard error in growth density was present across replicate 
populations treated with a high drug dose, supporting our results in C. glabrata. 
 
 
4.6 Conclusions of the Chapter 
 
We draw two main conclusions from our results: 
 
1) Growth kinetic parameters varied across C. glabrata strains: strain 3605 
isolated from a diabetic patient had a higher average growth rate but 
lower carrying capacity and yield than the lab reference strain 2001. 
 
2) A lower growth rate but higher carrying capacity of strain 2001 compared 
with strain 3605 was correlated with greater virulence and caspofungin 
dose response profile adaptation. 
 
In Chapter 5, we further characterise caspofungin adaptations across replicate 
populations within and between the independent in vitro evolution experiments. 
We test fitness costs in the absence of caspofungin and seek phenotypic and 
genotypic differences at population and sub-population levels to further test 
parallelism in evolution. 
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5. Chapter 5: Fitness Costs and Adaptations in 
Experimental Evolution of Caspofungin Resistance in 
C. glabrata Strain 2001 
 
5.1 Introduction 
 
In this Chapter, we extend our work from Chapter 4 that identified significant 
evolution of the caspofungin dose response profile of C. glabrata strain 2001. 
We characterise adaptations of evolved populations from the three independent 
14-day evolutionary experiments.  
 
Antibiotic resistance is often associated with fitness costs in different 
environments, which limit the rate of resistance evolution and type of mutations 
that can occur (Andersson et al., 2006; Hall et al., 2015). Pathogen fitness is 
described in terms of growth, virulence or transmission and costs are usually 
measured by growth rate (Cohen et al., 2003; Andersson et al., 2006) or 
competition between resistant and susceptible cells (Andersson and Hughes, 
2010) in the absence of antibiotic (MacLean et al., 2010). Costs depend on the 
physiological effects of resistance mechanisms (Andersson et al., 2006), for 
example mutations in enzymatic targets of drugs can have pleiotropic effects on 
normal cell functioning and stress resistance, which can prevent resistance 
mutations from being maintained (Vincent et al., 2013). Costs of resistance 
measured by growth rate or population density in stationary phase correlate 
with costs measured by selective effects inferred from competition assays (Hall 
et al., 2015). Conversely, fitness costs can be absent due to cost-free mutations 
(Ramadhan and Hegedus, 2005), co-selection of resistance with other traits, or 
environmental dependency of costs (Andersson et al., 2006; Hall et al., 2015). 
Costs could also appear absent due to further evolution and compensatory 
mutations that maintain resistance (Nagaev et al., 2001; Andersson et al., 2006; 
Nilsson et al., 2006) and virulence (Cohen et al., 2003).  
 
Typically, evolution of antimicrobial resistance is studied in bacteria and 
selection has occurred with cidal drugs (Blaser et al., 1987) at drug 
concentrations above the MIC (Minimum Inhibitory Concentration), the lowest 
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drug concentration required to cause a significant reduction in microbial growth 
to a specified level (usually 50 or 90% growth inhibition- CLSI, 2008). In 
particular, administration of a high drug dose which aims to inhibit all pathogens 
imposes a strong selective pressure for development of resistance (Read et al., 
2011). This selective region has been described as the ‘Mutant Selection 
Window’ and defines the antimicrobial concentrations between the MIC of wild-
type bacteria and the MIC of the most resistant mutant (Drlica, 2003). At these 
concentrations, high fitness cost mutations are predicted to develop due to the 
strong drug selection pressure and the high drug concentration that is 
necessary to maintain a competitive advantage of resistant cells over 
susceptible cells (Andersson and Hughes, 2014).  
 
Rapid rather than gradual antibacterial or antifungal dose increases and 
frequent dosing can cause population extinction and limit mutational capacity 
(Andes et al., 2006; Lindsey et al., 2013), but antifungal resistance mutations 
have occurred when drug is administered at a constant high dose (Anderson et 
al., 2003; Vincent et al., 2013). Drug-resistant mutants of S. cerevisiae that 
evolved on agar containing a high dose of fluconazole showed no fitness costs 
(Anderson et al., 2003), whereas fitness costs occurred in C. albicans 
populations treated with a high dose of amphotericin B in liquid media (Vincent 
et al., 2013). Fitness costs of resistance mutations occurred in serial clinical 
isolates from a patient treated with the fungicidal drug caspofungin (Singh-
Babak et al., 2012), but the repeatability of resistance mechanisms and 
associated fitness costs between replicate populations under controlled 
environmental conditions were not investigated.  
 
Positive selection and the repeatability of evolutionary adaptations can be 
determined by parallel evolution (Elena and Lenski, 2003; Palmer and Kishony, 
2013). Parallel evolution is defined as the same mutations or mutations in 
conserved gene targets emerging in independent lineages, which suggests 
positive selection of adaptive changes rather than chance mutations (Palmer 
and Kishony, 2013). In experimental evolution, parallelism is identified by 
comparing adaptation across replicate populations that have been founded from 
the same ancestral genotype and evolved under the same selective conditions 
 134 
(Elena and Lenski, 2003). Identification of similar phenotypic changes is 
predicted to underlie genotypic similarities (Bailey et al., 2015). 
 
Parallelism in adaptation has been found across bacterial and fungal replicate 
populations, but does not always occur. Parallelism across populations has 
occurred in metabolic genes during experimental evolution in constant nutrient-
limited environments, evidenced by conserved growth kinetic changes in S. 
cerevisiae (Ferea et al., 1999) and conserved non-synonymous mutations in E. 
coli (Lenski et al., 1991; Maddamsetti et al., 2017). In experimental evolution of 
E. coli, transient diversity in fitness did occur early in evolution but this was due 
to the timing and order of mutational acquisition rather than different adaptive 
pathways (Lenski et al., 1991). Parallelism can occur in the evolution of 
antibiotic resistance, whereby sequential increases in drug concentration have 
led to parallel changes in MIC and resistance mutations in S. cerevisiae 
(Anderson et al., 2003; Anderson, 2005) and in E. coli (Toprak et al., 2011).  
Alternatively, diversity in fitness adaptations and mutations across replicate 
populations has occurred in the evolution of antifungal resistance in C. albicans, 
due to chance mutations in different drug resistance mechanisms (Cowen et al., 
2000; 2001) which may have occurred due to smaller population sizes 
(Anderson et al., 2003).  
 
Fitness adaptations can also vary within populations, characterised by 
phenotypic and genotypic heterogeneity between sub-population clones, which 
can evolve over time within infection of a single patient (Mowat et al., 2011) and 
independently within replicate populations (Herron and Doebeli, 2013). Sub-
population heterogeneity is important to characterise because large differences 
in antibiotic susceptibility can occur between colonies of a patient sample, 
decreasing the reliability of standardised susceptibility testing for informing 
treatment options (Mowat et al., 2011). Heterogeneity could be maintained by 
clonal interference whereby equally beneficial mutations in different sub-
populations are selected, or by frequency-dependent interactions facilitated by 
niche differentiation through metabolic alterations to the environment created by 
a sub-population (Herron and Doebeli, 2013).    
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Evolutionary adaptations are typically quantified both phenotypically and 
genotypically to characterise changes in the selected trait and associated 
fitness effects (MacLean et al., 2010). During evolution of antibiotic resistance, 
a standard quantification of changing susceptibility is the MIC (minimum 
inhibitory concentration) (MacLean et al., 2010) of drug, or similarly the IC 
(inhibitory concentration) of drug, which can be used to define fungal growth 
inhibition at a range of different levels (Elefanti et al., 2013). This has commonly 
been used to track resistance at regular intervals during batch transfers and has 
detected resistance associated with mutations in fungi (Cowen et al., 2000; 
Anderson et al., 2003; Vincent et al., 2013) and in bacteria (Toprak et al., 2011). 
Fitness of mutants under the evolved selection pressure can be tested relative 
to the ancestor by measuring growth parameters such as length of lag phase, 
growth rate, final growth density and cell size (Vasi et al., 1994; Lenski et al., 
1998; Cowen et al., 2001). Within-population differences in colony morphology 
can also be measured to characterise population diversity, which may be 
associated with heterogeneity in drug resistance or virulence (Mowat et al., 
2011). Specific DNA targets associated with selected traits can be sequenced 
(Kugelberg et al., 2005) or the whole genome can be sequenced to identify 
mutations in unknown targets and obtain a global view of genetic changes 
associated with antibiotic resistance (Singh-Babak et al., 2012; Toprak et al., 
2011; Vincent et al., 2013; Oz et al., 2014).  
 
The evolutionary dynamics of echinocandin resistance evolution between and 
within populations and associated fitness costs in Candida glabrata are poorly 
understood. Echinocandins, in particular caspofungin, are fungicidal drugs that 
target the ß-(1,3)-glucan synthase enzyme and prevent synthesis of 
carbohydrate cross linkages in the cell wall, causing cell lysis (Kartsonis et al., 
2003). Mechanisms of caspofungin resistance resulting in elevated MIC values 
in clinical isolates have been described by drug target alterations due to non-
synonymous mutations in the homologous FKS1 and FKS2 genes of C. 
glabrata. Mutations in these genes, which encode catalytic subunits of the 
glucan synthase enzyme, occur in two conserved hotspot regions (Katiyar et al., 
2006; Perlin et al., 2007; Katiyar et al., 2012; Domán et al., 2015; Sanglard, 
2016). Mutations are most commonly reported in the hotspot 1 region of these 
genes in clinical isolates (Garcia-Effron et al., 2009; Perlin, 2011; Katiyar et al., 
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2012; Pham et al., 2014). Mutations in the FKS1 gene have conferred fitness 
and virulence costs in C. albicans (Ben-Ami et al., 2012). It is unclear whether 
fitness costs occur from mutations in FKS1 and FKS2 genes of C. glabrata as 
one study described no virulence cost of an FKS2 mutation (Borghi et al., 
2014), which conferred a growth kinetic fitness cost in another study (Singh-
Babak et al., 2012). 
 
5.2 Aims of the Chapter 
 
In this Chapter, we aim to extend our work from Chapter 4 which identified 
significant evolution of the caspofungin dose response across replicate 
populations of C. glabrata strain 2001 in three independent 14-day experimental 
evolutions. This involved daily serial transfers of cell populations at eight 
different caspofungin concentrations. We focus on characterising differences in 
growth characteristics across replicate populations, analysing fitness costs and 
phenotypic and genotypic adaptations.  We address three aims:  
 
1) To test whether fitness costs of caspofungin adaptation differ between 
replicate populations of C. glabrata strain 2001 evolved at post-IC50 
caspofungin concentrations. 
 
2) To determine whether caspofungin adaptations differ at a sub-population 
level by characterising colony morphology, virulence and gene targets 
associated with resistance. 
 
3) To investigate whether population heterogeneity can be independently 
evolved in separate 14-day caspofungin dose response evolution 
experiments. 
 
We studied in vitro fitness costs of caspofungin resistance by growth profiling in 
the absence of drug, revived population colonies pre-evolved in different 
caspofungin concentrations over 14 days (from dose response experiments 
described in Chapter 4). We chose post-IC50 concentrations as these posed a 
high selective pressure for adaptation (Read et al., 2011) and high fitness cost 
mutations may be expected to develop, as described previously for bacteria 
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(Andersson and Hughes, 2014). Whilst common mechanisms for caspofungin 
resistance are well described (Sanglard, 2016), parallelism of evolution and 
sub-population heterogeneity that may determine the predictability and 
additional mechanisms of caspofungin resistance at the population level, have 
not been explored. We compared fitness costs between and within evolved 
replicate populations from independent 14-day caspofungin dose response 
evolutions described in Chapter 4. We then tested for phenotypic and genotypic 
heterogeneity and virulence costs at the sub-population level in the independent 
evolutionary experiments. 
 
 
5.3 Materials and Methods 
 
5.3.1 Revival of Experimentally-Evolved Populations of C. glabrata Strain 
2001 from Caspofungin Dosing 
 
In Chapter 4, a single isogenic clone of C. glabrata strain 2001 founded 3 
replicate populations (technical replicates) at each of 8 different caspofungin 
concentrations and a media-only growth control. Daily serial transfers into 
identical medium (1% w/v glucose Synthetic Complete (SC) medium) and drug 
conditions were performed over 14 days. This experiment was repeated three 
times independently (biological replicates) over separate 14-day periods. Each 
daily growth cycle was run in a separate 96-well plate and cultures were frozen 
daily (-80oC) with glycerol at a final concentration of 15% v/v. To analyse 
caspofungin adaptations from the first independent experiment, replicate 
populations evolved at the three highest (post-IC50) caspofungin 
concentrations (0.78, 1.37 and 2.40 µg/ml) and media-adapted populations 
were revived from the final day of evolution (end of day 14). From the second 
and third independent experiments, replicate populations evolved at 0.78 µg/ml 
and media-adapted populations were revived from day 14. Frozen cells were 
scraped from the surface of culture wells and streaked on SC 1% w/v glucose 
agar plates, prior to incubation for 48 hours at 30oC. Single colonies were used 
to prepare overnight cultures or plates were stored in the fridge until use.  
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5.3.2 Growth Profiling of Single Colonies in the Absence of Caspofungin 
 
To test for fitness costs in the absence of caspofungin for day-14 populations 
that had evolved in 0, 1.37 and 2.4 µg/ml of caspofungin in the first 14-day 
experiment, 2 colonies were selected per revived population. As variation in 
colony size morphology occurred in revived populations that were evolved at 
0.78 µg/ml of caspofungin, 4 single colonies representing different 
morphologies were selected from each replicate population. Variation in colony 
size morphology also occurred in replicate population 1 that evolved in 1.37 
µg/ml so 3 colonies were selected from this population. From the second and 
third 14-day experiments, 2 population colonies were selected from each 
replicate population at 0 and 0.78 µg/ml. Colony size morphology variation was 
observed at 0.78 µg/ml so a single colony of the two different variants were 
selected, for comparison to colonies from Experiment 1 (E1). Overnight cultures 
were prepared from single colonies by inoculation in universal tubes containing 
SC 1% w/v glucose liquid medium and incubating at 30oC and 180 rpm for 18-
24 hours. The C. glabrata 2001 wild-type ancestral strain was also revived and 
an overnight culture was prepared. 
 
Following overnight incubation, a volume of culture from each colony was 
frozen in a final concentration of 15% v/v glycerol at -80oC. Remaining culture 
was centrifuged and washed once in 1 x PBS before re-suspending in an equal 
volume of SC 1% w/v glucose. A single 150 µl aliquot of each colony’s culture 
was added to a well of a 96-well plate and 150 µl of media was added in a 
separate well. Optical density at 650 nm was read in a Tecan M200 plate reader 
and growth density of each culture was calculated by subtraction of the media 
control reading. Dilutions necessary to reach an OD of 0.05 were prepared in 
SC 1% w/v glucose media (similarly to the methods of Singh-Babak et al. 
(2012)) in Eppendorf tubes and 4 replicate wells of 150 µl of each colony’s 
culture were added to a fresh 96-well plate, alongside the WT ancestor and 
media-only blank control wells. Cultures were diluted in 1 x PBS and plated on 
SC 1% glucose agar plates to calculate initial cell concentration, which was 
approximately 1.5 x 107 cells/ml. Growth profiling was performed in the Tecan 
plate reader at 30oC and 182 rpm for 24 hours with OD650nm readings taken 
every 20 minutes. Growth profiling of population colonies from the first 14-day 
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experiment was repeated in three independent experiments (N = 12 per 
colony), but in 1 independent experiment (N = 4) for population colonies from 
the second and third 14-day evolutions. 
 
5.3.3 Data Analysis and Statistics 
 
Data was imported into MATLAB (Matlab, 2012a) to fit the solution of the 
standard Verhulst logistic growth equation to the data, so that the exponential 
growth rate could be approximated from the data, similar to analysis described 
in Roemhild et al. (2015). The logistic growth model (1) and solution (2) used 
are as described in Reding-Roman et al. (2017) and in Chapter 4, with 
exclusion of the lag phase parameter L. 
 
 = rN(1- N/K); (1),  
where  represents population growth rate, r is exponential per capita growth 
rate (1/h), K is carrying capacity (stable optical density in stationary phase) and 
N represents population size. 
 
N(t) = ß + ; (2), 
where ß represents estimated optical density reading of the media blank, q is a 
parameter incorporating the initial population size N(0) and t is time (hrs). 
  
Following model fitting, optical density values of the wells containing cell 
suspension were blank-corrected by subtracting optical density of the media-
only wells. To calculate fitness costs of caspofungin adaptation, relative 
exponential growth rate and relative final optical density during the 24-hour 
growth profiles of colonies were compared within and between populations by 
dividing through fitness values by mean values of the wild-type ancestor, 
similarly to the methods of Roemhild et al. (2015). Relative growth values were 
presented in box plots and means with standard error bars were overlain to 
indicate the data spread, as recommended in Krzywinski and Altman (2014), 
using the R-package “plotrix” (Lemon, 2006). To deduce significant differences 
in growth parameters across population colonies and the wild-type ancestor, 
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statistical tests run were one-way ANOVA, Welch’s ANOVA and Kruskall-Wallis 
(as data from some samples was skewed) using R version 3.3.2 (R Core Team, 
2016). When differences in growth parameters across groups were detected, all 
tests produced highly significant p values (p < 0.001), so Tukey’s post hoc test 
was used to detect significant pairwise differences between population colonies.   
 
 
5.3.4 Phenotyping of Caspofungin-Evolved Colony Variants  
 
5.3.4.1 Colony Morphology 
 
Replicate populations were revived from frozen stocks and streaked on 
CHROMagar plates (BD Biosciences, Oxford, UK) to determine different colony 
sizes and ensure that all colonies were pink indicating that they were C. 
glabrata, rather than any contaminant that had entered the culture. Colony 
morphologies were also distinguished by dilution plating of colony cultures on 
SC 1% glucose agar plates.   
 
5.3.4.2 Growth on Different Carbon Substrates 
 
Colonies from populations that were revived for growth profiling (including the 
wild-type ancestor) were streaked on YPD (Yeast Peptone Dextrose) and YPG 
(Yeast Peptone Glycerol) agar plates and incubated at 30oC for up to 48 hours, 
similar to the methods of Singh-Babak et al. (2012). Dextrose (glucose) can be 
respired and fermented whereas glycerol can only be respired. 
 
5.3.4.3 Galleria mellonella Survival Assay 
 
G. mellonella wax moth larvae (Live Foods Direct, Sheffield, UK) were injected 
in the top left proleg with an inoculum size of 2.5 x 106 CFU/larva of one of the 
following strains: C. glabrata strain 2001 WT, population colony P1C1 or P1C2 
(day 14 population colonies evolved in 0.78 µg/ml from the first 14-day 
biological replicate experiment). Each injection group included 20 larvae and 
another injection group consisted of PBS-injected larvae to control against 
stress of injection. Larvae were incubated at 30oC in petri dishes containing a 
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filter paper disc and mortality was recorded daily for 10 days, by recording 
response to physical stimulation. Data was analysed in R version 3.3.2 (R Core 
Team, 2016) using the package ‘Hmisc’ (Harrell Jr et al., 2006) to plot Kaplan-
Meier survival plots, calculate mean survival times and compare survival 
between infection groups using the log-rank test. 
 
5.3.4.4 Dose Response Profiling 
 
We measured the caspofungin dose response profile over a single season for a 
single media-adapted colony (M1C1), a colony denoted “LCV” (large colony 
variant) (P1C1) and a colony denoted “SCV” (small colony variant) (P1C2) from 
the first and third 14-day experiments that showed significant sub-population 
heterogeneity in fitness costs. Frozen overnight cultures of each colony variant 
were revived on SC 1% glucose agar and fresh overnight cultures were 
prepared in SC 1% glucose liquid medium. Dose responses were measured in 
96-well plates over single 24-hour periods using the same medium with 
caspofungin concentrations ranging 0 - 2.40 µg/ml. For colony variants that 
were resistant to all concentrations up to 2.40 µg/ml, susceptibility to a two-fold 
dilution series from a maximum caspofungin concentration of 64 µg/ml was 
tested. The same methods for dose response measurement as described for 
the initial season of the in vitro evolution of caspofungin resistance experiment 
in Chapter 4, were followed. Dose responses were repeated three times 
independently and data was pooled, for population colonies from the first 14-
day experiment (N = 9 per caspofungin concentration). Dose responses were 
run once independently for each population colony from the third 14-day 
experiment (N = 3 per caspofungin concentration). The best-fit 4-parameter 
logistic dose response was fitted to dose response data from each population 
colony using the R-package ‘drc’ (Ritz et al., 2015), as described by Roemhild 
et al. (2015), which was used to estimate the IC50 and slope (gradient) model 
parameters. 
 
Pilot dose response assays were used to test susceptibility of the remainder of 
population colonies evolved at 0.78 µg/ml in the three 14-day evolutionary 
experiments, for which fitness in the absence of caspofungin was tested. For 
each revived population colony, a single replicate population was tested at each 
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of eight drug concentrations (0 – 2.4 µg/ml). OD (655nm) was measured after 
24 hours incubation with shaking and percentage growth relative to the no-drug 
treated control was plotted. 
 
5.3.5 Genotyping of Caspofungin Resistance Targets in Single Colonies 
 
Genomic DNA was extracted from the C. glabrata strain 2001 wild-type 
ancestor. From the first and third independent 14-day evolution experiments, 
DNA was extracted from the following revived day 14 population colonies: a 
media-adapted colony (M1C1), the LCV (large colony variant; P1C1) and SCV 
(small colony variant; P1C2). Five gene target regions previously associated 
with caspofungin resistance were PCR amplified and Sanger sequenced in 
each strain. 
 
5.3.5.1 Genomic DNA Extraction 
 
DNA was extracted from an overnight culture of each population colony grown 
in 1% w/v glucose SC medium for 24 hours. To release the DNA, mechanical 
cell lysis with glass beads was performed, using the protocol of yeast DNA 
extraction described by Libuda (2007) (A.4.1). Briefly, cells were grown 
overnight, centrifuged and mixed with Smash and Grab Solution, Phenol-
Chloroform and acid-washed glass beads. This ensured that the cells were 
broken open, proteins were precipitated and DNA was purified for subsequent 
ethanol precipitation, as described previously for DNA extraction from Candida 
strains (Riggsby et al., 1982; Wahyuningsih et al., 2000). The DNA pellet was 
re-suspended in 1 x TE and was refrigerated for up to a week before use or 
frozen at -20oC. DNA concentration was quantified with a nanodrop 
spectrophotometer and bands were visualized by running on a 0.8% w/v 
agarose gel containing ethidium bromide. DNA concentration of the revived 
population colonies from the third 14-day evolution ranged 37.5- 68.1 ng/µl. 
 
5.3.5.2 PCR Amplification of Gene Targets and Gel Electrophoresis 
 
PCR primers were ordered from Eurofins Genomics (Ebersburg, Germany). The 
HS1 and HS2 regions of the FKS1 and FKS2 genes were amplified using 
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primers previously described for C. glabrata by Thompson et al., (2008) and 
Zimbeck et al., (2010) (Table A.4.1.S1). The CDC6 gene was amplified using 
primers described for C. glabrata by Singh-Babak et al., (2012) (Table 
A.4.1.S1). Primer stock solutions were prepared from lyophilised primers by 
adding appropriate volumes of autoclaved MilliQ water to prepare 100 µM 
stocks. 20 µM working stock solutions were prepared by further dilution in MilliQ 
water and were frozen at -20oC until use. Genomic DNA from each population 
colony was diluted 1:10 to prepare template DNA for PCR reactions.  
 
Promega instructions for PCRs were followed for 50 µl reaction volumes 
(Promega, 2014), using GoTaq ® G2 Green Master Mix (Product code: M728A, 
Madison, USA). All PCR reactions contained the following volumes of reaction 
components: 25 µl GoTaq, 2 µl of forward primer, 2 µl of reverse primer, 1ul of 
DNA template and 20 µl of nuclease-free water (Product code: P119A). 2 
replicate reactions were run for each gene region of each population colony. 
The PCR programme was run as follows: initial DNA denaturation- 95oC for 2 
minutes; 35 cycles: denaturation- 94oC for 30 seconds, annealing- 55oC (FKS2 
HS1)/ 59oC (FKS1 HS1)/ 53oC (CDC6, FKS2 HS2)/ 58oC (FKS1 HS2) for 45 
seconds, extension- 72oC for 1 minute; final extension- 72oC for 5 minutes. 
PCR products were stored in the fridge for up to 1 week before running on a 
gel. 
 
To check for correct PCR amplification of the gene target regions, 5 µl volumes 
of PCR product from each population colony and the strain 2001 WT ancestor 
were run on an 0.8% w/v agarose gel containing ethidium bromide and bands 
were visualised under UV light. Separate gels were then run with 30 µl of PCR 
product from each reaction and DNA bands were excised from the gel using a 
scalpel whilst visualising the bands on a UV transilluminator. Each DNA band 
was added to a 2 ml screw-cap tube and tubes were weighed before and after 
to calculate the weight of the gel slice (mg). Gel slices were stored in the fridge 
before purification. DNA was purified by centrifugation using a silicone 
minicolumn and membrane binding solution to extract DNA and membrane 
wash solution to remove the remaining gel product (Wizard SV Gel and PCR 
Clean-Up- Promega, 2009) (A.4.1). As PCR reactions for each gene target of 
each population colony were run in duplicate, the two dissolved gel slices for 
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each were combined in a single silicone minicolumn to increase the DNA 
concentration. Eluted DNA from each minicolumn was quantified with a 
nanodrop spectrophotometer and DNA was frozen at -20oC until use.  
 
5.3.5.3 Sanger Sequencing Sample Preparation and Data Analysis 
 
Samples were prepared for Sanger sequencing using the ‘Sample Submission 
Guide for Value Read Tubes’ from Eurofins Genomics (Ebersburg, Germany). 
Premixed samples were prepared in a 17 µl final volume in a 1.5 ml 
microcentrifuge tube. Purified DNA was diluted in nuclease-free water to a final 
concentration of 5 ng/µl in 15 µl volume. The final 2 µl volume consisted of 
either 10uM of the forward or reverse primer of the PCR-amplified gene target. 
The same primers were used for sequencing as for the PCR reactions. The 
FKS1 and FKS2 hotspot 1 and 2 gene targets were sequenced in both the 
forward and reverse directions and the CDC6 gene was just sequenced in the 
forward direction. 
 
Samples were sent to Eurofins Genomics (Ebersburg, Germany) for sequencing 
and DNA sequence data was analysed by nucleotide and amino acid sequence 
alignment against the C. glabrata strain ATCC 2001/ CBS138 reference 
genome (Gene target GenBank accession numbers: FKS1- XM_446406, FKS2- 
XM_448401, CDC6- XM_448250; Dujon et al., 2004; Garcia-Effron et al., 
2009), using MEGA (Molecular Evolutionary Genetics Analysis) software 
(MEGA7: Kumar et al., 2016). 
 
 
5.4 Results 
 
5.4.1 Fitness Costs of Caspofungin Adaptation Between and Within 
Evolved Replicate Populations of C. glabrata Strain 2001 in Experiment 1 
 
We observed a significant shift in the caspofungin IC50 (50% inhibitory 
concentration) of strain 2001 between days 1 and 14 in Experiment 1 of 14-day 
evolution of populations on a caspofungin gradient (Figure 4.8). As growth 
increased from negligible to detectable levels across replicate populations at 
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post-IC50 concentrations (Figure 4.8), we tested for fitness costs of resistance 
by growth profiling in the absence of caspofungin. When reviving day 14 
populations, we observed morphological variation within populations (individual 
colonies), particularly for 0.78 µg/ml-evolved populations. During a single 
season, we saw no significant difference in relative intrinsic growth rate across 
colonies from the three replicate populations evolved in media alone or in 2.4 
µg/ml of caspofungin, and the wild-type ancestor (Figure 5.1; left panels; Table 
A.4.2.S1).  
 
In contrast, highly significant growth rate differences across colonies both within 
and between populations occurred for 0.78 and 1.37 µg/ml evolved populations 
(Figure 5.1; left panels; Table A.4.2.S1). For 0.78 µg/ml, significant sub-
population differences only occurred in replicate population 1 and colonies 2- 4 
were significantly different from the ancestor (Table A.4.2.S2). P1C2 had a 
significantly lower growth rate than all other colonies from the three populations, 
so we denoted this colony as a “small colony variant” (SCV) (Figure 5.1). We 
denoted P1C1 evolved at 0.78 µg/ml as a “large colony variant”, due to lack of 
significant deviation in growth rate from the wild-type ancestor. For 1.37 µg/ml, 
significant sub-population differences were only found in replicate population 2 
(Table A.4.2.S2). Colony 2 in this population was significantly different from the 
ancestor. Smaller differences in growth rate occurred between colonies for 1.37 
µg/ml than for 0.78 µg/ml evolved populations and no population colonies were 
significantly different from all others across 1.37 µg/ml evolved populations. 
 
We compared the final growth density reached in stationary phase (OD (24 
hours)) across day 14 population colonies previously evolved at 0, 0.78, 1.37 
and 2.40 µg/ml caspofungin. We found no significant differences in OD (optical 
density) at 24 hours between colonies evolved in 0.00 and 2.40 µg/ml 
caspofungin, but we did find significant differences across replicate populations 
evolved at 0.78 and 1.37 µg/ml and within population differences at 0.78 µg/ml 
only (Figure 5.1; right panels; Table A.4.2.S1; Table A.4.2.S2). For 0.78 µg/ml, 
colony P1C2 had a significantly higher growth density than P1C4 but was not 
significantly different from all other population colonies and the ancestor.  
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Figure 5.1. Fitness costs of caspofungin adaptation in individual colonies of 
parallel-evolved populations of C. glabrata strain 2001 in Experiment 1 (E1) of the 
14-day evolution. Growth kinetic measurements are shown for colonies revived from 
day 14 from each of three populations (separated by vertical lines) previously evolved 
in media alone (0.00 µg/ml), 0.78 µg/ml, 1.37 µg/ml or 2.40 µg/ml of caspofungin. 
Colony growth kinetics were measured in the same medium (SC 1% w/v glucose) in 
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the absence of caspofungin over 24 hours. Relative growth values presented were 
calculated by dividing through by average values of the WT ancestor (2001WT), similar 
to Roemhild et al. (2015; Fig. S4). Relative growth values of 1 (shown by dotted line) 
indicate no change from WT. Growth assays were performed three times 
independently and data pooled from all experiments is presented (N = 12 per colony 
measurement). Boxplots show the median value as a horizontal line, 1st and 3rd 
quartiles as box limits, whiskers marking 1.5 x interquartile range in both directions and 
empty plotted points as outliers. Black points and error bars overlaying each box 
represent mean and standard error. Left panels show growth rate (1/h) which is the 
logistic parameter r (exponential growth rate). Growth rate: P < 0.0001 between 
colonies evolved in 0.78 and 1.37 µg/ml (Kruskal-Wallis/ One-way ANOVA tests); P > 
0.05 between colonies evolved in 0.00 and 2.40 µg/ml (Kruskal-Wallis test). Right 
panels show OD (optical density) reached at 24 hours: P < 0.001 between colonies 
evolved in 0.78 and 1.37 µg/ml; P > 0.05 between colonies evolved in 0.00 and 2.40 
µg/ml. P1C1 in 0.78 µg/ml is denoted as LCV (“large colony variant”) and P1C2 in 0.78 
µg/ml is denoted as SCV (“small colony variant”). 
 
 
 
5.4.2 Phenotyping of Sub-Population Colony Diversity in a Single 
Caspofungin-Evolved Replicate Population in Experiment 1 
 
To further phenotypically characterise sub-population diversity, we selected 
colonies P1C1 and P1C2 from replicate population 1 evolved at 0.78 µg/ml, as 
P1C1 had a significantly lower relative growth rate than all other population 
colonies but growth rate of P1C2 was not significantly different from the 
ancestor (Figure 5.1; left panels). The growth profile of P1C2 was flatter 
(Figure 5.2a.2) and appeared to reach an early plateau followed by further 
growth such that final density was similar to that of P1C1 (Figure 5.2a.1). We 
denoted colony P1C2 as a “small colony variant” (SCV) as it formed much 
smaller colonies on agar than P1C1- a “large colony variant” (LCV). This 
difference in colony morphology was observed for growth on the carbon 
substrates glucose (YPD plates: Figure 5.2b.2) and glycerol (YPG plates: 
Figure 5.2b.1), the latter being a non-fermentable carbon source so colony 
growth indicated respiratory function. Colony morphology of the large colony 
variant was similar to that of the wild-type ancestor. Reviving a sample of the 
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entire replicate population on CHROMagar clearly demonstrated the sub-
population diversity in colony size (Figure 5.2c). All colonies were pale-dark 
pink indicating that all colonies were C. glabrata rather than bacterial or fungal 
contaminants. We also identified these differences in colony size in the same 
population revived from day 7, the mid-point of the evolutionary experiment. To 
determine the stability of the small colony phenotype, we serially passaged 
three replicate populations of the day 14 revived SCV in the same medium over 
14 days in the absence of caspofungin and found that the phenotype was 
entirely preserved.  
 
 
Figure 5.2. Growth profiling, substrate usage and colony morphology of 
individual colonies revived from a single 0.78 µg/ml caspofungin-adapted 
population of C. glabrata strain 2001. Growth assays and phenotyping are shown for 
colonies P1C1 and P1C2 revived from population 1 at day 14 that had been evolved in 
0.78 µg/ml caspofungin (Figure 5.1), in comparison to the strain 2001 wild-type 
(WT) ancestor. Data are from 1 biological replicate of the revived colony variants. (a.1-
3) show growth profiles measured by OD (optical density) over 24 hours in the same 
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media (1% w/v glucose SC) in the absence of caspofungin. Growth was measured 
across 4 replicate cultures from each colony and the blue profile shows the means and 
standard error bars. The red profiles show mean predicted OD values from a best fit 
logistic growth model with standard errors shown. Per capita growth rate (1/h) is 
calculated from the logistic model fit and final growth density (OD) is also reported. 
(b.1) and (b.2) show growth on YPG (Yeast Peptone Glycerol) and YPD (Yeast 
Peptone Dextrose) respectively, for the C. glabrata strain 2001 wild-type (WT) 
ancestor, P1C2 and P1C1 (left to right). Colony growth was slower on YPG than YPD 
so plates were incubated for 48 hours and 24 hours respectively. Colony size of P1C2 
was much smaller than that of P1C1 so the colonies were denoted “SCV” (small colony 
variant) and “LCV” (large colony variant) respectively. (c) Population 1 evolved at 0.78 
µg/ml over 14 days (containing P1C1 and P1C2) was revived by streaking on 
CHROMagar and white/pink colonies indicate C. glabrata. Larger, darker pink colonies 
are the “LCV” and smaller, paler colonies are the “SCV”. 
 
 
We then compared the virulence of an intermediate dose of the wild-type 
ancestor, small and large colony variant in the wax moth larval model Galleria 
mellonella to determine whether the caspofungin-adapted colonies with different 
growth rates showed fitness costs. Using an inoculum dose of 2.5 x 106 
CFU/larva, we found no significant difference in virulence between the three 
strains when larvae were incubated at 30oC (Figure 5.3), the same temperature 
to which the colonies were adapted during the 14-day evolution experiment. 
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Figure 5.3. Comparative survival of Galleria mellonella with injection of C. 
glabrata strain 2001 WT and 0.78 µg/ml caspofungin-evolved colonies. Groups of 
20 G. mellonella wax moth larvae were injected with 2.5 x 106 CFU/larva of either the 
WT ancestor of strain 2001, the SCV (P1C2) or the LCV (P1C1) (as denoted in Figure 
5.2). Data is from 1 biological replicate. Larvae were incubated at 30oC and mortality 
was recorded daily for 10 days. Log-rank test compared survival across the 3 groups; 
P = 0.4365. Mean survival times (days): 2001 WT = 6.70 +/- 0.66; SCV = 6.30 +/- 0.62; 
LCV = 5.85 +/- 0.52. 
 
 
5.4.3 Independent Evolution of Fitness Costs and Adaptations within 
Populations in Experiments 2 and 3 of the 14-Day Caspofungin Evolution 
 
To identify whether sub-population diversity could be independently-evolved, 
we measured growth kinetics of day 14 colonies evolved in 0.78 µg/ml 
caspofungin in Experiment 2 of the 14-day experiment described in Chapter 4, 
completed over a separate 14-day period. We found significant differences in 
growth rate (Figure 5.4; left panels; Table A.4.2.S3) and final optical density 
(Figure 5.4; right panels; Table A.4.2.S3) between replicate populations in 
media-adapted and in 0.78 µg/ml-adapted populations, although no significant 
sub-population diversity occurred, apart from differences in final optical density 
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between colonies in the second media-adapted population. We, therefore, did 
not find small and large colony variants co-isolated in any replicate population.  
 
 
Figure 5.4. Fitness costs of caspofungin adaptation in colonies of day 14 
populations of C. glabrata strain 2001 from Experiment 2 (E2) of the 14-day 
evolution. Growth measurements are shown for colonies revived from day 14 from 
each of three populations (separated by vertical lines) previously evolved in media 
alone (0.00 µg/ml) or 0.78 µg/ml caspofungin. Growth kinetics were measured in the 
same medium (SC 1% w/v glucose) in the absence of caspofungin for 24 hours. 
Relative growth values presented were calculated by dividing through by average 
values of the WT ancestor (2001WT), similar to data presentation in Roemhild et al. 
(2015; Fig. S4). Relative growth values of 1 (shown by dotted line) indicate no change 
from WT. Growth assays were performed in one experiment and N = 4 per colony 
measurement, except for the WT ancestor for which N = 12 (same dataset used for 
relative fitness calculation as for first evolution experiment). Boxplots show the median 
value as a horizontal line, 1st and 3rd quartiles as box limits, whiskers marking 1.5 x 
interquartile range in both directions and empty plotted points as outliers. Black points 
and error bars overlaying each box represent mean and standard error. Left panels 
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show intrinsic growth rate (1/h): 0.00 µg/ml- One-way ANOVA (F6, 29 = 19.61, P = 
5.27e-09); 0.78 µg/ml- One-way ANOVA (F6, 29 = 45.11, P = 2.08e-13). OD (right 
panels): 0.00 µg/ml- Kruskal-Wallis chi-squared = 23.634, df = 6, P = 0.0006098; One-
way ANOVA: F6, 29 = 8.033, P = 3.68e-05; 0.78 ug/ml- Kruskal-Wallis chi-squared = 
29.68, df = 6, P = 4.521e-05; One-way ANOVA: F6, 29 = 13.14, P = 3.84e-07. Small and 
large colonies were not co-isolated in any of the three populations evolved at 0.78 
µg/ml. 
 
 
We then measured growth kinetics of day 14 colonies evolved in 0.78 µg/ml 
caspofungin from Experiment 3 (E3) of the 14-day evolution. We found highly 
significant differences in relative growth rate between replicate populations 
evolved in 0.78 µg/ml and in media-adapted replicate populations (Figure 
5.5(a); left panels; Table A.4.2.S4). A slightly significant within population 
difference was seen for the first media-adapted population but not in the other 
two populations. For 0.78 µg/ml, significant sub-population differences in growth 
rate were observed in all 3 replicate populations but were most significant in 
population 1, showing that sub-population heterogeneity similar to that 
observed in the biological replicate 1 experiment could be evolved in an 
independent 14-day period. P1C2 had a significantly lower growth rate than all 
other population colonies, including the ancestor so we denoted it as a “small 
colony variant” (SCV). P1C1 from the same population did not have a 
significantly different growth rate from the wild-type ancestor so was denoted as 
a “large colony variant” (LCV).  
 
Relative OD at 24 hours was not significantly different across media-evolved 
populations but significant differences were found across 0.78 µg/ml-evolved 
populations and within the first replicate population (Figure 5.5(b); right panels; 
Table A.4.2.S4). Colony P1C1 had a significantly lower, and colony P1C2 had a 
significantly greater, relative final OD than the wild-type ancestor. Differences in 
colony growth rates were supported by the much smaller colony size for P1C2 
than P1C1 that we observed on 1% w/v glucose SC agar (Figure 5.5(b)). The 
growth profiles of the two colony variants demonstrated maximisation of either 
growth rate (P1C1) or total growth density (P1C2) (Figure 5.5(c)). We, 
however, did not find sub-population differences in colony size in the same 
population revived from days 3, 5 or 7 of the evolution of dose response 
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experiment. To test the stability of the small colony phenotype, we serially 
passaged three replicate populations of the day 14 revived SCV in the same 
medium over 14 days in the absence of caspofungin. We found reversion back 
to the wild-type colony size for some colonies in one replicate population after 
six days, with complete reversion in all populations by the end of the experiment 
(day 14). 
 
 
 
 
(a) 
(b) 
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(c) 
 
Figure 5.5. Fitness costs and caspofungin adaptations in colonies of day 14 
populations of C. glabrata strain 2001 evolved at 0.00 or 0.78 µg/ml from 
Experiment 3 (E3) of the 14-day evolution. (a) Growth measurements are shown for 
2 colonies revived from day 14 from each of three populations (separated by vertical 
lines) previously evolved in media alone (0.00 µg/ml) or 0.78 µg/ml caspofungin. 
Growth was measured in the same medium (SC 1% w/v glucose) in the absence of 
caspofungin for 24 hours. Relative growth values were calculated by dividing through 
by average values of the WT ancestor (2001WT), similar to data presentation in 
Roemhild et al. (2015; Fig. S4). Relative growth values of 1 (shown by dotted line) 
indicate no change from WT. Growth assays were performed in one experiment and N 
= 4 per colony measurement, except for the WT ancestor for which N = 12 (same 
dataset used as for first evolution experiment). Boxplots show the median value as a 
horizontal line, 1st and 3rd quartiles as box limits, whiskers marking 1.5 x interquartile 
range in both directions and empty plotted points as outliers. Black points and error 
bars overlaying each box represent mean and standard error. Left panels show 
exponential growth rate (1/h). Right panels show final optical density reached after 24 
hours of growth. Growth rate: 0.00 µg/ml- One-way ANOVA (F6, 29 = 33.8, P = 8.11e-
12); 0.78 µg/ml- One-way ANOVA (F6, 29 = 146.3, P < 2e-16). OD: 0.00 µg/ml- Kruskal-
Wallis chi-squared = 12.293, df = 6, P = 0.05575; 0.78 µg/ml- Kruskal-Wallis chi-
squared = 27.764, df = 6, P = 0.0001041; Welch’s ANOVA (unequal variances): F6.00, 
10.33 = 167.12, P = 1.127e-09; One-way ANOVA: F6, 29 = 17.91, P = 1.46e-08. The “small 
colony variant” (SCV) and “large colony variant” (LCV) identified at 0.78 µg/ml 
caspofungin are labelled. (b) SC 1% w/v glucose agar plates showing colony size of 
P1C1 (left) and P1C2 (right), two population colonies from day 14 of evolution in 0.78 
µg/ml caspofungin. (c) Growth profiles for colonies P1C1 (LCV; left) and P1C2 (SCV; 
right) evolved at 0.78 µg/ml. Growth profile is shown by the blue line representing the 
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mean of 4 technical replicates with standard error bars. The red line represents the 
mean predicted optical density values from the logistic growth model fit, with standard 
errors. 
 
 
5.4.4 Characterising Caspofungin Susceptibility of Small and Large 
Colony Variants in Independent 14-Day Caspofungin Evolution 
Experiments 
 
We identified the presence of a “small colony variant” (SCV) and “large colony 
variant” (LCV) within a single replicate population evolved for 14 days in 0.78 
µg/ml caspofungin in Experiments 1 (Figures 5.1-3) and 3 (Figure 5.5). We 
then measured the caspofungin dose response profiles of a single media-
adapted population colony, the SCV and LCV from these two independent 14-
day experiments. 
 
In Experiment 1, we found that the large colony variant had significantly lower 
IC50 – IC95 values than the wild-type ancestor (Figure 5.6(b); Figure 
A.4.2.S1; S3; Table A.4.2.S5), although the dose response profiles of the large 
colony variant and media-adapted strain were highly overlapping (Figure 
5.6(a)). The large colony variant was more sensitive than the wild-type ancestor 
to caspofungin concentrations between 0.26 and 0.78 µg/ml. This is despite its 
isolation from a population that had been evolved in 0.78 µg/ml caspofungin for 
14 days. The gradient of inhibition was not significantly different between the 
large colony variant and wild type and the profiles of the large colony variant 
and media-adapted colony showed high similarity (Figure 5.6(a) and (b)).  
 
Importantly, the small colony variant was not inhibited by any caspofungin 
concentrations used in the dose response for the other colonies (0-2.40 µg/ml) 
(Figure 5.6(c)), with relative growth remaining approximately constant across 
all caspofungin concentrations, but with variation across technical replicates. To 
find the inhibitory concentration of caspofungin, we tested a much larger range 
of caspofungin concentrations up to 64 µg/ml, as described previously 
(Wiederhold, 2009) and found that the small colony variant had an IC50 of 2.61 
+/- 0.136 µg/ml, approximately 10-fold greater than the large colony variant co-
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isolated from the same evolved population (Figure 5.6(d)). We found that the 
resistance level was preserved in three replicate populations of the day 14 
revived SCV after 14 days of serial propagation in identical medium in the 
absence of caspofungin, by measuring the sensitivity of a single colony from 
each population after day 14 (IC50 values: 2.40 +/- 0.146 µg/ml, 2.33 +/- 0.678 
µg/ml and 2.70 +/- 0.480 µg/ml). 
 
We conducted pilot dose response assays to test the caspofungin susceptibility 
of the other colony variants that were revived from populations evolved at 0.78 
µg/ml in Experiment 1 (Figure 5.1). The IC50 of all revived population colonies 
apart from E1 P1C4 fell between 0.78 and 1.37 µg/ml (Figure A.4.2.S5(a)). This 
was greater than the IC50s of the wild-type ancestor, media-adapted and LCV 
strains from Experiment 1 but much lower than the IC50 of the SCV strain in 
Experiment 1(Figure 5.6). The IC50 of colony E1 P1C4 was around 2 µg/ml, 
which was greater than that of all other strains except the SCV. This was 
associated with a significantly lower growth rate than the other population 
colonies apart from the SCV and E1 P1C3 (Table A.4.2.S2). 
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Experiment 1 
 
Figure 5.6. Dose response profiles for C. glabrata strain 2001 WT ancestor and 
colony variants from day 14 of Experiment 1 of the 14-day evolution of 
caspofungin resistance. Dose responses show relative growth % which is measured 
from final optical density (24 hours) from technical replicates grown at 8 different 
caspofungin concentrations, divided through by the mean OD of media-alone grown 
cells. Four parameter logistic dose response curves were fitted to data in each plot 
using the R package “drc” (Ritz et al., 2015), as described by Roemhild et al. (2015) 
and fits were used to predict the IC50: 50% growth inhibitory concentration of 
caspofungin presented on the plots (with SE of the estimated value) for each strain. 
(a), (b), (c): WT dose response is plotted from data pooled from day 1 of the three 
independent 14-day caspofungin evolution experiments described in Chapter 4 (N = 9 
for each caspofungin concentration). Data for the other colony variants represents 
pooled data from three 24-hour dose responses performed on separate days (N = 9 for 
each caspofungin concentration). (a) WT dose response compared with M1C1 (MA)- a 
single media-adapted colony. (b) WT compared with LCV (large colony variant); 
comparison of IC50: P = 0.0454; comparison of slope: P = 0.6558.  (c) WT compared 
with SCV (small colony variant). No model fit is shown for SCV as none of the 
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caspofungin concentrations tested were inhibitory. (d) Dose response for the SCV at a 
higher range of caspofungin concentrations: 2-fold dilutions ranging 0 – 64 µg/ml. The 
4-parameter logistic dose response model was fitted to estimate IC50. 
 
In pilot dose response assays for revived colonies from populations evolved at 
0.78 µg/ml in Experiment 2 (Figure 5.4), the IC50s of all colonies were between 
0.78 and 1.37 µg/ml, with no population colonies showing high level resistance 
(Figure A.4.2.S5(b)). The IC50 was greater than 1 µg/ml for all colonies apart 
from E2 P1C1. This lower IC50 of E2 P1C1 was correlated with a significantly 
higher growth rate in the absence of caspofungin than colonies E2 P3C1 and 
E2 P3C2 (Table A.4.2.S3), although the relationship between IC50 and growth 
rate would need to be verified over a larger number of population colonies. No 
population colonies showed as large of a reduction in growth rate as occurred 
with the highly resistant SCV in Experiment 1. 
 
In Experiment 3, we found no significant difference between the IC50 or slope 
of the dose response between the wild-type and media-adapted colonies 
(Figure 5.7(a); Table A.4.2.S6), but the media-adapted colony had significantly 
lower IC65- IC95 values than the wild type and was more sensitive to 
caspofungin concentrations between 0.26 and 0.78 µg/ml (Figure A.4.2.S2; 
S3). The large colony variant showed a significant increase in its IC50 
compared with the wild-type ancestor (Figure 5.7(b)) however the gradient of 
inhibition was not significantly different as relative growth of the large colony 
variant was still negligible at the highest two concentrations. The estimated 
IC50 of the large colony variant was 0.83 µg/ml, which was 2.6-fold greater than 
that of the wild-type ancestor and exceeded the dose of 0.78 µg/ml to which the 
population was evolved over 14 days. The large colony variant had significantly 
greater IC5 - IC60 values compared with the wild type and was less sensitive to 
caspofungin concentrations between 0.05 - 0.78 µg/ml (Figure A.4.2.S2; S3). 
Importantly, the small colony variant was not sensitive to caspofungin 
concentrations ranging 0- 2.40 µg/ml, and relative growth remained at 
approximately 100% (Figure 5.7(c)). Over a larger range of caspofungin 
concentrations, we found that the IC50 of the small colony variant was 4.71 +/- 
0.236 µg/ml, which was 5.7-fold greater than the large colony variant co-
isolated from the same evolved population (Figure 5.7(d)). 
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We conducted pilot dose response assays to test the caspofungin susceptibility 
of the other colony variants that were revived from populations evolved at 0.78 
µg/ml in Experiment 3 (Figure 5.5(a)). The IC50s of all population colonies 
were between 0.78 and 1.37 µg/ml, showing decreased caspofungin 
susceptibility compared with the wild-type ancestor and media-adapted strain 
but lower level resistance than the SCV strain in Experiment 3 which had a very 
low growth rate (Figure 5.7). Colony E3 P2C1 had an IC50 below 1 µg/ml 
which was lower than the IC50s of the other colonies tested in this pilot 
experiment (Figure A.4.2.S5(c)). The IC50 of E3 P2C1 was similar to that of 
the E3 LCV and these two colonies had significantly greater relative growth 
rates in the absence of caspofungin than all other colonies (Table A.4.2.S4), 
indicating a link between decreased caspofungin susceptibility and a lower 
growth rate. 
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Experiment 3 
 
Figure 5.7. Dose response profiles for C. glabrata strain 2001 WT ancestor and 
colony variants from day 14 of Experiment 3 of the 14-day evolution of 
caspofungin resistance. Dose responses show relative growth % which is measured 
from final optical density (24 hours) from technical replicates grown at 8 different 
caspofungin concentrations, divided through by the mean OD of media-alone grown 
cells. Four parameter logistic dose response curves were fitted to data in each plot 
using the R package “drc” (Ritz et al., 2015), as described by Roemhild et al. (2015) 
and fits were used to predict the IC50: 50% growth inhibitory concentration of 
caspofungin presented on the plots (with SE of the estimated value) for each strain. 
(a), (b), (c): WT dose response is plotted from data pooled from day 1 of the three 
independent 14-day caspofungin evolution experiments described in Chapter 4 (N = 9 
for each caspofungin concentration). Data for the other colony variants in all plots 
represent single 24-hour dose responses performed on separate days (N = 3 for each 
caspofungin concentration). (a) WT dose response compared with M1C1 (MA)- a 
single media-adapted colony; comparison of IC50: P = 0.1940; comparison of slope: 
0.7932. (b) WT compared with LCV (large colony variant); comparison of IC50: P = 
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0.0011; comparison of slope: P = 0.8536. (c) WT compared with SCV (small colony 
variant). No model fit is shown for SCV as none of the caspofungin concentrations 
tested were inhibitory. (d) Dose response for the SCV at a higher range of caspofungin 
concentrations: 2-fold dilutions ranging 0 – 64 µg/ml. The 4-parameter logistic dose 
response model was fitted to estimate IC50. 
 
 
Three replicate populations of the revived SCV from day 14 of Experiment 3 
were serially propagated in identical medium but in the absence of caspofungin 
over 14 days to test the stability of resistance. At the end of the experiment, we 
found that the highly caspofungin resistant phenotype was lost in all populations 
(Figure A.4.2.S4), consistent with reversion to the wild-type colony size 
described earlier. By measuring the dose response of a single colony from each 
population, we found that the IC50 values were significantly greater than the 
wild-type ancestor in two populations (0.49 +/- 0.023 µg/ml (Figure A.4.2.S4a) 
and 0.44 +/- 0.019 µg/ml (Figure A.4.2.S4b)) but not in the third population 
(0.34 +/- 0.055 µg/ml (Figure A.4.2.S4c)). The gradient of inhibition (slope) was 
not significantly different from the wild-type in any of the three populations. 
 
5.4.5 Genetic Characterisation of Common Caspofungin Resistance 
Targets in Small and Large Colony Variants 
 
To determine genetic mechanisms for differences in caspofungin susceptibility 
between the small and large colony variants isolated from biological replicates 1 
and 3 of the 14-day evolution experiment, we amplified and Sanger-sequenced 
common gene targets associated with caspofungin resistance (Figure 5.8) 
(Thompson et al., 2008; Singh-Babak et al., 2012). We extracted genomic DNA 
from the wild-type C. glabrata strain 2001 ancestor, media-adapted, small and 
large colony variants and amplified the desired gene targets, shown by gel 
electrophoresis of PCR products (Figure 5.8(a)). We found no nucleotide or 
amino acid changes in the hotspot 1 region of the homologous genes FKS1 and 
FKS2 (Figure 5.8(b),(c)) in any of the strains from the first and third biological 
replicate caspofungin dose response experiments, in comparison with the 
reference genome (Dujon et al., 2004) (Figure 5.8(d)). No mutations occurred 
in hotspot 2 of FKS1 or FKS2, resulting in homologous amino acid sequences 
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in all strains, consisting of ‘1340-DWVRRYTL-1348’ (Garcia-Effron et al., 2009) 
for FKS1 and ‘1374-DWIRRYTL-1381’ (Perlin, 2015) for FKS2. We also found 
no nucleotide changes in CDC6, a gene that is involved in DNA replication in 
which mutation has previously caused a small resistance increase (Singh-
Babak et al., 2012).  
 
 
 
Figure 5.8. Genomic DNA extraction, PCR amplification and Sanger sequencing 
of caspofungin resistance gene targets in colony variants of C. glabrata strain 
2001. Qualitative results of gene target amplifications shown for a single media-
adapted colony (MA), LCV (large colony variant) and SCV (small colony variant) 
revived from the 0.78 µg/ml caspofungin-evolved population at day 14 in Experiment 1. 
Gene target amplifications of the wild-type ancestor (WT) are also shown. Results were 
identical for single MA, LCV and SCV colonies revived from the 0.78 µg/ml 
caspofungin-evolved population at day 14 in the third experimental evolution. (a) 
Genomic DNA was extracted from colony variants and amplification of 3 gene target 
regions are shown: FKS1 HS1, FKS2 HS1 and CDC6, using primers previously 
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described for C. glabrata (Table A.4.1.S1). High intensity bands indicate amplified 
product. (b) Figure adapted from Kartsonis et al. (2003). Diagram of fungal cell wall 
showing caspofungin enzymatic target β-(1,3)-glucan synthase, which is prevented 
from synthesising β-(1,3)-glucan cross-linkages in the cell wall. (c) Figure taken from 
Perlin (2015). Diagram of transmembrane structure of glucan synthase enzyme in the 
fungal cell wall and location of channels containing the hotspot target regions (HS1 and 
HS2) that are commonly mutated with caspofungin resistance. (d) Alignment of hotspot 
1 (HS1) sequence of amino acids coded from the FKS1 and FKS2 genes of the ATCC 
2001 reference strain, SCV and LCV, MA (media-adapted) and WT (wild-type) 
ancestor. The amplified HS1 region of the FKS genes contains a homologous 
sequence of amino acids previously described as a common target for caspofungin 
resistance mutations (Garcia-Effron et al., 2009). Purified DNA was Sanger sequenced 
and nucleotide and amino acid sequences were aligned using MEGA software (Kumar 
et al., 2016). No nucleotide or amino acid changes were detected.  
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5.5 Discussion 
 
 
Antibiotic resistance can evolve under different dosing regimens (Palmer and 
Kishony, 2013) and is quantified both phenotypically and genotypically 
(MacLean et al., 2010), with mutations often conferring fitness costs (Andersson 
et al., 2006). The dynamics of resistance evolution across parallel populations 
are often quantified in bacteria (Toprak et al., 2011; Lindsey et al., 2013; Palmer 
and Kishony, 2013), but the evolutionary development of mechanisms and 
phenotypic effects of antifungal resistance across and within parallel fungal 
populations are not well understood. It is important to investigate the parallelism 
of antifungal resistance evolution to determine positive selection of resistance 
determinants (Elena and Lenski, 2003) at the individual and population level. 
We take the first steps to investigate parallelism of antifungal adaptation, by 
measuring fitness costs and phenotypic adaptations to the antifungal 
caspofungin across population colonies of the C. glabrata wild-type strain 2001 
at post-IC50 caspofungin concentrations. We identified differences in fitness 
costs across and within parallel populations in independent evolutionary 
experiments and found sub-population diversity in colony phenotype in the 
absence of commonly mutated caspofungin resistance targets. Our results 
contribute to understanding the phenotypic effects and repeatability of 
caspofungin adaptation under controlled conditions and offer insight into a 
potentially novel mechanism of population-level antifungal resistance in C. 
glabrata. 
 
 
We found that growth kinetic fitness costs of caspofungin adaptation varied 
between replicate populations evolved at the post-IC50 concentration of 0.78 
µg/ml, in the three biological replicates of 14-day evolution. In experimental 
evolution of fluconazole resistance in C. albicans, differences in growth rates 
and stationary cell densities were found across drug-evolved replicate 
populations due to mutations in different gene targets, highlighting chance 
selection of different resistance mechanisms (Cowen et al., 2000; 2001; 2002). 
This may be relevant to caspofungin resistance adaptations as different 
mutations in the FKS genes, encoding the catalytic subunits of the glucan 
synthase enzyme for cell wall synthesis (Garcia-Effron et al., 2009), result in 
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different caspofungin susceptibility levels (Arendrup and Perlin, 2014) and may 
or may not result in fitness costs from reduced catalytic efficiency (Garcia-Effron 
et al., 2009; Borghi et al., 2014). The fitness costs are likely to be associated 
with positive selection of resistance mechanisms during caspofungin treatment, 
rather than genetic drift in small populations (Elena and Lenski, 2003), due to 
the cidal rather than static mode of drug action (Kartsonis et al., 2003) and lack 
of fitness cost variation across control media-evolved populations in biological 
replicate 1 (Figure 5.1).  
 
Across independent population colonies of C. glabrata strain 2001 that were 
evolved at 0.78 µg/ml for 14 days, higher resistance levels with IC50 values 
greater than 2.4 µg/ml were associated with larger significant growth rate fitness 
costs in the absence of caspofungin. Subsequent serial transfers in media in 
the absence of caspofungin supported the co-maintenance of high level 
resistance with a low growth rate. In contrast, smaller increases in IC50 were 
associated with smaller or negligible growth rate fitness costs. These results are 
consistent with a negative relationship between resistance level and fitness in 
the evolution of antibiotic resistance in bacteria. In clinical isolates of P. 
aeruginosa, low level resistance determined by MIC conferred a negligible 
growth rate cost whereas high level resistance always conferred fitness costs 
(Kugelberg et al., 2005). A similar relationship was described in a meta-analysis 
of antibiotic resistance mutations against a range of different antibiotics (Melnyk 
et al., 2015) and could be explained by trade-offs in energy investment between 
large-effect resistance mutations and other cellular processes. 
 
Alternatively, larger fitness costs could be caused by higher level resistance 
resulting from multiple mutations that pleiotropically disrupt normal cell 
physiology (Kugelberg et al., 2005; Melnyk et al., 2015). Differences in 
resistance levels between caspofungin-evolved fungal population colonies 
could be due to different evolved mutations, as described for FKS genes for 
which susceptibility level is dependent on the amino acid substitution (Arendrup 
and Perlin, 2014). Alternatively, epistatic interactions between multiple 
mutations (Anderson, 2005) in single evolved colonies could be responsible for 
between-colony fitness cost differences.       
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At 2.4 µg/ml, we observed no fitness costs across replicate populations, which 
contrasts with the theory that fitness costs are greater at higher drug 
concentrations (Andersson and Hughes, 2014). As we did not collect data on 
the resistance level of revived population colonies that were evolved at 2.4 
µg/ml, we cannot conclude whether the lack of fitness costs signified rapid 
resistance evolution followed by compensatory adaptation, or phenotypic 
persistence. Resistance may have evolved faster due to greater selective 
pressure, as described previously for high fungicide doses (Mikaberidze et al., 
2017). This could have allowed more time for compensatory mutations that 
mitigate fitness costs to have occurred, as described in bacteria (Andersson et 
al., 2006) and fungi (Singh-Babak et al., 2012). Alternatively, colonies that 
survived at 2.4 µg/ml could have been phenotypic persisters that were able to 
tolerate drug treatment but did not have detectable resistance, as described in 
bacterial (Keren et al., 2004; Lewis, 2007; Day, 2013) and fungal infections 
(LaFleur et al., 2006). 
 
We found significant sub-population heterogeneity in fitness costs in a single 
technical replicate population, in two out of three independent 14-day 
evolutionary experiments in 0.78 µg/ml. This suggests positive selection of 
heterogeneity as a population-level mechanism of caspofungin resistance. This 
supports the parallel evolution of metabolic population heterogeneity in 
experimental populations of E. coli (Herron and Doebeli, 2013), whereby 
populations were dimorphic in colony size and in preferential growth on glucose 
or acetate (Friesen et al., 2004). Sub-population diversity can be maintained by 
clonal interference whereby beneficial mutations in different population clones 
are co-selected (Herron and Doebeli, 2013). Studying sub-population diversity 
has clinical relevance because dynamic within-strain phenotypic and genotypic 
heterogeneity occurs in patient samples over time, for example during lung 
infection with Pseudomonas aeruginosa (Mowat et al., 2011). It is necessary to 
characterise multiple population clones to fully understand antibiotic resistance 
development and to optimally design treatments. 
 
We found that population heterogeneity in growth rate fitness costs was 
associated with differences in colony size but similar abilities to utilise different 
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carbon substrates. The colony with the lowest relative growth rate had a much 
smaller size (“small colony variant”) compared with another population colony 
with no significant reduction in growth rate compared with the ancestral strain 
(“large colony variant”). This supports previous description of spontaneous 
emergence of the petite phenotype- significantly smaller colonies on agar- in 
haploid and diploid forms of the yeast S. cerevisiae due to deletion of part of the 
mitochondrial genome that results in respiratory deficiency (Bernardi, 1979). 
This reduced colony size and impaired oxidative phosphorylation associated 
with slower growth rate is also found in bacteria and can result in persistent and 
recurrent infections, in Staphylococcus aureus (Proctor et al., 1995; Singh et al., 
2009) and a range of other bacterial species (Proctor et al., 2006). As the small 
colony phenotype leads to increased survival and is caused by a similar 
physiological mechanism in both prokaryotes and eukaryotes, it is likely that it is 
an evolutionary adaptation to environmental change (Day, 2013). 
 
Previous studies have described in vivo selection of petite mutants in C. 
glabrata isolates from patients undergoing azole (Bouchara et al., 2000) or 
echinocandin therapy (Singh-Babak et al., 2012). Interestingly, both large and 
small colonies were found in patient samples and the small colony was unable 
to grow on the nonfermentable carbon source glycerol, compared with growth 
on glucose, indicating respiratory deficiency due to deletion of mitochondrial 
DNA (Bouchara et al., 2000). These findings contrast with our results, as our 
“small colony variant” was able to grow on both glucose and glycerol, 
suggesting respiratory function, therefore another potentially growth-related 
mutation associated with caspofungin adaptation was likely to be causing the 
fitness cost. We also found no reduction or an increase in relative growth 
density in our small compared with large colonies, whereas yeast petites have 
previously been described to have a lower yield due to increased fermentation 
(Verduyn, 1991).  
 
In bacterial infections, persister cells are important in stressful environments, for 
example under drug pressure, and are characterised as slower growers which 
enter a dormant state that allows tolerance of bacteriocidal treatment and 
population survival (Keren et al., 2004; Lewis, 2007; Day, 2013). Persisters are 
solely phenotypic variants and are part of naturally existing phenotypic 
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heterogeneity in an isogenic population (Balaban et al., 2004), so re-growth 
results in formation of both large and small colonies. Yeast phenotypic 
persisters have also been described in biofilms treated with fungicidal agents 
(LaFleur et al., 2006). This contrasts with our findings in C. glabrata as the small 
colony phenotype was maintained in our single season fitness cost growth 
assays, and over 14 daily serial transfers in the absence of caspofungin for the 
small colony from the biological replicate 1 experiment.  
 
We compared virulence of our C. glabrata small and large colony variants in the 
wax moth larval infection model G. mellonella and found no significant 
difference in larval survival between the ancestor or either of the colony 
variants. This contrasts with studies in S. cerevisiae (Weger et al., 2002) and C. 
glabrata (Brun et al., 2005) which described significantly reduced virulence of 
petite mutants in murine models compared with the parental strains, which was 
attributed to the slower growth rate of petites (Brun et al., 2005). Small colony 
variants of S. aureus have also shown reduced virulence (Musher et al., 1977). 
Alternatively, recent work has described that pathogen growth rate is not always 
positively correlated with virulence and a slower growth may be linked with 
higher virulence due to consideration of other life history factors (Leggett et al., 
2017). We propose that it is growth density rather than growth rate that better 
predicts virulence as we saw highly significant growth rate differences between 
our small and large colony variants but non-significant differences in growth 
density.  
 
As our small and large colony variants were isolated from a caspofungin-
evolved population that showed significant adaptation (increase in growth 
density) during 14 days of experimental evolution, we may have expected that 
resistance mutations occurred with an associated virulence cost, as was 
previously seen in murine models with caspofungin-resistant mutants of C. 
albicans (Ben-Ami et al., 2012) and C. glabrata (Singh-Babak et al., 2012). Our 
data supports that of Borghi et al. (2014) who found no virulence cost of 
caspofungin-resistant FKS2 mutants of C. glabrata in G. mellonella, which 
highlights differences between the two model systems or in growth or genetic 
properties of the resistant strains.  
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We found that our small colony variants had significantly decreased 
caspofungin susceptibility compared with the large colony variants isolated from 
the same population. This supports previous discovery of a sub-population of C. 
albicans or C. tropicalis biofilm cells that can tolerate high concentrations of 
chelating agents that are fungicidal (Harrison et al., 2007). This increases 
overall population tolerance to fungicide. A sub-population of tolerant cells 
named as persisters also exists when C. albicans biofilms, but not planktonic 
cultures, are treated with the cidal agents amphotericin B and chlorhexidine 
(LaFleur et al., 2006). These studies indicate that spatial structure within a 
biofilm was necessary to generate population heterogeneity, but heterogeneity 
may have occurred in our experiments as a result of temporal variation in 
resource and drug concentration in batch cultures, rather than spatial variation 
(Levin, 1972; Rainey et al., 2000).  
 
One study has described co-isolation of a C. glabrata petite mutant alongside a 
regular size isolate during serial evolution of C. glabrata within a patient 
receiving caspofungin therapy (Singh-Babak et al., 2012). This petite mutant 
had higher caspofungin resistance and cross-resistance to azoles and 
amphotericin B than the co-isolate. Whilst the heat shock protein Hsp90 and 
downstream phosphatase calcineurin were required for FKS gene-mediated 
resistance in the regular size isolate, the petite was resistant to calcineurin 
inhibitors perhaps due to upregulation of other genes. Importantly, the petite 
phenotype itself was not intrinsically resistant to caspofungin as artificial 
generation of petites via ethidium bromide treatment did not confer resistance.  
 
Other studies have described generation of C. glabrata petite mutants in in vitro 
(Defontaine et al., 1999; Sanglard et al., 2001) and in vivo (Bouchara et al., 
2000) selection experiments with azoles. These mutants are azole resistant and 
can be co-isolated with larger colonies with azole sensitivity equal to the wild 
type (Bouchara et al., 2000). The petite phenotype was due to deletion of 
mitochondrial DNA (Defontaine et al., 1999; Bouchara et al., 2000; Sanglard et 
al., 2001) and petites were intrinsically azole resistant when artificially 
generated with ethidium bromide in the absence of azole exposure (Sanglard et 
al., 2001). Petites generated with azole or ethidium bromide treatment showed 
upregulation of ATP-binding cassette (ABC) transporter CDR genes. This 
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suggests that drug efflux (Sanglard, 2016) is a mechanism of antifungal 
resistance in petites.  
 
Importantly, we found no mutations in the hotspot 1 and 2 regions of the FKS1 
or FKS2 genes or in the CDC6 gene in our co-isolated small and large colony 
variants from two independent evolutionary experiments. This contrasts with 
numerous studies that exclusively describe caspofungin resistance as a result 
of mutations in the homologous FKS genes encoding different catalytic subunits 
of the glucan synthase enzyme, which is the cellular target of caspofungin 
(Kartsonis et al., 2003; Katiyar et al., 2006; Perlin et al., 2007; Katiyar et al., 
2012). Non-synonymous mutations are most commonly described in the hotspot 
1 region of these genes in clinically resistant isolates (Garcia-Effron et al., 2009; 
Perlin, 2011; Katiyar et al., 2012; Pham et al., 2014), encoding a 
transmembrane channel of the glucan synthase (Perlin, 2015). Mutations are 
most common in the FKS2 gene (Katiyar et al., 2012) and the most common 
amino acid change is from serine to proline at amino acid position 663 (S663P) 
(Zimbeck et al., 2010). Mutations occur less commonly in hotspot 2 of the FKS 
genes (Garcia-Effron et al., 2009; Perlin, 2011) and are absent in some clinical 
isolates (Pham et al., 2014).  
 
In addition, mutations in the CDC6 (Cell Division Cycle) gene following FKS2 
mutation can confer a small caspofungin resistance increase in clinical isolates 
(Singh-Babak et al., 2012). The Cdc6 protein plays an important role in DNA 
replication initiation in S. cerevisiae by forming pre-replicative complexes 
(Cocker et al., 1996), but has only been considered a target of caspofungin 
resistance in one study (Singh-Babak et al., 2012). In total, 8 non-synonymous 
mutations in previously non-characterised targets, in addition to FKS2 mutation, 
were found by whole genome sequencing of the final clinical isolate (regular 
size isolate) of a patient treated with caspofungin (Singh-Babak et al., 2012). It 
is likely that other genes will have a role in caspofungin resistance in clinical 
studies, as large-scale gene deletion assays in C. glabrata revealed 28 novel 
genes involved in caspofungin tolerance. These were related to cell integrity 
pathways, calcineurin signalling and transcriptional regulation (Schwarzmüller et 
al., 2014).  
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Population heterogeneity also exists in antibiotic-treated populations and is 
described as heteroresistance, whereby subpopulations of bacteria exhibit 
differences in their antibiotic susceptibility levels (El-Halfawy and Valvano, 
2015). Most commonly, bacterial cultures predominantly consist of a susceptible 
population with a small sub-population of highly resistant cells. This poses a 
clinical challenge and can result in poorer treatment outcomes, as resistance 
can go undetected in standardised susceptibility testing of single colonies from 
patient samples rather than a representative analysis of the whole population by 
characterising several colonies (Mowat et al., 2011). Mechanisms of 
heteroresistance could be genetic, epigenetic or nongenetic but are not fully 
understood (El-Halfawy and Valvano, 2015), therefore it is unclear whether 
heteroresistance can be maintained through serial passages in the absence of 
antibiotic. One clinical study described selection of resistant cells and 
replacement of sensitive cells in a heteroresistant bacterial population treated 
with antibiotic over time (Hernan et al., 2009). Heteroresistance may be seen as 
an intermediate stage of resistance for a population transitioning from full 
susceptibility to full resistance (Superti et al., 2009).  
 
We found in one independent evolutionary experiment that the large colony that 
was co-isolated with the resistant small colony, when in isolation could not grow 
in the caspofungin concentration to which it was evolved. This suggests that 
presence of the small colony variant during the evolutionary experiment 
maintained the large colony in the population over 14 days. Our data supports 
previous co-isolation of sensitive and resistant mutants in a bactericidal-evolved 
population of E. coli, whereby sensitive cells could survive at drug 
concentrations above their MIC and resistant cells were resistant to higher drug 
concentrations than those to which they were evolved (Lee et al., 2010). The 
mechanism of population-level resistance was due to chemical communication 
between resistant and sensitive cells and separate drug resistance mutations in 
resistant cells that increased overall population survival in antibiotic conditions. 
Alternatively, heteroresistance in bacterial populations can be maintained by 
within-population division of labour between optimising growth rate or stress 
resistance (Wang et al., 2014) or by antibiotic degradation (Medaney et al., 
2016). Heteroresistance in C. glabrata has occurred in vivo during fluconazole 
treatment and may be responsible for persistent infections, but was not 
 172 
described for echinocandins (Ben-Ami et al., 2016). Metabolic exchange and 
cooperation between cells has been described in yeast communities (Campbell 
et al., 2015; 2016) but studies into the population mechanisms of drug 
resistance in fungal pathogens have not been completed and require future 
research. 
 
5.6 Conclusions of the Chapter 
 
We draw three main conclusions from our results: 
 
1) Fitness costs of caspofungin adaptation vary across and within parallel 
populations of C. glabrata evolved at caspofungin post-IC50 
concentration, measured by differences in growth rate and final growth 
density in the absence of caspofungin. 
 
2)  Sub-population diversity in fitness costs is associated with differences in 
colony sizes and caspofungin susceptibility levels, but growth on non-
fermentable carbon source and virulence is unaffected. 
 
3) Sub-population heterogeneity can be independently evolved in a 
separate evolutionary experiment and could be a positively selected 
population-level mechanism of antifungal resistance. 
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6. Chapter 6: Discussion 
 
6.1 Thesis Overview 
 
Fungal human pathogens pose a severe threat to human health due to the rise 
of invasive fungal disease with high mortality in immunocompromised patients 
and the emergence of drug-resistant species (Brown et al., 2012). Research 
into the interactions between Candida species at different resource levels, the 
effect of species interactions on host survival with different clinical strains and 
the influence of pathogen growth strategies on antifungal adaptation have not 
been studied in detail. This thesis addressed these key topics and the main 
research findings in each of these areas are presented below. The approach for 
experimental work involved in vitro and in vivo studies in microbial ecology and 
evolution using clinical pathogenic Candida species. We used simple, controlled 
short and long-term batch culture experiments and manipulated the culture 
medium by using artificial media, varying glucose concentration or applying 
antifungal treatment through time. Using experimental evolution, we were able 
to test larger sample sizes to increase replicability of the results, sample 
evolving populations during the experiment and revive evolved populations for 
further phenotypic analysis. This expands the applicability of these research 
tools, commonly used in model bacterial and yeast species (Buckling et al., 
2009) to study evolution of mixed-species interactions in clinical infections and 
evolution of antifungal resistance in C. glabrata.  This discussion will end with 
thesis conclusions and perspectives on future research questions raised by the 
results.   
 
6.2 Competition for Resources in Dual Species in vitro and in vivo 
Environments 
 
Mixed fungal species communities commonly exist as commensals in different 
host body sites and lead to mixed-species infections (Jenkinson and Douglas, 
2002). Species of the Candida genus are the fourth most common cause of 
bloodstream infections (Wisplinghoff et al., 2004) and C. albicans and C. 
glabrata are often co-isolated (Coco et al., 2008). Competition for resources 
occurs within microbial communities in the human body (Dethlefsen et al., 2006) 
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but the influence on ecological dynamics and species interactions in mixed-
fungal species infections in clinically-relevant and model host environments 
remain to be characterised. We aimed to investigate whether resource level 
influenced the outcome of in vitro species competition during short and long-
term experiments. We then aimed to characterise species interactions in the 
invertebrate host model Galleria mellonella, which could be incubated at 
physiological temperatures and injected with precise pathogen inoculum doses 
(Desalermos et al., 2012).  
 
In Chapter 2, we co-cultured C. albicans and C. glabrata in a range of different 
glucose concentrations in batch cultures in clinically-relevant synthetic urine 
media to mimic urinary tract infections. Similar to previous studies (Nilsson, 
2012; Beardmore et al. (in prep)), we found that competition outcomes were 
dependent on resource level. C. albicans was fitter at lower resource 
concentrations and C. glabrata was fitter at higher resources, resulting in long-
term domination of the respective species, depending on resource 
concentration. Other in vitro dual-Candida species competition experiments 
have found either C. albicans domination (Kirkpatrick et al., 2000) or exclusion 
(Thein et al., 2007; Rossoni et al., 2015) but the effect of different resource 
concentrations on outcomes was not tested. Similar resource-dependent 
competition outcomes have been described between S. cerevisiae and Candida 
utilis (Postma et al., 1989a). These results may be explained by differing 
species glucose transporter affinities, or fermentation by C. glabrata (Van Urk et 
al., 1990) resulting in less efficient glucose utilisation (Pfeiffer et al., 2001) at 
low concentrations. Increased fitness of C. glabrata in high glucose is consistent 
with its frequent isolation from diabetic patients (Fidel et al., 1996). 
 
In Chapter 2, we found that C. albicans fitness was negative frequency-
dependent. Previous studies in bacteria and fungi have calculated negative 
frequency dependence in competitor fitness due to genotype selection when 
rare but disadvantage when common (Haldane and Jayakar, 1963; Turner et 
al., 1996; Feldgarden et al., 2003; MacLean et al., 2006). When fitness of two 
competitors is equal, stable co-existence is predicted long-term (Antonovics and 
Kareiva 1988; Ayala and Campbell, 1974; Rainey et al., 2000; Feldgarden et 
al., 2003; Vellend, 2010) and has been confirmed experimentally (Turner et al., 
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1996). We predicted that C. glabrata and C. albicans would show long-term co-
existence at intermediate glucose concentrations for species frequencies at 
which relative fitness of the two species was equal. Instead, we saw exclusion 
of C. albicans over time. Our results may be due to mutational change, which 
could have improved glucose utilisation of C. glabrata (Brown et al., 1998). We 
provide one example where negative frequency-dependence cannot be used to 
predict long-term competition outcomes but we do not claim that this result 
would be seen for other microbial species or under different environmental 
conditions. Candida species are parts of communities of other microbial species 
in different host sites, which may modify Candida species interactions 
(Jenkinson and Douglas, 2002; de Muinck et al., 2013). 
 
In Chapter 3, we injected G. mellonella larvae with dual Candida species 
inocula of different clinical strains of C. albicans, C. glabrata and C. krusei and 
compared larval survival between dual and single species strain infections. This 
allowed us to deduce species interactions in the context of virulence in a model 
host. We found species synergism evidenced by increased larval mortality in 
dual compared with single species infection. Our results were consistent with 
synergistic pathogenesis and infection burden in dual Candida species infection 
of in vitro epithelia (Silva et al., 2011; Alves et al., 2014) and a murine model 
(Tati et al., 2016), but the effects on host survival were not tested with different 
clinical strain combinations in previous studies. 
 
Our results from Chapter 3 contrast with antagonistic interactions described in 
recent dual Candida species infection of G. mellonella, tested just with lab 
strains of each species (Rossoni et al., 2015). This may be due to differences in 
larval source or other lab conditions (Cook and McArther, 2013), resulting in 
higher virulence of Candida species lab strains or decreased larval immunity in 
our experiments. 
 
Our results from Chapters 2 and 3 show that C. glabrata and C. albicans form 
ecological interactions in physiologically-relevant environments and that 
competition for resources influences species domination or virulence. Our 
results contribute to understanding mixed-fungal species interactions in 
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commensal and pathogenic environments, which may help to better predict 
infection outcomes.  
 
It would be interesting to investigate the population dynamics of dual Candida 
species infection in G. mellonella to determine the changes in species fitness 
underlying the synergistic interactions that we found, for comparison to in vitro 
species fitness described in Chapter 2. We hypothesise that the burden of 
either C. albicans, C. glabrata or both species would be greater during dual 
than single species infections. It would be interesting to investigate the 
metabolic or molecular mechanisms determining antagonistic or synergistic 
responses and whether a mixture of the two types of interactions could occur in 
infections.  
 
6.3 C. glabrata Clinical Strain Variation in Competitive Abilities, Species 
Interactions and Growth Kinetics 
 
Candida species colonise a range of body sites and host patients which vary in 
resource levels (Brown et al., 2014). Glucose is the main carbon source needed 
for growth (Gagiano et al., 2002) and yeast species have developed metabolic 
adaptations to utilise glucose at different concentrations (Ozcan et al., 1996; Yin 
et al., 2003). It is unknown how C. glabrata clinical strains vary in competitive 
abilities and growth properties in different resource environments. We aimed to 
investigate whether in vitro competitive abilities and in vivo interactions between 
C. albicans and C. glabrata varied with C. glabrata strain. We also aimed to 
investigate differences in C. glabrata strain growth properties when grown in 
isolation on glucose.  
 
In Chapter 2, we compared in vitro competitive abilities of C. glabrata clinical 
strains by competing them with C. albicans over a single season and found that 
relative fitness quantitatively varied across the strains. This may be caused by 
genetic differences between strains due to their adaptations to different host 
environmental niches. 
 
In Chapter 3, we tested different C. glabrata clinical strains in dual infection with 
C. albicans in the G. mellonella model and found that the strength of synergistic 
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species interaction was dependent on C. glabrata strain. A greater synergistic 
response was correlated with higher C. glabrata strain virulence and a greater 
host immune response. Our results are consistent with prior literature that 
described differences in infection burden and tissue colonisation in dual 
Candida species infection of a murine infection model with different strains of C. 
glabrata (Tati et al., 2016). Differences in C. glabrata strain virulence have been 
described in a recent study of G. mellonella infection (Ames et al., 2017), but 
our results show the first experimental test and evidence for variation in host 
immune response triggered by different C. glabrata strains, with greater 
melanisation of a single strain previously associated with higher pathogen dose 
and larval mortality (Ames et al., 2017). 
 
In Chapter 4, we compared the growth profiles of C. glabrata clinical strains 
over a range of physiologically-relevant glucose concentrations in simple 
nutrient media during single-season experiments. We found that growth rate 
and carrying capacity were positively correlated at low glucose concentrations 
and negatively correlated at high glucose concentrations (Reding-Roman et al., 
2017). Growth rate was maximised at intermediate glucose. Yield (efficiency of 
biomass production) was a decreasing function of glucose concentration. These 
trends are consistent with those described in strains of E. coli due to a switch 
from respiration to fermentation at higher glucose concentrations (Reding-
Roman et al., 2017). The rate-yield trade-off has also been described in S. 
cerevisiae (Zakrzewska et al., 2011). We found within strain variation in the 
shape of the growth rate/carrying capacity and growth rate/yield profiles 
(Reding-Roman et al., 2017). Of the strains we tested, a C. glabrata strain 
isolated from a diabetic patient had the highest average growth rate and lowest 
carrying capacity and yield, compared with a wild-type lab strain. Our results 
provide proof of principle that C. glabrata strains from different host patient 
environments exhibit different growth traits, but we do not claim that the diabetic 
strain that we characterised is representative of all strains isolated from diabetic 
patients. 
 
Our results from Chapters 2, 3 and 4 highlight the need to consider different 
species strains when studying mixed-fungal species interactions. Adaptations to 
different resource levels in host environments can influence strain growth 
 178 
properties and virulence. Studying strain growth at a range of physiologically-
relevant glucose concentrations is important for understanding differences in 
pathogenesis at different body sites and in diabetic patients with elevated 
glucose levels (Fidel et al., 1996; Brown et al., 2014a). This could contribute to 
better characterisation of the virulence of single and dual species fungal 
infections and to better predict infection outcomes in different environments. It 
would be interesting to investigate genetic mechanisms underlying the growth 
and virulence differences of C. glabrata strains. 
 
6.4 Influence of Pathogen Growth Strategies on Virulence and Antifungal 
Adaptation  
 
C. glabrata has shown an epidemiological increase, which is of concern due to 
its greater than 50% death rate, high resistance to the antifungal fluconazole 
(Fidel et al., 1999; Gudlaugsson et al., 2003; Pfaller et al., 2012) and multidrug 
resistance to the major drug classes. We have shown that clinical C. glabrata 
strains vary in their growth properties but it is unknown how differing growth 
strategies (higher growth rate or carrying capacity) influence virulence and 
antifungal susceptibility. Antifungal susceptibility testing is often performed 
under standardised conditions in vitro, which do not consider the influence of 
different host environmental conditions and strain virulence on susceptibility, 
resulting in clinical treatment failures (Sanglard and Odds, 2002; Anderson, 
2005; Kanafani and Perfect, 2008). We aimed to investigate the influence of 
different strain growth properties on host survival and evolutionary adaptation to 
the antifungal caspofungin, a first-line therapy drug to which clinical resistance 
is increasing (Alexander et al., 2013). We aimed to test for growth kinetic fitness 
costs of caspofungin adaptation and sub-population diversity in phenotypic 
adaptations.  
 
In Chapter 4, we compared virulence of two strains of C. glabrata in the 
invertebrate model G. mellonella and used in vitro experimental evolution in 
simple nutrient media to compare caspofungin adaptation of the two strains 
across replicate populations. We found that a lower growth rate but higher 
carrying capacity was correlated with greater virulence and decreased 
susceptibility to caspofungin over time. Our data supports a study in S. 
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cerevisiae in which lower growth rates were correlated with higher resistance to 
host-imposed stresses due to greater energy investment in stress protection 
than growth (Zakrzewska et al., 2011). Our data also supports recent evidence 
that pathogen growth rate is not necessarily positively correlated with virulence, 
due to conflicting factors such as other pathogen strategies that aid evasion of 
host immunity or maximise pathogen fitness (Leggett et al., 2017). It also 
supports the principle that a slower growth rate renders pathogens more 
resistant to drug treatment (Gilbert et al., 1990; Claudi et al., 2014). 
 
In contrast, our data is inconsistent with studies that describe pathogen growth 
rate as a fitness measure determining virulence (Anderson and May, 1982; 
Perlman, 2009). We do not claim that a lower growth rate is necessarily linked 
to greater virulence, rather that the balance between growth rate and carrying 
capacity is associated with virulence. We found that a higher carrying capacity 
is correlated with greater virulence but we do not claim direct causation. 
 
In Chapter 5, we tested for fitness costs and adaptations to caspofungin 
treatment by growth profiling and plating revived, evolved populations of the 
wild-type strain of C. glabrata, the strain with a lower average growth rate and 
higher carrying capacity. We found within and between population variation in 
fitness costs and sub-population diversity in growth rate, colony size and 
antifungal susceptibility. In independently-evolved populations, we co-isolated 
small, highly caspofungin-resistant colonies and larger, more sensitive colonies.  
The small colony had a significantly lower growth rate but comparable carrying 
capacity (final growth density) to the large colony. The between-population 
variation in fitness costs supports previous fitness divergence across 
populations of C. albicans that were experimentally evolved with fluconazole 
(Cowen et al., 2000; 2001). A small colony phenotype has previously been 
described in both fungal and bacterial populations exposed to environmental 
stress (Day, 2013). Heteroresistance, the presence of resistant and sensitive 
colonies in a population, has evolved in bacterial drug-treated populations (Lee 
et al., 2010; El-Halfawy and Valvano, 2015). It is possible that metabolite 
exchange can increase stress resistance in fungal communities (Campbell et 
al., 2015; 2016) but this has not been explored in C. glabrata.  
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Our caspofungin-resistant C. glabrata small colony grew on a non-fermentable 
carbon source and we saw no virulence difference between the small and large 
colony variants. This suggests that our small colony was not a yeast petite 
mutant that is deficient in respiratory function and virulence capacity (Singh-
Babak et al., 2012). We were able to re-grow our small colony suggesting that it 
was a genotypic variant, rather than a phenotypic variant as described 
previously for bacteria and fungi (Balaban et al., 2004; LaFleur et al., 2006). We 
found that large differences in growth rate did not alter virulence, suggesting 
that carrying capacity (growth density) is a more reliable predictor of virulence. 
Interestingly, we saw a high level of caspofungin resistance in our small colony 
in the absence of mutations in commonly described caspofungin resistance 
target genes (Garcia-Effron et al., 2009). This suggests that mutation in another 
gene target not commonly associated with caspofungin resistance occurred, for 
example in other cell integrity genes or transcriptional regulators 
(Schwarzmüller et al., 2014).   
 
Our results show that different pathogen growth properties of C. glabrata strains 
can be correlated with virulence and that experimental evolution of 
echinocandin resistance can be studied in the lab and compared between 
strains. Our work provides evidence of phenotypic effects and repeatability of 
caspofungin adaptation. We described a potentially novel mechanism of 
antifungal resistance in C. glabrata, demonstrating the importance of 
population-level heterogeneity in resistance (El-Halfawy and Valvano, 2015). 
These results could improve understanding of pathogen evolution of antifungal 
resistance in infections and may lead to better characterisation of fungal strains 
in different patients. This may lead to consideration of additional host 
environmental parameters when using in vitro susceptibility testing to inform 
clinical susceptibility prediction. Within-patient strain diversity in drug adaptation 
or virulence could also be characterised (Mowat et al., 2011).  
 
We hypothesise that a greater final pathogen growth density is correlated with 
greater virulence and antifungal resistance. It would be interesting to test this 
hypothesis over a larger range of C. glabrata clinical strains and we could 
further test evolution of growth strategies associated with virulence by growth 
profiling C. glabrata strains that have been serially-passaged through the G. 
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mellonella model, as tested for C. albicans adaptation to a murine host (Lüttich 
et al., 2013) and Aspergillus flavus adaptation to G. mellonella (Scully and 
Bidochka, 2005). Following caspofungin treatment, we hypothesise that co-
isolation of small and large colony variants in some populations is a stable 
resistance mechanism as the sensitive large colony was maintained in the 
population at inhibitory drug concentrations. We could further test this by 
investigating population dynamics of the two colony variants over serial 
transfers and characterising genetic mechanisms of resistance in the small 
colony.  
 
Our results demonstrate the importance of species interactions and clinical 
strain variation in better understanding the drug susceptibility and virulence of 
Candida infections. Our finding that higher glucose levels in clinically-relevant 
environments can increase the prevalence of intrinsically drug-resistant C. 
glabrata, could inform optimal treatment design for infections in different 
patients and body sites that vary in glucose levels, particularly in diabetic 
patients. It is therefore important to consider the metabolic dimension when 
designing antimicrobial treatments (Allison et al., 2011). As substantial variation 
in growth parameters can occur between species strains isolated from different 
patient infections, this highlights the need for improved diagnostics, given our 
finding that two initially susceptible C. glabrata strains showed contrasting 
abilities to adapt to high caspofungin concentrations over time. Measuring the 
key growth characteristics of clinical strains, such as carrying capacity, under 
different environmental conditions of relevance to infections could allow better 
prediction of strain adaptability to antifungals.  
 
As well as consideration of strain-specific growth properties and virulence, our 
results highlight the importance of detecting the presence and measuring the 
repeatability of evolved within-population diversity in phenotypic properties and 
antifungal resistance. In the clinical context, a population could relate to a site-
specific patient isolate that shows significant variation in phenotype between 
individual population clones, as described in bacterial cystic fibrosis infections 
(Mowat et al., 2011). In addition, the presence of high-level echinocandin 
resistance in the absence of mutation in commonly-described FKS gene hotspot 
targets (Katiyar et al., 2006) could mean that using FKS gene sequencing to 
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detect clinical resistance (Shields et al., 2012) is ineffective in some cases. 
Standardised clinical antimicrobial susceptibility testing is limited, as sampling 
only a few clones from a patient isolate could mean that highly-resistant sub-
population clones are undetected, reducing treatment efficacy and leading to 
further drug resistance evolution. Overall, our results add insight for improved 
characterisation of fungal infections and consideration of the role of host 
environment on pathogen growth strategies.  
 
6.5 Conclusions 
 
We draw four main conclusions from the research outcomes of this thesis: 
 
1) Competition for resources occurs between fungal pathogens in nutrient 
media and in an invertebrate model host. Interactions result in long-term 
species exclusion or increased host mortality in dual compared with 
single species infection. 
 
2) C. glabrata clinical strains form different strength interactions with C. 
albicans in dual infections. C. glabrata strains also quantitatively vary in 
growth properties on glucose in single species cultures. 
 
3) A lower average growth rate and higher carrying capacity in C. glabrata 
can be associated with higher virulence and greater antifungal 
adaptation. 
 
4) Caspofungin resistance in C. glabrata could be maintained by co-
existence of resistant and sensitive colony variants. 
 
6.6 Future Perspectives 
 
Current and future challenges in tackling invasive fungal infections, particularly 
those caused by species of the Candida genus, lie in improving diagnostics and 
therapeutics to address increasing drug resistance and the threat of new 
emerging pathogens (Kullberg and Arendrup, 2015). As the number of 
immunosuppressed patients in hospitals increases, Candida species infections 
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will become more prevalent in those with serious pathologies such as cancer 
(Farmakiotis et al., 2014) and HIV (Diamond, 1991). A major risk factor for 
increasing infection prevalence is the overuse of broad spectrum antibiotics, 
which eliminate commensal bacteria that have an important role in preventing 
fungal overgrowth (Saiman and Ludington, 2001; Kumar and Singhi, 2013). The 
increasing prevalence of diabetes among the human population (WHO, 2016) 
will also contribute to increased infection, particularly by C. glabrata (Goswami 
et al., 2006). Drug-resistant fungal infections will pose a major future challenge, 
particularly due to difficulty in developing novel drugs that will target a larger 
range of pathogen sites without affecting human cells (Baldauf et al., 2000; 
Anderson, 2005). The emergence of new pathogenic species with global 
epidemiology, multi-drug resistance and broad-spectrum invasive disease, is a 
real threat as evidenced by the recent and rapid appearance of Candida auris 
(Chowdhary et al., 2017). 
 
In this thesis, we have described resource competition in mixed-Candida 
species infections, differing growth properties and adaptations of C. glabrata 
clinical strains and the influence of pathogen growth traits on virulence and 
antifungal adaptation. This research provides a basis for future investigation of 
evolutionary trade-offs between resource competition, virulence and antifungal 
resistance in single and mixed-Candida species infections. This thesis has 
shown that these types of questions can be addressed for clinical fungal 
pathogens using controlled in vitro experiments and manipulation of different 
environmental parameters to better understand infection in different host sites 
or patients. The relevance of in vitro experiments to in vivo infection 
environments can be tested by the use of a simple host model.   
 
Previous studies have shown that it is possible to investigate trade-offs between 
resource competition and antimicrobial resistance in pathogenic species. Smith 
and Holt (1996) highlighted that resource concentrations could be manipulated 
to influence the balance between resistant and sensitive species, whilst Allison 
et al. (2011) described increased antibiotic activity by combining drug treatment 
with metabolite administration. Manipulation of resource concentration can 
change the balance between resistant and sensitive species if sensitive species 
are better competitors, leading to elimination of drug-resistant competitors 
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(Goldhaber, 1994). Models have been developed to study the best strategies to 
eliminate resistant strains in bacterial infections, by increasing the cost of 
resistance and encouraging faster growth of sensitive strains (Gomes et al., 
2013). Recently, a combination of different resource levels and antifungal 
fluconazole treatment concentrations have been used in vitro to find conditions 
that will select for sensitive C. albicans and eliminate resistant C. glabrata 
(Nilsson, 2012; Beardmore et al., (in prep)). The influence of different C. 
glabrata strains, antifungals and interaction with virulence in a host model 
remains to be investigated.    
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Appendices 
 
A.1. Chapter 2 Appendix 
 
A.1.1 Supplementary Materials and Methods 
 
YPD (Yeast Peptone Dextrose) Media 
 
20 g/l  Bacteriological peptone (Product code: LP0037; Oxoid Ltd, Basingstoke, 
Hampshire, England) 
 
20 g/l   D-glucose anhydrous (Product code: G/0500/61; Fisher Scientific UK, 
Bishop Meadow Road, Loughborough, UK) 
 
10 g/l   Yeast extract (Product code: LP0021; Oxoid Ltd) 
 
18 g/l   Bacteriological agar (if making YPD agar) (Product Code: MC006; Lab 
M Limited, 1 Quest Park, Moss Hall Road, Heywood, Lancashire, UK) 
 
Dissolve in distilled, DI (de-ionised) water 
 
SC (Synthetic Complete) Media 
 
6.9 g/l   Yeast Nitrogen Base (YNB) without amino acids, with ammonium 
sulphate (Product ref. no: CYN0410; Formedium Ltd, Hunstanton, England) 
 
0.79 g/l  Complete drop-out mix (all amino acids) (Product ref. no: DCS0019; 
Formedium Ltd) 
 
D-glucose anhydrous concentration was varied from 20g/l standard 
 
Dissolve in distilled, DI water 
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A.1.2 Supplementary Figures and Tables 
 
 
Figure A.1.2.S1: C. glabrata (left) and C. albicans (right) monocultures on 
CHROMagar plates. C. glabrata forms pink/purple colonies and C. albicans forms 
blue/green colonies.  
 
 
 
Figure A.1.2.S2: Layout of 96-well plate for one-season and serial transfer 
competitions for a range of initial species ratios. Experimental layout is similar to 
that of Nilsson (2012) and Beardmore et al. (in prep). a) One-season competitions: final 
volume of each well is 150 µl; those containing cell suspensions used 75 µl of media/ 
75 µl of cells, so final cell concentration of each well was half of that estimated via 
haemocytometer counts. Synthetic Urine media was added to triplicate wells in 
columns 5, 7 and 9 as well as 4, 6, 8 and 10. Column 2 contained 6 replicate media 
controls, each of 150 µl volume. Triplicate volumes of C. glabrata were added to 
column 5 as monoculture controls; as for C. albicans in column 10. The five remaining 
columns contained triplicates of the five species ratios (90:10, 70:30, 50:50, 30:70, 
10:90) respectively (C. glabrata: C. albicans). All remaining wells contained 150 µl of 
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distilled, de-ionised water. The plate was incubated for 24 hours at 30oC and 180 rpm.  
b) Competitions over serial transfers: Row B is set up as Day 1 and 75ul of media is 
added to each of the wells shown in the blue-shaded areas, apart from B2 which is 
filled with 150 µl SU media as the control. 75 µl of cells are then added to the media 
wells as follows: monoculture controls- Well 4 is C. glabrata; Well 10 is C. albicans. 
Wells in columns 6-8 are the 3 replicates of the co-culture. All intervening wells in the 
row and the outer border of the plate are filled with 150 µl water. Each day, wells of the 
subsequent row are prepared with 145 µl of fresh media/water as per the layout of the 
row above and 5 µl of each of the previous day suspensions are simultaneously 
transferred into this row. The transparent plate seal is removed and replaced with a 
fresh seal daily. (Transfer method from Emily Cook, Haynes group, June 2014). 
 
 
Figure A.1.2.S3. One-season competitions between C. glabrata and C. albicans 
for five initial fractions of C. albicans and each of six different glucose 
concentrations in SU media.  The data shown in this plot is a combination of all data 
from Figure 2.3. Relative fitness of C. albicans is calculated as the Malthusian growth 
parameter and data for each glucose concentration (% w/v) is plotted in a different 
shade of blue, with darker blue indicating higher glucose. N = 9 for each initial fraction 
at each glucose concentration. The best fit linear trendline is plotted for each glucose 
concentration. 
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Table A.1.2.S1. C. glabrata Strains. 
 
Strain Genotype/ Host Origin Reference/ Source 
 
ATCC 2001 Sequenced Wild-Type 
reference strain, isolated 
from human faeces 
(pathogenic) 
 
American Type Culture 
Collection 
(Kitada et al. 1995) 
(Koszul et al. 2003) 
 
BG2 Wild-Type strain derived 
from parental B strain; 
clinical isolate from 
human vaginitis 
 
(Cormack and Falkow 
1999) 
BG2 Δssk2 Derived from BG2 strain; 
mutational inactivation of 
MAPKKK gene SSK2: 
defective Sln1 branch of 
osmotic stress signalling 
(Gregori et al. 2007) 
NCPF 3605 Wild-Type clinical isolate 
from a human with 
diabetes in the UK in 
1989 
 
UKNCC: National 
Collection of Pathogenic 
Fungi, Bristol, 2001. 
NCPF 3309 Wild-Type clinical isolate 
from human faeces 
 
UKNCC: National 
Collection of Pathogenic 
Fungi, Bristol, 2001. 
 
 
 
Table A.1.2.S2. Statistical results from Wilcoxon signed-rank tests to determine 
significant deviation of C. albicans relative fitness from 1 in one-season 
competition in 0.1% w/v glucose SC media. Significance of C. albicans relative 
fitness from a value of 1 was calculated for five initial C. albicans fractions using the 
two-tailed, one-sample Wilcoxon non-parametric test as populations were non-normally 
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distributed. The mean initial C. albicans fraction is shown and is an average of three 
plated replicates. Relative fitness was calculated in 9 replicate populations following 
one-season competition. Negative relative fitness values and highly skewed values 
(relative fitness > 10) were excluded in the figures and statistical analyses. See Figure 
2.2 for plot. 
 
 
 
 
 
Table A.1.2.S3.  Statistical results from Wilcoxon signed-rank tests or one-
sample t-tests to determine significant deviation of C. albicans relative fitness 
from 1 in one-season competition for glucose concentrations in SU media. 
Statistical results are shown for glucose concentrations in which species co-existence 
was not predicted from the linear regression. See Figure 2.3 for plot. 
 
SU 0.05% glucose: 
Initial C. albicans 
fraction 
V-statistic P-value 
0.09 28 0.01563 
0.28 45 0.003906 
0.51 45 0.003906 
0.71 43 0.01172 
0.89 35 0.1641 
 
 
SU 0.1% 
glucose: Initial 
C. albicans 
fraction 
t-value df P-value 
0.11 4.42 8 0.002226 
Initial C. albicans 
fraction 
V-statistic P-value 
0.03 44 0.007812 
0.10 45 0.003906 
0.23 45 0.003906 
0.38 45 0.003906 
0.66 45 0.003906 
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0.26 3.7511 8 0.005615 
0.44 2.0762 6 0.08317 
0.69 2.1806 8 0.06081 
0.85 2.6921 7 0.03099 
 
 
SU 4% glucose: 
Initial C. 
albicans fraction 
t-value df P-value 
0.11 -0.37086 8 0.7204 
0.32 
-2.2941 8 0.05094 
0.53 -7.3705 8 7.838e-05 
0.69 -15.128 8 3.607e-07 
0.85 -10.393 8 6.359e-06 
 
 
Table A.1.2.S3 continued- different initial competition densities. See Figure 2.7a 
for plots. 
 
SU 1% glucose: 
107 cells/ml: 
Initial C. 
albicans fraction 
t-value df P-value 
0.10 -2.2947 8 0.05089 
0.30 -9.7 7 2.614e-05 
0.50 -11.875 8 2.321e-06 
0.70 -12.447 8 1.621e-06 
0.89 -8.5016 8 2.811e-05 
 
SU 4% glucose: 
107 cells/ml: 
Initial C. 
albicans fraction 
V-statistic P-value 
0.10 1 0.01563 
0.33 0 0.003906 
0.54 0 0.003906 
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0.70 0 0.003906 
0.91 0 0.003906 
 
SU 0.1% 
glucose: 103 
cells/ml: Initial 
C. albicans 
fraction 
t-value df P-value 
0.088525531 31.413 8 1.147e-09 
0.39497314 19.877 8 4.277e-08 
0.511993024 14.24 8 5.761e-07 
0.706162137 7.011 8 0.0001114 
0.920388091 4.539 5 0.006174 
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Table A.1.2.S4. Statistical results from t-tests for significance of the slope of the 
negative frequency-dependent relationship for one-season competitions 
between C. albicans and C. glabrata at different glucose concentrations and 
competition cell densities. Statistical results are presented from analysis of the best-
fit least-squares linear regression line in Excel, plotted for C. albicans relative fitness in 
replicate populations at five initial C. albicans fractions. Negative relative fitness values 
and highly skewed values (relative fitness > 10) were excluded in the figures and 
statistical analyses. See Figures 2.3 and 2.7 for plotted regression lines with R-
squared correlation coefficients.  
 
~ 106 
cells/ml: 
Glucose 
concentration 
(% w/v) 
Slope t-value df P-value 
0.05 -4.52 -2.58 43 0.01343 
0.10 0.38 0.63 40 0.5333 
0.50 -2.96 -4.69 41 3.005E-05 
1.00 -1.49 -5.54 43 1.696E-06 
2.00 -1.16 -2.92 43 0.005566 
4.00 -0.42 -3.48 43 0.001166 
 
 
 
Glucose 
concentration 
(% w/v); cell 
density 
(cells/ml) 
Slope t-value df P-value 
 
1.00; 107 
-0.15 -1.22 42 0.2294 
 
4.00; 107 
-0.19 -2.47 42 0.01760 
 
0.10; 103 
-0.012 -0.17 40 0.8606 
 193 
Table A.1.2.S5: Statistical results of significant pairwise comparisons from Tukey 
post hoc tests following one-way ANOVA tests on daily C. albicans fractions 
during long-term competition in 1% w/v glucose SU media. Significant pairings are 
described for daily differences in C. albicans fraction for three different initial fractions 
and three different initial competitor densities (see text). HF = high frequency; IF = 
intermediate frequency; LF = low frequency; ID = intermediate density; HD = high 
density; LD = low density. See Figure 2.6 for plots. 
 
Frequency/ density dependent 
competition 
Significant daily C. albicans fraction 
pairings 
HF days 0, 1 and 2 different from each other 
and all other days; P = 0.00 *** 
day 3 from days 7 and 9; P < 0.01 ** 
day 4 and day 9; P < 0.05 * 
IF day 0 different from all days except day 1 
and day 1 different from all days except 
day 0; P = 0.00 *** 
day 2 different from all other days: P < 
0.01 ** 
day 3 from days 7 and 9: P < 0.01 ** 
LF, ID day 0 different from all days except day 1; 
P < 0.05 * 
day 1 different from all days except day 0; 
P < 0.001 *** 
day 2 different from all days except day 3; 
P < 0.01 ** 
HD day 0 different from all days except day 1; 
P < 0.001 *** 
day 1 different from all days except day 0; 
P < 0.001 *** 
day 2 different from all days except day 3; 
P < 0.001 *** 
day 3 different from all days except day 2; 
P < 0.01 ** 
LD day 0 and day 1 different from all days 
except each other; P < 0.001 *** 
day 2 different from all days; P < 0.01 **  
 194 
A.2 Chapter 3 Appendix  
 
A.2.1 Supplementary Tables 
 
 
Table A.2.1.S1. Statistical results from log-rank tests for survival curve 
comparisons between infective doses and temperatures for single species C. 
albicans and C. glabrata infections of G. mellonella. Statistical analyses represent 
comparisons between survival curves from Figure 3.1. Pairwise comparisons are 
presented from OASIS 2 software and compare survival between three doses and two 
temperatures for each species. P-values are corrected (Bonferroni) to account for 
multiple comparisons. 
 
C. glabrata: 
temperature (oC); 
dose (CFU/larva) 
Chi-
squared 
P-value 
corrected
_P-value 
Mean survival 
time (days) +/- 
SE 
30; 1.25 x 106  v.s.   
30; 2.5 x 106 
8.96 0.0028 0.0138 
3.93 +/- 0.36 v.s. 
3.20 +/- 0.28 
30; 1.25 x 106 v.s.   
30; 5 x 106 
23.29 0.0000014 0.000007 
3.93 +/- 0.36 v.s. 
1.75 +/- 0.19 
30; 2.5 x 106 v.s.   
30; 5 x 106 
8.38 0.0038 0.0189 
3.20 +/- 0.28 v.s. 
1.75 +/- 0.19 
37; 1.25 x 106 v.s.   
37; 2.5x106 
28.93 7.50e-08 3.70e-07 
4.90 +/- 0.25 v.s. 
3.00 +/- 0.20 
37; 1.25 x 106 v.s.   
37; 5 x 106 
86.66 0 0 
4.90 +/- 0.25 v.s. 
1.95 +/- 0.09 
37; 2.5 x 106 v.s.   
37; 5 x 106 
22.8 0.0000018 0.000009 
3.00 +/- 0.20 v.s. 
1.95 +/- 0.09 
30; 1.25 x 106 v.s.  
37; 1.25x10^6 
0.91 0.3405 1 
3.93 +/- 0.36 v.s. 
4.90 +/- 0.25 v.s. 
30; 2.5 x 106 v.s.   
37; 2.5 x 106 
0.16 0.6856 1 
3.20 +/- 0.28 v.s. 
3.00 +/- 0.20 v.s. 
30; 5 x 106 v.s.   
37; 5 x 106 
0.15 0.7024 1 
1.75 +/- 0.19 v.s. 
1.95 +/- 0.09 
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C. albicans: 
temperature (oC); 
dose (CFU/larva) 
Chi-
squared 
P-value 
corrected_
P-value 
Mean survival 
time (days) +/- 
SE 
30; 1 x 105 v.s.  
30; 2 x 105 
35.51 2.60e-09 1.30e-08 
6.54 +/- 0.16 v.s. 
4.59 +/- 0.28 
30; 1 x 105 v.s.  
30; 4 x 105 
148.38 0 0 
6.54 +/- 0.16 v.s. 
1.26 +/- 0.12 
30; 2 x 105 v.s.  
30; 4 x 105 
85.73 0 0 
4.59 +/- 0.28 v.s.  
1.26 +/- 0.12 
37; 1 x 105 v.s.  
37; 2 x 105 
47.7 0 0 
5.59 +/- 0.20 v.s. 
2.95 +/- 0.21 
37; 1 x 105 v.s.  
37; 4 x 105 
159.43 0 0 
5.59 +/- 0.20 v.s. 
1.06 +/- 0.03 
37; 2 x 105 v.s.  
37; 4 x 105 
92.89 0 0 
2.95 +/- 0.21 v.s. 
1.06 +/- 0.03 
30; 1 x 105 v.s.  
37; 1 x 105 
36.9 0 0 
6.54 +/- 0.16 v.s. 
5.59 +/- 0.20 
30; 2 x 105 v.s.  
37; 2 x 105 
24.25 8.50e-07 4.20e-06 
4.59 +/- 0.28 v.s. 
2.95 +/- 0.21 
30; 4 x 105 v.s.  
37; 4 x 105 2.03 0.154 0.7701 
1.26 +/- 0.12 v.s. 
1.06 +/- 0.03 
 
 
Table A.2.1.S2. Results from survival analyses of single and dual species 
Candida infections of G. mellonella, using infective doses from Rossoni et al. 
(2015). Statistical results are from log-rank tests (Cox PH in R) used to compare 
survival curves presented in Figure 3.2. Letters in brackets in column 1 denote plots 
from Figure 3.2, to which the statistical results relate. Mean survival times with 
standard errors are presented for a descriptive comparison of survival between 
infection groups. 
Survival curve comparison Chi-
squared 
value 
P-value Mean 
survival 
time 
(hours) +/- 
SE 
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Table A.2.1.S3. Statistical results from log-rank tests for survival curves of single 
species C. albicans infection and dual species C. albicans-C. glabrata strain 
infections of G. mellonella. Statistical analyses show comparisons between survival 
curves in Figure 3.3. Separate single species infections for two doses of C. albicans 
(a) C. albicans SBC153/  
1 x 106 CFU/larva;  
C. glabrata ATCC 2001/ 1 x 106 
CFU/larva  
70.94 0.0000 18.00 +/- 
0.00;  
 
71.75 +/- 
4.48 
(b) C. albicans SBC153/  
1 x 106 CFU/larva;  
 
C. albicans SBC153/  
2 x 106 CFU/larva;  
 
C. albicans SBC153/  
1 x 106 CFU/larva,  
C. glabrata ATCC 2001 1 x106 
CFU/larva 
0.29 0.8655 18.00 +/- 
0.00 
 
18.00 +/- 
0.00 
 
18.63 +/- 
0.63 
(c) C. albicans SBC153/  
1 x 106 CFU/larva;  
 
C. krusei ATCC 6258/ 1 x 106 
CFU/larva- bio rep 2 
11.93 0.0005512 18.00 +/- 
0.00;  
 
46.88 +/- 
7.73 
(d) C. albicans SBC153/  
1 x 106 CFU/larva;  
 
C. albicans SBC153/  
2 x 106 CFU/larva;  
 
C. albicans SBC153/  
1 x 106 CFU/larva,  
C. krusei ATCC 6258 x106 CFU/larva 
0.00 1.0000 18.00 +/- 
0.00;  
 
18.00 +/- 
0.00;  
 
18.00 +/- 
0.00;  
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were run alongside each dual species infection and pairwise comparisons with each 
dual species infection are presented.  
 
Single/ dual species 
infection pairwise 
comparison (CFU/larva) 
Chi-
squared 
P-value 
corrected
_P-value 
Mean survival 
time (hours) 
+/- SE 
Figure 3.3(a) (C. glabrata strain BG2) 
Ca 2 x 105 v.s.   
Ca 4 x 105 38.53 0 0 
50.75 +/- 3.73 
v.s. 23.38 +/- 
1.94 
Ca 2 x 105 v.s.   
Cg/Ca 2 x 105/ 2 x 105 6.11 0.0135 0.0269 
50.75 +/- 3.73 
v.s. 37.5 +/- 
3.98 
Ca 4 x 105 v.s.   
Cg/Ca 2 x 105/ 2 x 105 9.15 0.0025 0.005 
23.38 +/- 1.94 
v.s. 37.5 +/- 
3.98 
Figure 3.3(b) (C. glabrata strain 3605) 
Ca 2 x 105 v.s.   
Ca 4 x 105 25.54 
4.30e-
07 8.70e-07 
36.56 +/- 3.34 
v.s. 20.06 +/- 
0.97 
Ca 2 x 105 v.s.   
Cg/Ca 2 x 105/ 2 x 105 0.15 0.7028 1 
36.56 +/- 3.34 
v.s. 34.13 +/- 
2.94 
Ca 4 x 105 v.s.   
Cg/Ca 2 x 105/ 2 x 105 22.45 
0.00000
22 
0.000004
3 
20.06 +/- 0.97 
v.s. 34.13 +/- 
2.94 
Figure 3.3(c) (C. glabrata strain 1184) 
Ca 2 x 105 v.s.   
Ca 4 x 105  23.5 
0.00000
12 
0.000002
5 
41.88 +/- 3.85 
v.s. 22.5 +/- 
1.74 
Ca 2 x 105 v.s.   
Cg/Ca 2 x 105/ 2 x 105 26.69 
2.40e-
07 4.80e-07 
41.88 +/- 3.85 
v.s. 21.75 +/- 
1.80 
Ca 4 x 105 v.s.   
Cg/Ca 2 x 105/ 2 x 105 0.1 0.7484 1 
22.5 +/- 1.74 
v.s. 21.75 +/- 
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1.80 
Figure 3.3(d) (C. glabrata strain 3309) 
Ca 2 x 105 v.s.   
Ca 4 x 105 39.02 0 0 
48.63 +/- 4.42 
v.s. 20.38 +/- 
0.90 
Ca 2 x 105 v.s.   
Cg/Ca 2 x 105/ 2 x 105 14.27 0.0002 0.0003 
48.63 +/- 4.42 
v.s. 30.63 +/- 
2.65 
Ca 4 x 105 v.s.   
Cg/Ca 2 x 105/ 2 x 105 11.65 0.0006 0.0013 
20.38 +/- 0.90 
v.s. 30.63 +/- 
2.65 
 
 
Table A.2.1.S4. Statistical results from log-rank tests for single species C. 
albicans infection and dual species C. albicans-C. krusei strain infections of G. 
mellonella. Statistical analyses show comparisons between survival curves in Figure 
3.4. Pairwise comparisons between single species C. albicans infections and between 
single and dual species infections are reported.  
 
Single/ dual species 
infection pairwise 
comparison (CFU/larva) 
Chi-
square
d 
P-value 
corrected
_P-value 
Mean survival 
time (hours) 
+/- SE 
Figure 3.4(a) 
Ca SBC153 2 x 105 v.s.   
Ca SBC153 4 x 105 17.92 
0.00002
3 0.000046 
36.25 +/- 3.57 
v.s. 20.63 +/- 
1.27 
Ca SBC153 2 x 105 v.s.  
Ck/Ca 2 x 105/ 2 x 105 14.35 0.0002 0.0003 
36.25 +/- 3.57 
v.s. 22.00 +/- 
1.59 
Ca SBC153 4 x 105 v.s.  
Ck/Ca 2 x 105/ 2 x 105 0.12 0.7272 1 
20.63 +/- 1.27 
v.s. 22.00 +/- 
1.59 
Figure 3.4(b)     
Ca 18804 2 x 105 v.s.  
Ca 18804 4 x 105 36.03 0 0 
40.38 +/- 4.05 
v.s. 18.63 +/- 
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0.26 
Ca 18804 2 x 105 v.s.  
Ck/Ca 2 x 105/ 2 x 105 34.51 
4.30e-
09 8.50e-09 
40.38 +/- 4.05 
v.s. 18.75 +/- 
0.29 
Ca 18804 4 x 105 v.s.  
Ck/Ca 2 x 105/ 2 x 105 0.1 0.7499 1 
18.63 +/- 0.26 
v.s. 18.75 +/- 
0.29 
 
 
Table A.2.1.S5. Statistical results from log-rank tests for single species C. 
albicans and C. glabrata strain infections of G. mellonella at equally virulent 
doses. Statistical analyses show comparisons between survival curves in Figure 3.5. 
All pairwise comparisons are reported. 
 
Single species infection 
dose (CFU/larva) 
Chi-
squared 
P-value 
corrected_P-
value 
Mean survival 
time (hours) 
+/- SE 
C.albicans 2 x 105 v.s.  C. 
glabrata BG2 5 x 106 0.76 0.3827 0.7654 
62 +/- 6.31 v.s.  
57 +/- 4.41 
C.albicans 2 x 105 v.s.  
C.glabrata 1184 1.25 x 106 1.43 0.2315 0.4629 
62 +/- 6.31 v.s.  
70.63 +/- 6.75 
C. glabrata BG2 5 x 106 v.s.  
C.glabrata 1184 1.25 x 106 4.13 0.0421 0.0841 
57 +/- 4.41 v.s.  
70.63 +/- 6.75 
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A.3. Chapter 4 Appendix  
 
A.3.1 Supplementary Figures and Tables 
 
 
 
Figure A.3.1.S1. Growth rate (r) for five C. glabrata strains measured over a range 
of glucose concentrations in Synthetic Complete medium. Data is replotted from 
Figure 4.3(a) to show separate two-dimensional representations of each strain’s data 
and fitted model prediction. Each model prediction with 95% CIs was obtained by fitting 
an equation to the data that assumed growth rate (r) to vary as a Monod function 
multiplied by yield (biomass produced per mg ml
-1
 of glucose) (Meyer et al., 2015; 
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Equation (2)- Reding-Roman et al., 2017). N = 9 per glucose concentration per strain 
and the colour gradient for the plotted points indicates increasing glucose 
concentration. The model prediction is a robust fit to the data for all strains (adjusted R
2
 
values = strain 2001: 0.7854; strain 3309: 0.7233; strain 3605: 0.8121; strain BG2: 
0.6326; strain BG2Δssk2: 0.5516). Data plots and model fitting were completed by 
Carlos Reding-Roman, University of Exeter. 
 
 
 
Figure A.3.1.S2. OD at carrying capacity (K) for five C. glabrata strains measured 
over a range of glucose concentrations in Synthetic Complete medium. Data is 
replotted from Figure 4.3(b) to show separate two-dimensional representations of each 
strain’s data and fitted model prediction. Glucose concentration is plotted as an 
increasing function on the x-axis and is also indicated by the light-dark colour gradient 
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of plotted points. Each model prediction with 95% CIs was obtained by fitting an 
equation to the data that assumed K to be a product of yield and glucose concentration 
(Equation (4)- Reding-Roman et al., 2017). N = 9 per glucose concentration per strain. 
The model prediction is a robust fit to the data for all strains (adjusted R2 values = 
strain 2001: 0.9788; strain 3309: 0.9854; strain 3605: 0.9792; strain BG2: 0.9840; 
strain BG2Δssk2: 0.9278). Data plots and model fitting were completed by Carlos 
Reding-Roman, University of Exeter.     
 
 
 
 
Figure A.3.1.S3. Yield for five C. glabrata strains measured over a range of 
glucose concentrations in Synthetic Urine medium. Data is replotted from Figure 
4.3(c) to show separate two-dimensional representations of each strain’s data and 
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fitted model prediction. Yield was calculated as K divided by glucose concentration (mg 
ml-1) and represents the efficiency of biomass production. Each model prediction with 
95% CIs was obtained by fitting an equation to the data that assumed yield to depend 
on environmental glucose concentration rather than being a fixed constant (Meyer et 
al., 2015; Equation (5)- Reding-Roman et al., 2017). N = 9 per glucose concentration 
per strain and the colour gradient for the plotted points indicates increasing glucose 
concentration. The model prediction is a robust fit to the data for all strains (adjusted R2 
values = strain 2001: 0.995; strain 3309: 0.98; strain 3605: 0.99; strain BG2: 0.95; 
strain BG2Δssk2: 0.98). Data plots and model fitting were completed by Carlos Reding-
Roman, University of Exeter. 
 
 
Yield	=	2.64		± 0.078	 Yield	and	K	=	0.69	± 0.0061		
K	=	0.26	± 0.0078		
Yield	=	1.59	± 0.049	 Yield	and	K	=	0.43	± 0.0068		
K	=	0.16	± 0.0049		
 
 
Figure A.3.1.S4. Growth curves of C. glabrata strains 2001 and 3605 at low and 
intermediate glucose concentrations, with fitted logistic models and calculated 
growth parameters. Plots for 2001 (top) and 3605 (bottom) show change in OD over 
24 hours (blue line fitted to means and SE bars shown per time point). The red line on 
each plot is the best fit of the logistic model and shows predicted means and standard 
error bars for each time point. Growth parameter values (growth rate and K (carrying 
capacity)) were estimated from the logistic fit and are shown with their standard errors. 
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Yield was calculated as K/ % (w/v) glucose, so K and yield are equal at 1% w/v 
glucose. N = 15 (technical replicates) for each strain and glucose concentration. 0.1% 
glucose = 1 mg ml-1 glucose (“low glucose”); 1% glucose = 10 mg ml-1 glucose 
(“intermediate glucose”). The peaks in OD around 7 hours for each strain grown in 1% 
glucose could represent transient cell clumping, and they are excluded by the logistic 
fits to calculate the best fit growth parameters. 
 
 
 
Figure A.3.1.S5 Relative growth of populations of C. glabrata strains 2001 and 
3605 evolving on a gradient of caspofungin concentrations over 14 days. 
Populations of each strain were grown across eight different caspofungin 
concentrations and a no-drug condition and were serially transferred at the end 
of each 24-hour period. Relative growth % is calculated as the final optical 
density of a drug-treated population at the end of a 24-hour period as a 
percentage of the average final optical density of the no-drug treated 
populations. Data is shown for days 1, 7 and 14 and is combined from the three 
independent 14-day experiments (3 populations per drug treatment), such that 
N = 9 per drug concentration per day. Plotted points represent mean relative 
growth with standard error bars shown. (a) Strain 2001; (b) Strain 3605. 
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Figure A.3.1.S6. Evolution of caspofungin dose response profile of C. glabrata 
strains 2001 and 3605 in three independent experiments. Left panels show 
evolution of strain 2001; right panels show evolution of strain 3605. Plots represent 
model fits (4-parameter logistic dose response) to the data presented in Figure 4.9 and 
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95% confidence intervals for the predictions shown by coloured shaded regions. Days 
1, 7 and 14 dose responses are plotted (black, green, blue respectively) and IC50 
estimates with their standard errors predicted from the logistic model are presented for 
each curve. Comparison of IC50 parameters- 2001 E1: Day 1 compared with Day 7,14, 
P < 0.01; 2001 E2: Day 1 compared with Day 14, P = 0.00; 2001 E3: Day 1 compared 
with Day 7,14, P < 0.001; 3605 E1, E2, E3: no significant differences apart from E3: 
Day 1 and Day 7, P < 0.05. Comparison of slopes- 2001 E1: no significant differences; 
2001 E2: Day 1 and 7,14, P < 0.01; 2001 E3: Day 1 and 14, P < 0.01; 3605 E1, E2, E3: 
no significant differences apart from E2: Day 1 and 14, P < 0.05.  
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Figure A.3.1.S7. Caspofungin IC estimates from dose-response fits across 
populations of C. glabrata strain 2001 evolving on a gradient of caspofungin 
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concentrations in three 14-day experiments. Following fitting of 4-parameter logistic 
dose response profiles to data from days 1, 7 and 14 (Figure A.3.1.S6; left panels), 
the R-package ‘drc’ (Ritz et al., 2015) was used to calculate IC (inhibitory 
Concentration) estimates for growth inhibitory levels ranging 5 - 95%, with 5% 
increments. The estimated inhibitory caspofungin concentrations (µg/ml) are plotted 
with 95% confidence intervals from the model predictions. The data from Days 1 
(black), 7 (green) and 14 (blue) are plotted and significant differences between IC 
estimates between days at each inhibitory level are deduced from non-overlapping 
95% confidence intervals, indicating statistical significance at P < 0.05 (Greenland et 
al., 2016). The three separate plots represent each of the 14-day evolutionary 
experiments. 
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Figure A.3.1.S8. Evolution 
of C. glabrata strain 2001 
dose response profile in 
1% w/v (10 mg ml-1) 
glucose SC medium- 
Experiment 1. 
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Figure A.3.1.S9. 
Evolution of C. glabrata 
strain 3605 dose 
response profile in 1% 
w/v (10 mg ml-1) glucose 
SC medium- Experiment 
1. 
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Figure A.3.1.S10. 
Evolution of C. glabrata 
strain 2001 dose response 
profile in 1% w/v (10 mg 
ml-1) glucose SC medium- 
Experiment 2. 
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Figure A.3.1.S11. 
Evolution of C. glabrata 
strain 3605 dose 
response profile in 1% 
w/v (10 mg ml-1) glucose 
SC medium- Experiment 
2. 
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Figure A.3.1.S12. 
Evolution of C. glabrata 
strain 2001 dose 
response profile in 1% 
w/v (10 mg ml-1) glucose 
SC medium- Experiment 
3. 
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Figure A.3.1.S13. Evolution 
of C. glabrata strain 3605 
dose response profile in 
1% w/v (10 mg ml-1) 
glucose SC medium- 
Experiment 3. 
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Figure A.3.1.S8-13. Evolution of populations of C. glabrata strains 2001 and 3605 
on a gradient of caspofungin concentrations in 1% w/v (10 mg ml-1) glucose SC 
medium over 3 separate 14-day experiments. Each dose response profile plotted 
across evolving populations, shows growth of three replicate populations at eight 
caspofungin concentrations and a no drug control. Relative growth is the % growth of 
each replicate population relative to the no drug control, measured as optical density 
(OD) after 24 hours of growth of each replicate population divided by the mean OD of 
the no drug-treated population. All data points are shown and the solid line on each 
plot is the best-fit 4-parameter logistic model (R package ‘drc’; Ritz et al., 2015). Each 
plot shows estimated IC50 +/- SE. Note that dose responses were not measured on 
days 6 and 13 in Experiment 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 216 
Figure A.3.1.S14. Strain 2001 growth kinetics- Experiment 3, day 1. 
 
 
Figure A.3.1.S15. Strain 3605 growth kinetics- Experiment 3, day 1. 
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Figure A.3.1.S16. Strain 2001 growth kinetics- Experiment 3, day 7. 
 
 
Figure A.3.1.S17. Strain 3605 growth kinetics- Experiment 3, day 7. 
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Figure A.3.1.S18. Strain 2001 growth kinetics- Experiment 3, day 14. 
 
 
Figure A.3.1.S19. Strain 3605 growth kinetics- Experiment 3, day 14. 
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Figures A.3.1.S14-19. Growth kinetics of populations of C. glabrata strains 2001 
and 3605 during evolution on a gradient of caspofungin concentrations in 
Experiment 3. Growth profile data is shown for the three replicate populations of each 
strain evolving at each of 8 caspofungin concentrations (0.05- 2.40 µg/ml) and no drug 
control at day 1 (initial season), day 7 (evolution midpoint) and day 14 (final season) for 
Experiment 3, as representative of the three 14-day evolution experiments. The blue 
line on each sub-plot labelled with a specific caspofungin concentration (µg/ml) shows 
change in mean OD (Ab650) of the three replicate populations with standard error 
bars, that were serially-transferred at that concentration over 14 days. The red line with 
error bars represents means and standard errors from the best-fit model prediction of 
logistic growth. Growth rate (r) and K (carrying capacity) were estimated from the 
model fit and final OD at 24hrs and AUC (Area Under Curve) were calculated from 
growth profile data. In all plots, yield and K are directly proportional as all populations 
were grown at the same glucose concentration (10 mg ml-1). 
 
 
Table A.3.1.S1. Statistical results for Strain 2001 dose response slope 
comparisons during caspofungin evolution. Data is presented for pairwise 
comparisons of the slope (gradient of the dose response: Hill coefficient) of the dose 
response model fit, comparing days 1, 7 and 14 from each of the three independent 
evolutionary experiments. See Figure 4.9 (left panels) for plots of dose responses for 
days 1, 7 and 14. ‘Estimate’ represents the difference in the estimated slopes from the 
two dose response model fits, along with the standard error of the predicted difference. 
The P-value is presented for the null hypothesis that the difference between the two 
slope estimates is 0 (Ritz et al., 2015). 
 
Experiment/ 
Day 
comparison 
 
Estimate Standard 
error 
t-value P-value 
E1 
 
Day 1,7 -1.336828   10.378007 -0.128814   0.8979 
Day 1,14 -0.950887    7.849947 -0.121133   0.9039 
Day 7,14 0.385942 11.981738 0.032211 0.9744 
E2 
 
Day 1,7 28.44084 8.33619 3.41173 0.0011 
Day 1,14 26.45505 8.43861 3.13500 0.0025 
Day 7,14 -1.98580     2.46053 -0.80706   0.4224 
E3 
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Day 1,7 6.6328 4.6184 1.4362 0.1555 
Day 1,14 11.8122 4.0066 2.9482 0.0044 
Day 7,14 5.1794 3.4872 1.4853 0.1420 
 
Table A.3.1.S2. Statistical results for Strain 2001 IC50 comparisons during 
caspofungin evolution. Data is presented for pairwise comparisons of IC50 (50% 
inhibition of relative growth) between days 1, 7 and 14 from the three independent 
evolutionary experiments. See Figure 4.9 (left panels) for plots of dose responses and 
IC50 values for days 1, 7 and 14. ‘Estimate’ represents the difference in the estimated 
IC50s from the two dose response model fits, along with the standard error of the 
predicted difference. The P-value is presented for the null hypothesis that the 
difference between the two IC50 estimates is 0 (Ritz et al., 2015). 
 
Experiment/ 
Day 
comparison 
 
Estimate Standard 
error 
t-value P-value 
E1 
 
Day 1,7 -0.41140 0.15098 -2.72486 0.0081 
Day 1,14 -0.56714  0.20706 -2.73902   0.0078 
Day 7,14 -0.15575 0.24488 -0.63603 0.5269 
E2 
 
Day 1,7 -0.055059    1.786510 -0.030819   0.9755 
Day 1,14 -1.187030 0.147994 -8.020780 0.0000 
Day 7,14 -1.131971 1.792495 -0.631506 0.5298 
E3 
 
Day 1,7 -0.462929    0.053968 -8.577904   0.0000 
Day 1,14 -0.822344    0.228445 -3.599747   0.0006 
Day 7,14 -0.359415    0.231780 -1.550677   0.1256 
 
 
Table A.3.1.S3. Statistical results for Strain 3605 dose response slope 
comparisons during caspofungin evolution. Data is presented for pairwise 
comparisons of the slope (gradient of the dose response: Hill coefficient) of the dose 
response model fit, comparing days 1, 7 and 14 from each of the three independent 
evolutionary experiments. See Figure 4.9 (right panels) for plots of dose responses for 
days 1, 7 and 14. ‘Estimate’ represents the difference in the estimated slopes from the 
two dose response model fits, along with the standard error of the predicted difference. 
The P-value is presented for the null hypothesis that the difference between the two 
slope estimates is 0 (Ritz et al., 2015). 
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Experiment/ 
Day 
comparison 
 
Estimate Standard 
error 
t-value P-value 
E1 
 
Day 1,7 4.53329 19.62506 0.23099 0.8180 
Day 1,14 12.22120 10.68275 1.14401 0.2566 
Day 7,14 7.68791 16.58974 0.46341 0.6445 
E2 
 
Day 1,7 13.36121 10.32088 1.29458 0.1998 
Day 1,14 19.30953 9.42642 2.04845 0.0443 
Day 7,14 5.94832 8.70717 0.68315 0.4968 
E3 
 
Day 1,7 3.59080 13.31957 0.26959 0.7883 
Day 1,14 11.48590 5.87053 1.95653 0.0545 
Day 7,14 7.89510 12.71709 0.62083 0.5368 
 
 
Table A.3.1.S4. Statistical results for Strain 3605 IC50 comparisons during 
caspofungin evolution. Data is presented for pairwise comparisons of IC50 (50% 
inhibition of relative growth) between days 1, 7 and 14 from the three independent 
evolutionary experiments. See Figure 4.9 (right panels) for plots of dose responses 
and IC50 values for days 1, 7 and 14. ‘Estimate’ represents the difference in the 
estimated IC50s from the two dose response model fits, along with the standard error 
of the predicted difference. The P-value is presented for the null hypothesis that the 
difference between the two IC50 estimates is 0 (Ritz et al., 2015). 
 
Experiment/ 
Day 
comparison 
 
Estimate Standard 
error 
t-value P-value 
E1 
 
Day 1,7 -0.10788     0.11359 -0.94976   0.3456 
Day 1,14 -0.24857     0.28774 -0.86386   0.3907 
Day 7,14 -0.14068     0.28536 -0.49300   0.6236 
E2 
 
Day 1,7 0.00014077 0.02355323 0.00597649 0.9952 
Day 1,14 0.02222307 0.02810450 0.79072992 0.4318 
Day 7,14 0.02208230 0.03001192 0.73578440 0.4644 
E3 
 
Day 1,7 -0.132946    0.055470 -2.396710   0.0193 
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Day 1,14 -0.118399    0.163250 -0.725259   0.4707 
Day 7,14 0.014547 0.166048 0.087609 0.9304 
 
 
 
A.4 Chapter 5 Appendix  
 
A.4.1 Supplementary Materials and Methods 
 
Genomic DNA Extraction S. cerevisiae and S. pombe (method taken from 
Libuda (2007) 
Protocol:  
1. Grow a 10 ml overnight culture, spot onto YPD to check markers 2. Pellet 
cells, decant supernatant and resuspend in 0.5 ml water 
3. Transfer to a 1.7 ml micro-centrifuge tube 
4. Pellet 5 seconds and decant supernatant  
5. Briefly vortex pellet to resuspend in remaining medium  
6. Add: 0.2 ml Smash and Grab Solution 0.2 ml Phenol-Chloroform  
0.3 grams Acid-washed glass beads  
7. Vortex for 2-5 minutes using the multi-tube holder or 10 minutes on multi-tube 
vortexer in the cold room  
8. Add 0.2 ml of TE to each tube 
9. Spin 5 minutes in centrifuge 
10. Transfer aqeous phase to new tube 
11. Add 1.0 ml EtOH and mix to ethanol precipitate 
12. Spin down 5 minutes, decant supernatant 
13. Resuspend pellet in 0.4 ml TE 
14. Add 30 µg RNase and incubate for 5 minutes at 370 15. Add 10 µl 4M 
ammonium acetate and 1.0 ml EtOH 16. Ethanol precipitate on ice for 5 minutes 
17. Spin down 10 minutes 
18. Optional wash with 0.5 ml 70% EtOH 
19. Air dry pellet and resuspend in 100 µl TE  
Smash and Grab Solution (100mL)  
10 mL 10% SDS (1%) 
2 mL 100x Triton-X100 (2%) 2 mL 5 M NaCL (100mM) 
1 mL 1 M Tris pH 8.0 (10 mM)  
(1 mM)  
Mix in beaker, adding the detergents while the solution is mixing. Filter sterilise.  
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Table A.4.1.S1. Primers for PCR amplification and Sanger sequencing of 
caspofungin resistance gene targets. Five gene target regions of C. glabrata were 
amplified using forward and reverse primers described previously (Thompson et al., 
2008; Zimbeck et al., 2010; Singh-Babak et al., 2012). The FKS1 and FKS2 genes are 
homologous. 
 
Gene target Primer Primer sequence (5’- 3’) 
FKS1 HS1 FKS1HS1F  
 
FKS1HS1R  
 
CCATTGGGTGGTCTGTTCACG 
GATTGGGCAAAGAAAGAAATACGAC 
FKS2 HS1 FKS2HS1F  
 
FKS2HS1R  
 
GCTTCTCAGACTTTCACCG 
CAGAATAGTGTGGAGTCAAGACG 
FKS1 HS2 FKS1HS2F        
 
FKS1HS2R       
 
GGTATTTCAAAGGCTCAAAAGGG 
ATGGAGAGAACAGCAGGGCG 
FKS2 HS2 FKS2HS2F        
 
FKS2HS2R        
 
 TCTTGACTTTCTACTATGCG 
CTTGCCAATGTGCCACTG 
CDC6 CDC6F 
CDC6R 
TCGCTGTACATAACAGGTCC 
CAGTATATGGTTGAAAGACC 
 
 
A.4.2 Supplementary Figures and Tables 
 
Table A.4.2.S1. Comparison of growth rate (1/h) and final OD (24 hours) across 
population colonies at different caspofungin concentrations, revived from day 14 
of the first experimental 14-day caspofungin evolution. Populations were revived 
from the 3 highest caspofungin concentrations and the no-drug control. Growth rates 
relative to the strain 2001 WT ancestor were calculated for 12 replicates of each 
population colony at each drug concentration. Growth rates were statistically compared 
across population colonies for each drug concentration and the WT ancestor (N = 
number of population colonies compared): 0.00 µg/ml: N = 7; 0.78 µg/ml: N = 13; 1.37 
µg/ml: N = 8; 2.40 µg/ml N = 7. The Kruskal-Wallis test was used to identify between-
colony differences as colony sample data was non-normally distributed.  
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Caspofungin 
concentration (µg/ml) 
Kruskal-Wallis 
chi-squared 
df P-value 
Growth rate (h-1) 
0.00 10.741 6 0.09672 
0.78 67.902 12 7.891e-10 
1.37 39.806 7 1.371e-06 
2.40 6.0784 6 0.4145 
OD (24 hours) 
0.00 6.772 6 0.3424 
0.78 41.448 12 4.123e-05 
1.37 27.214 7 0.000305 
2.40 12.393 6 0.05376 
 
 
Table A.4.2.S2. Significant pairwise differences in growth rate (h-1) and final OD 
(24 hours) between population colonies revived from day 14 following evolution 
at 0.78 µg/ml or 1.37 µg/ml in the first caspofungin dose response evolution. 
Growth rate, 0.78 µg/ml: Kruskal-Wallis test- P = 7.891e-10; Welch’s ANOVA for 
unequal variances- F12.00, 54.95 = 28.425, P < 2.2e-16; One-way ANOVA- F12,143 = 11.58; 
P = 4.94e-16. Growth rate, 1.37 µg/ml: Kruskal-Wallis test (P = 1.371e-06); One-way 
ANOVA: F7,88 = 5.07, P = 7.27e-05. OD (24 hours), 0.78 µg/ml: Kruskal-Wallis test (P = 
4.123e-05); Welch’s ANOVA for unequal variances (F12.00, 55.17 = 12.859, P = 5.331e-
12); One-way ANOVA: F12,143 = 3.424; P = 0.000196. OD (24 hours), 1.37 µg/ml: 
Kruskal-Wallis test (P = 0.000305); Welch’s ANOVA: F7.00, 36.99 = 16.551, P = 1.161e-
09; One-way ANOVA: F7,88 = 4.856; P = 0.000116. Due to test results concordance, we 
used Tukey’s post hoc test to deduce pairwise significant between-colony differences 
in growth rate. The colonies shown in bold are significantly different from the others 
listed in the respective row.  
 
Pairwise comparisons between 
population colonies 
Adjusted P-value 
Growth rate (h-1): 0.78 µg/ml 
2001WT- P1C2; P1C3; P1C4 0.0000 
2001WT- P2C1 0.0348 
P1C1- P1C2; P1C3; P1C4 < 0.001 
 226 
P1C2- P2C1; P2C2; P2C3; P2C4; 
P3C1; P3C2; P3C3; P3C4 
< 0.001 
P1C3- P2C3; P2C4; P3C2 < 0.05  
P1C3- P3C1; P3C3 < 0.01  
P1C3- P3C4 0.0001 
P1C4- P2C3; P2C4; P3C1; P3C2 < 0.05  
P1C4- P3C3 0.0032 
P1C4- P3C4 0.0003 
Growth rate (h-1): 1.37 µg/ml 
P2C2- 2001WT 0.0482 
P1C2- P2C2; P3C2 < 0.05  
P1C3- P2C2 0.0007 
P1C3- P3C2 0.0013 
P2C1- P2C2; P3C2 < 0.05  
OD (24 hours): 0.78 µg/ml 
P1C2- P1C4; P3C1 < 0.05 
P1C2- P2C2; P3C3; P3C4 < 0.01  
P2C3- P3C3 0.0469 
OD (24 hours): 1.37 µg/ml 
P3C2- 2001WT; P1C2 < 0.05  
P3C2- P1C3; P2C1; P2C2 < 0.01  
 
 
Table A.4.2.S3. Significant pairwise differences in relative growth rate (h-1) and 
relative OD (24 hours) between population colonies revived from day 14 in  
Experiment 2 of 14-day caspofungin evolution. Growth rate, 0.00 µg/ml: One-way 
ANOVA- (P = 5.27e-09). Growth rate, 0.78 µg/ml: One-way ANOVA (P = 2.08e-13). 
OD (24 hours): 0.00 µg/ml: Kruskal-Wallis test (P = 0.0006098); One-way ANOVA: P = 
3.68e-05. OD (24 hours), 0.78 µg/ml: Kruskal-Wallis test (P = 4.521e-05); One-way 
ANOVA: P = 3.84e-07. We used Tukey’s post hoc test to deduce significant pairwise 
colony differences in growth rate. The colonies shown in bold are significantly different 
from the others listed in the respective row. 
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Pairwise comparisons between 
population colonies 
Adjusted P-value 
Growth rate (h-1): 0.00 µg/ml 
2001WT- M1C2 0.0159 
2001WT- M2C1; M2C2; M3C1; M3C2 < 0.001  
M1C1- M2C1; M3C2 < 0.05  
M1C1- M3C1 0.0004 
M3C1- M1C2 0.0059 
Growth rate (h-1): 0.78 µg/ml 
2001WT- P2C2 0.0442 
P3C1- 2001WT; P1C1; P1C2; P2C1; 
P2C2 
0.0000 
P3C2- 2001WT; P1C1; P1C2; P2C1; 
P2C2 
0.0000 
OD (24 hours): 0.00 µg/ml 
2001WT- M1C2 0.0024 
2001WT- M2C2 0.0001 
M1C2- M3C1 0.0426 
M2C2- M2C1; M3C1 < 0.01  
OD (24 hours): 0.78 µg/ml 
2001WT- P2C1; P2C2; P3C2 < 0.001 
2001WT- P3C1 0.0156 
P2C2- P1C1; P1C2 < 0.05  
 
 
Table A.4.2.S4. Significant pairwise differences in growth rate (h-1) and OD (24 
hours) between population colonies revived from day 14 from Experiment 3 of 
caspofungin evolution. Growth rate, 0.00 µg/ml: One-way ANOVA (P = 8.11e-12). 
Growth rate, 0.78 µg/ml: One-way ANOVA (P < 2e-16). OD (24 hours), 0.78 µg/ml: 
Kruskal-Wallis test (P = 0.0001041); Welch’s ANOVA for unequal variances: P = 
1.127e-09; One-way ANOVA: P = 1.46e-08. We used Tukey’s post hoc test to deduce 
pairwise significant between-colony differences in growth rate. The colonies shown in 
bold are significantly different from the others listed in the respective row. 
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Pairwise comparisons between 
population colonies 
Adjusted P-value 
Growth rate (h-1): 0.00 µg/ml 
2001WT- M1C1 0.0031 
2001WT- M1C2; M2C1; M2C2; M3C1; 
M3C2 
< 0.0001 
M1C1- M1C2; M2C1; M2C2; M3C1; 
M3C2 
< 0.05 
Growth rate (h-1): 0.78 µg/ml 
2001WT- P1C2; P2C2; P3C1; P3C2 0.0000 
P1C1- P1C2; P2C2; P3C1; P3C2 0.0000 
P1C2- P2C1; P2C2; P3C1; P3C2 0.0000 
P2C1- P2C2; P3C1; P3C2 < 0.01 
P3C2- P2C2; P3C1 < 0.001 
OD (24 hours): 0.78 µg/ml 
2001WT- P1C1; P1C2 < 0.0001 
P1C1- P1C2; P3C2 < 0.001 
P1C2- P2C1; P2C2; P3C1 0.0000 
P1C2- P3C2 0.0019 
 
 
Table A.4.2.S5. Comparison of IC50 and slope (gradient) parameters for the 4-
parameter logistic dose response model fit for colony variants from Experiment 
1. See Figure 5.6 for dose response profiles. R-package ‘drc’ was used for dose 
response fitting and parameter comparison (Ritz et al., 2015; Roemhild et al., 2015). 
Note that WT-MA and MA-LCV comparisons could not be reported as ‘NA’ was 
returned in statistical results. 
 
Colony 
comparison 
Estimate SE t-value P-value 
IC50 
WT-LCV 0.0555414 0.0276071 2.0119 0.0454 
Slope 
WT-LCV -70.684 158.385 -0.4463 0.6558 
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Table A.4.2.S6. Comparison of IC50 and slope (gradient) parameters for the 4-
parameter logistic dose response model fit for colony variants from Experiment 
3. See Figure 5.7 for dose response profiles. R-package ‘drc’ was used for dose 
response fitting and parameter comparison (Ritz et al., 2015; Roemhild et al., 2015).  
 
Colony 
comparison 
Estimate SE t-value P-value 
IC50 
WT-MA 0.071381 0.054660 1.3059 0.1940227 
WT-LCV -0.500325    0.149573 -3.3450 0.0010912 
MA-LCV -0.571706    0.154138 -3.7091 0.0003134 
Slope 
WT-MA -93.183     354.686 -0.2627   0.7932 
WT-LCV -21.797     117.900 -0.1849   0.8536 
MA-LCV 71.386 373.758 0.1910 0.8488 
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Figure A.4.2.S1. Dose response model predictions with confidence regions for C. 
glabrata strain 2001 WT ancestor and colony variants from day 14 of Experiment 
1 of caspofungin evolution. Dose responses show predicted relative growth % which 
is measured as final optical density (24 hours) of caspofungin-grown cells as a 
percentage of mean final OD of media-alone grown cells. Four parameter logistic dose 
response curves with 95% confidence interval shaded regions were fitted using the R 
package “drc” (Ritz et al., 2015), as described by Roemhild et al. (2015) and were used 
to predict the IC50: 50% growth inhibitory concentration of caspofungin presented on 
the plots (with SE of the estimated value) for each strain. (a), (b), (c): WT dose 
response is estimated from combined data from day 1 of the three independent 14-day 
caspofungin evolution experiments described in Chapter 4 (N = 9 for each caspofungin 
concentration). Dose responses for the other colony variants in all plots are fitted to 
pooled data from three 24-hour dose responses performed on separate days (N = 9 for 
each caspofungin concentration). (a) WT dose response compared with M1C1 (MA)- a 
single media-adapted colony. (b) WT compared with LCV (large colony variant); 
comparison of IC50: P = 0.0454; comparison of slope: P = 0.6558.  (c) WT compared 
with SCV (small colony variant). (d) Dose response for the SCV at a higher range of 
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caspofungin concentrations: 2-fold dilutions ranging 0 – 64 µg/ml. The 4-parameter 
logistic dose response model was fitted to estimate IC50. 
 
 
Figure A.4.2.S2. Dose response profile predictions with confidence regions for C. 
glabrata strain 2001 WT ancestor and colony variants from day 14 of Experiment 
3 of caspofungin evolution. Dose responses show predicted relative growth % which 
is measured as final optical density (24 hours) of caspofungin-grown cells as a 
percentage of mean final OD of media-alone grown cells. Four parameter logistic dose 
response curves with 95% confidence interval shaded regions were fitted using the R 
package “drc” (Ritz et al., 2015), as described by Roemhild et al. (2015) and fits were 
used to predict the IC50: 50% growth inhibitory concentration of caspofungin presented 
on the plots (with SE of the estimated value) for each strain. (a), (b), (c): WT dose 
response is estimated from combined data from day 1 of the three independent 14-day 
caspofungin evolution experiments described in Chapter 4 (N = 9 for each caspofungin 
concentration). Dose responses for the other colony variants in all plots were fitted to 
single 24-hour dose responses performed on separate days (N = 3 for each 
caspofungin concentration). (a) WT dose response compared with M1C1 (MA)- a 
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single media-adapted colony; comparison of IC50: P = 0.1940; comparison of slope: 
0.7932. (b) WT compared with LCV (large colony variant); comparison of IC50: P = 
0.0011; comparison of slope: P = 0.8536. (c) WT compared with SCV (small colony 
variant). Note that no model fit is shown for SCV as the data do not fit a sigmoidal 
shape as none of the caspofungin concentrations tested were inhibitory. (d) Dose 
response for the SCV at a higher range of caspofungin concentrations: 2-fold dilutions 
ranging 0 – 64 µg/ml. The 4-parameter logistic dose response model was fitted to 
estimate IC50. 
 
 
 
 233 
Figure A.4.2.S3. Caspofungin IC estimates over a range of inhibitory levels from 
dose-response fits to sensitivity tests of the wild-type ancestral strain of C. 
glabrata 2001, media-adapted and large colony variants. Following fitting of 4-
parameter logistic dose response profiles to strain data from Experiments 1 (Figure 
A.4.2.S1) and 3 (Figure A.4.2.S2), the R-package ‘drc’ (Ritz et al., 2015) was used to 
calculate IC (inhibitory Concentration) estimates for growth inhibitory levels ranging 5 - 
95%, with 5% increments. The estimated inhibitory caspofungin concentrations (µg/ml) 
are plotted with 95% confidence intervals from the model predictions. Data from the 
WT ancestor (black), media-adapted (grey) and LCV (large colony variant) (blue) are 
plotted and significant differences between IC estimates between strains at each 
inhibitory level are deduced from non-overlapping 95% confidence intervals, indicating 
statistical significance at P < 0.05 (Greenland et al., 2016). Note that the caspofungin 
IC estimates are plotted on different scales in the two plots, due to higher caspofungin 
sensitivity of the large colony variant in biological replicate 1 than 3. Data for media-
adapted strains from the two independent experiments is highly similar (Figure 
A.4.2.S1; S2) and is only presented on one plot. 
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Figure A.4.2.S4. Dose response profiles for the C. glabrata ATCC 2001 WT 
ancestor and a single colony from each of three replicate populations founded 
from the SCV from Experiment 3 after 14 days propagation without caspofungin. 
Similar to Figure 5.7, dose responses show relative growth % with four parameter 
logistic model fits to the data using the R package “drc” (Ritz et al., 2015), as described 
by Roemhild et al. (2015). Each plot shows the dose response from a separate 
replicate population (N = 3 for each caspofungin concentration), in comparison to the 
wild-type ancestor (N = 9 per caspofungin concentration). Comparison of IC50 values 
to WT: (a) P = 0.0003355, (b) P = 0.004628, (c) P = 0.7972. Comparison of gradient 
(slope) values to WT: (a) P = 0.7081, (b) P = 0.9064, (c) P = 0.2990. 
 
 235 
 
 
Figure A.4.2.S5. Pilot dose response assays for the revived population colonies 
of C. glabrata strain 2001 evolved at 0.78 µg/ml for 14 days in three independent 
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experiments. Dose response assays are presented for colonies that were revived from 
populations evolved at 0.78 µg/ml in the three independent 14-day experiments for 
which fitness costs in the absence of caspofungin were tested, apart from the SCV and 
LCV colonies from Experiments 1 and 3. Relative growth was calculated as the final 
OD at 24 hours of a drug-treated population as a percentage of the final OD of the no-
drug treated population. Relative growth was measured for a single replicate of each 
drug concentration per population colony. The dotted line on each plot represents 50% 
relative growth inhibition and the IC50 for each population colony is approximated from 
the intersect of the dotted line with the dose response profile. Population colonies: (a) 
Experiment 1; (b) Experiment 2; (c) Experiment 3. 
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